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ABSTRACT 
 
JASON ROSENBAUM GOLDSMITH: Mechanisms of mu opioid receptor 
mediated protection from multiple models of acute injury 
Under the direction of Christian Jobin 
 
Numerous intestinal pathologies involve breakdown of the intestinal 
barrier, including Inflammatory Bowel Diseases and ischemia/reperfusion injury.  
Damage to the intestinal barrier leads to immune system activation, resulting in 
further damage to the intestinal epithelium; this generates  a positive feedback-
loop leading to sustained intestinal injury.  Current therapies focus on treating the 
symptoms of intestinal damage or suppressing the immune system, and do not 
treat the underlying intestinal damage.  This work explores the role of mu opioid 
receptor (MOR) signaling in the protection and recovery from acute intestinal 
injury.  MOR signaling is responsible for the analgesic properties of opiates such 
as morphine.  This work establishes for the first time that MOR signaling 
promotes intestinal epithelial survival and restitution during and after acute 
intestinal injury, using multiple models of injury in two different animal species.  In 
zebrafish larvae, we created a model of acute intestinal injury using the non-
steroidal anti-inflammatory drug (NSAID) glafeinine, which was shown to involve 
induction of cell stress with blockade of proper endoplasmic reticulum (ER) and 
mitochondrial stress responses, leading to intestinal epithelial cell (IEC) 
apoptosis.  Administration of the MOR agonist DALDA protected against this 
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injury by restoring the proper cellular stress responses.  In mice, we established 
that DALDA administration could protect and enhance recovery from a chemical 
(dextran sodium sulfate) model of acute colitis.  This effect correlated with 
increased IEC STAT3 phosphorylation, an effect known to be protective in the 
intestine.  Additionally, we established that DALDA administration protected mice 
from small intestine ischemia/reperfusion-induced injury.  Using an IEC-specific 
MOR knockout strain of mice that we developed, we established that the DALDA-
mediated protection was due to IEC-specific MOR signaling.  Pharmacological 
blockade of PI3K signaling demonstrated that MOR-mediated protection from 
ischemia/reperfusion injury is also PI3K-dependent.  Together, this work 
establishes for the first time that enterocyte-mediated MOR signaling is intestinal-
protective, engaging numerous, likely related pathways in the intestinal 
epithelium.  This suggests that opioid-based therapy should be explored in 
patients for the treatment pathologies involving intestinal injury.        
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CHAPTER 1  
INTRODUCTION 
Human intestinal pathologies and the need for new therapeutics 
The gastrointestinal system is responsible for the absorption of nutrients 
and excretion of waste products.  Therefore, preserving intestinal homeostasis 
plays a central role in the overall health of an organism.  Intestinal homeostasis is 
achieved in part by the maintenance of a functional barrier composed of a single 
monolayer of IECs, which isolates the host from the highly antigenic luminal 
milieu [1].  Numerous events can lead to an impaired mucosal barrier including 
genetic predisposition [1], radiation exposure [2], ischemic episodes [3], and 
medication use (non-steroidal anti-inflammatory drugs—ie NSAIDs [4]).  Events 
leading to compromised barrier function have also been associated with 
inflammatory bowel diseases (IBD) [1, 5].  Additionally, loss of the intestinal 
barrier is the principle driver of the more serious complications of ischemia and 
radiation induced injury in the intestine—specifically sepsis and subsequent 
organ failure [2, 6-9].  Unfortunately, there is a near complete absence of 
pharmacological agents to enhance epithelial restitution in the face of these 
conditions.  Current treatment strategies involve only supportive care or 
eliminating the source of intestinal injury.       
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One of the most notorious examples of an intestinal disorder involving a 
compromised barrier is IBD.  In humans, IBD is the result of dys-regulated 
interactions between a genetically susceptible host and their commensal gut 
microbiota [1, 10, 11].   IBD affects 1.4 million Americans and there is no cure for 
the disease [12].  Pharmacological treatment centers around the use of anti-
inflammatories and immunosuppressants [13]. However, current drugs are non-
specific and have deleterious side-effects, such as serious and opportunistic 
infections, increased risk of lymphoma, and death [14].  Additionally, patients 
often become non-responsive to therapies over time [14-16], leaving surgery and 
its associated risks as the only recourse [14].   
The current model of IBD pathogenesis involves an improper, sustained 
immune response to commensal bacteria in a genetically susceptible host [1, 11].  
This sustained immune reaction results in epithelial damage, which leads to 
further immune activation due to loss of the intestinal barrier—creating a vicious 
positive-feedback loop.  The intestine itself is under constant cellular stress, and 
proper responses to this stress are critical for maintaining an intact barrier.  
Recently, one set of genetic susceptibility factors in the pathogenesis of IBD that 
have gained increasing focus are primary defects in the maintenance of the 
intestinal barrier resulting from hampered cell stress responses such as 
autophagy [17, 18].  Specifically, single nucleotide polymorphisms (SNPs) in x-
box binding protein-1 (XBP1) have been linked with IBD [19]. XBP1 is a 
downstream mediator of the unfolded protein response (UPR) that occurs in the 
face of ER (endoplasmic reticulum) stress and leads to autophagy [20].  In mice, 
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loss of intestinal epithelial cell (IEC)-specific XBP1 results in increased ER stress 
and Paneth cell apoptosis [19].  These mice develop spontaneous enteritis and 
have enhanced susceptibility to dextran sodium sulfate (DSS)-induced colitis, 
suggesting that loss of proper UPR responses can lead to a defective intestinal 
barrier, including loss of the intestine-protective Paneth cells [18].  
Another gastro-intestinal pathology characterized by compromised barrier 
function is radiation-induced intestinal injury.  More than 50% of cancer patients 
receive radiation as part of their therapeutic regime [2].  While the small bowel is 
rarely a target of such treatment, its size and location results in it receiving 
significant doses of ionizing radiation, leading to subsequent collateral damage in 
the gut [2].  Even with the low-doses typically used in modern therapy (< 2 Gy per 
treatment), over 70% of patients are estimated to have GI side effects within 3 
weeks of therapy [2].  These symptoms typically include abdominal pain, 
diarrhea, nausea, vomiting  and dehydration; while more severe, chronic 
symptoms include dysmotility, strictures and fistulae [2].  Particularly high levels 
of radiation can also lead to bacteremia and sepsis, although such radiation 
levels tend to be the result of accidental exposure—whether from medical error 
or a nuclear accident [2]—and not from deliberate therapeutic interventions.  
Radiation-induced small bowel injury is generally understood to result from 
damage to and loss of the rapidly proliferating intestinal stem cells.  This leads to 
depletion of differentiated epithelial cells and loss of barrier function [7].  
Currently, there are no treatments for radiation-induced intestinal injury, and 
patient care centers around the management of the resulting symptoms [2].   
4 
 
Ischemia-reperfusion (I/R) injury is a third source of intestinal barrier 
damage.  The intestine can become hypoxic from a variety of sources, including 
atherosclerotic blockade, hemorrhage, veinous emboli, surgical clamping, and 
cardiac tamponade [3].  In all of these cases, enteric blood supply must be 
reduced by at least 50% to overcome compensatory mechanisms [8].  
Additionally, ischemia is seen during chronic inflammation, which occurs during 
colitis [3], and is one of the driving factors in the pathogenesis of the newborn 
disease, necrotizing enterocolitis (NEC) [21].  Paradoxically, the restoration of 
blood flow (reperfusion) enhances the damage to the intestine through the 
introduction of oxygen free-radicals and increase in immune activation [3].  In 
severe cases, I/R injury can result in multiple organ dysfunction syndrome 
(MODS), with a mortality rate of approximately 30% [6].    
I/R injury is currently believed to occur in a ‘three-hit’ model.  In the first 
hit, blood flow is lost, resulting in signaling events directed towards the 
prevention of further injury, such as the activation of transcription factors 
including hypoxia-inducible factor (HIF) [22] and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) [23].  The second hit in this model is 
reperfusion, as the rapid introduction of oxygen enhances and sustains the 
inflammatory response [3].  The third hit is a chronically sustained intestinal 
immune response that results from intestinal barrier damage, due to bacterial 
translocation across the mucosa, bacteremia, and sepsis—all of which support 
further inflammatory responses and resulting intestinal damage—creating a 
positive feedback loop (like in IBD) of inflammation and intestinal damage [3].  In 
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I/R injury, the consequences of this positive feedback loop are perhaps most 
typified by NEC [21], where the sustained response results in progressive loss of 
a newborn’s intestinal track, resulting the death of 2-4% of all very low birth 
weight infants [24].  At the molecular level, the dual-edged nature of the 
inflammatory response is best typified by studies of the NF-κB pathway.  In a 
definitive study by Chen et al., enterocyte-specific loss of the essential catalytic 
activator of NF-κB, IKKβ (IκB kinase β), resulted in decreased systemic 
inflammatory responses that can lead to MODS during I/R injury but also resulted 
in several apoptotic damage in the enterocytes [23].  This dual-edged nature of 
the inflammatory response and its signaling effectors add to the complexity of 
treating this pathology. 
 IBD, radiation-injury, and I/R injury all provide clear examples of the type 
of profound human pathology that can occur with loss of the intestinal barrier 
compounded by a sustained immune reaction (Figure 1).  Unfortunately, current 
management of such diseases is mostly supportive, focusing on treating the 
resulting symptoms (radiation, I/R injury, and IBD) as well as suppressing the 
inflammatory responses that leads to further intestinal damage (generally seen in 
IBD).  Treatments that enhance epithelial healing and restore barrier function 
represent a novel means to approaching these severe GI illnesses and if 
validated, could radically alter patient therapy.  Treatments focused on healing 
have seen some initial validation in both murine models of intestinal inflammation 
and in human IBD patients with the use of trophic factors that promote wound 
healing and restore the intestinal barrier function [5, 25, 26].  However, more 
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work needs to be done before restoration of barrier function can become a 
mainstay of intestinal therapy.  
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Figure 1:  Intestinal injury and immune activation lead to a cycle of 
intestinal damage.  In IBD, genetic susceptibility is generally viewed as required 
to have sustained inflammation.  In ischemia/reperfusion and radiation-induced 
injury, the immune activation and resulting enhancement of intestinal injury is 
part of the acute, pathogenic process.   
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Wound healing, epithelial restitution and related signaling 
Development of therapies that target intestinal healing requires an 
understanding of the host response to intestinal injury.  This healing process and 
host response is also  termed restitution/wound-healing [10].  At baseline, the gut 
is already highly migratory and proliferative—the monolayer of IECs migrates at a 
rate of 5-10 μm/hr and is renewed every 2 to 5 days [27]. During injury, this 
baseline process is enhanced further.  Once a restitution response has been 
engaged, cells at the edge of the wound undergo a de-differentiation process and 
migrate into the wounded area.  They then undergo cytoskeletal rearrangement 
[28], re-differentiate, and finally re-establish tight junction barriers with their 
neighboring cells [10, 29].  This process does not require epithelial proliferation, 
but cellular renewal is needed to replenish the decreased enterocyte pool after 
injury [28].  Numerous signals are implicated in the maintenance of the mucosal 
barrier such as epidermal growth factors (EGF) [7], transforming growth factors 
(TGF-β) [30, 31], and cytokines such as IL-22 [32]; they act through a 
combination of pro-migratory, proliferative and/or anti-apoptotic activities.  A 
variety of pathways including NF-κB, MAPK, STAT3, GSK3β/β-catenin [33] and 
PI3K/Akt [10, 34] have been demonstrated to be involved in intestinal wound 
healing.  
Regardless of the upstream factors that lead to the initiation of wound 
healing, the result is specific set of programmed cellular events that occur during 
the restitution process.  Upon initiation of wound healing cells lose their columnar 
polarity, undergoing massive restructuring of their actin cytoskeleton [27].  This is 
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controlled by the Rho family of small GTPases (Rho, Rac, Cdc42) [27].  Rho 
regulates the presence of stress fibers and adhesions, while Rac regulates the 
formation of lamellipodia and membrane ruffles and Cdc42 initiates filopodial 
extensions at the migrating cell edge [27]. The activity of these small GTPases 
drives cellular migration into the wound, after which the cell regains its columnar 
polarity and re-establishes adhesions and tight junctions with its neighbors [27].  
Proliferation then ensues hours to days after injury, replenishing the population of 
enterocytes [31].   
Relevant models of wound healing/restitution 
This dissertation involves numerous model systems to explore wound 
healing and restitution in the intestinal epithelium (Table 1).  In vitro the main 
assay used is the scratch assay, where a monolayer of IECs is grown in culture, 
and then subjected to a scratch, usually with a pipette tip [27].  The migration 
distance or the speed of cells moving into the wound is then measured.  The 
central role of TGF-β in intestinal wound healing was first established with such a 
system [30, 31].   
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Model In vivo/in vitro Key Features Weaknesses 
Scratch Assay In vitro - Rapid and easy to use 
- Directly measures 
migration rate 
- Artificial system 
- Uses cell lines 
DSS Colitis In vivo - Rapid, reproducible 
injury 
- Low background for 
signaling 
- innate-immune-
dependent 
- adaptive-immune-
independent 
- Chemical-based 
injury 
- Not 
physiologically 
relevant 
- Background and 
sex-specific 
severity 
I/R injury In vivo - Physiologically and 
clinically relevant 
 
- Labor-intensive 
- Noisy background 
for signaling 
studies 
Glafenine/Zebra-
fish injury 
In vivo - Rapid injury (12 hours) 
- Can use zebrafish 
imaging modalities 
- New, unexplored 
system 
- Non-mammalian 
Table 1:  Models used in these studies. 
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One of the standard animal systems for the study of wound healing is 
DSS-induced colitis.  Administration of the detergent DSS in the drinking water 
for several days results in acute colitis characterized by bloody diarrhea, weight 
loss, ulcerations, and granulocyte infiltration [35].  DSS is believed to be directly 
toxic to enterocytes in the basal crypts [35], and damage is thought to be 
exacerbated through innate immune activity.  Specifically, blockade of neutrophil 
recruitment via knockout or antibody neutralization of the chemokine receptor 
CXCR2 abrogated DSS-induced damage [36].  However, studies in mice with 
conditionally depleted macrophages and dendritic cells (created using a 
transgenic line with Fas-mediated apoptosis of these cell lineages) demonstrated 
that macrophages/dendritic cells are important in protection from DSS-mediated 
injury, and that their loss enhances injury and neutrophil activity [37].  In contrast 
to the important role of the innate immune system in this model, DSS-colitis is 
largely adaptive-immune independent, as T-cell and B-cell deficient severe 
combined immunodeficiency (SCID) mice also develop severe colitis with DSS 
administration [38].   
The roles of the numerous signaling pathways involved in wound healing 
have been explored in the DSS model of colitis.  Transgenic mice with a 
dominant negative TGF-β receptor demonstrate enhanced injury in this model 
[39].  Similarly, enterocyte-specific STAT3-knockout mice [32] and enterocyte-
specific NF-κB (RelA-subunit) knockout mice [40] both experience enhanced 
DSS-injury.  Functional β-catenin is also important in protection from DSS-injury, 
as transgenic mice with reduced expression of the Wnt anatgonist Dkk1 have 
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enhanced recovery [41].  The presence of commensal bacteria in the intestine 
drives some of these protective pathways, demonstrated by exacerbated DSS-
colitis in germ-free mice [42].  This pattern was also observed in mice deficient 
for the Toll-like receptor (TLR) adaptor MyD88 (myeloid differentiation primary 
response gene).  These mice lack the ability to sense many bacterial products 
[43] and activate downstream signaling including the NF-κB pathway. 
The second model explored in these studies is the ischemia-reperfusion 
model of injury.  In this injury model, anesthetized animals (usually mice or rats) 
have branches of the superior mesenteric artery (along with collateral branches) 
clipped with aneurysm clamps for 30-60 minutes [23].  After the ischemic period, 
the clamps are removed for a variable amount of time before sacrifice, to induce 
the reperfusion phase of injury [23].  This system is in general less well-studied 
than the DSS-model of injury.  NF-κB-mediated signaling was shown to be 
important in the protection of enterocytes during I/R injury, but also to potentiate 
the systemic inflammatory responses characteristic of this model [23].  GSK3β 
signaling has also been implicated in protection from ischemic injury, likely due to 
the sensing of bacterial products via the intracellular sensor Nod2 [33, 44].  
These same studies showed that germ-free mice have enhanced damage due to 
I/R injury, suggesting that sensing the commensal microbiota is important in the 
wound healing response of this model [33, 44].  In contrast, however, MyD88-/- 
mice showed decreased susceptibility to I/R injury [45].  MyD88-/- mice are 
deficient in their ability to respond to bacterial products, including the potent 
endotoxin lipopolysaccharide through TLR4, and TLR4-deficient mice are also 
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less susceptible to I/R injury [46].  The contrasting data between the germ-free 
and MyD88-/- and TLR4-null mice demonstrate that the role of the microbiota in 
protection from intestinal I/R injury is still poorly understood (reviewed extensively 
by Kinross, et al. 2009 [3]).   
While these two models of intestinal injury have provided key insights into 
the wound healing response, direct in vivo observation of the restitution response 
in real-time is not possible with murine systems.  In recent years, the zebrafish 
(Danio rerio) has gained significant attention as a model organism [47].  It has 
numerous strengths that make it particularly well-suited for its use in the study of 
wound healing, including transparency through early adulthood.  Significant key 
findings, including the role of H2O2 signaling in the wound healing process, were 
first discovered in the zebrafish [48-50].  A detailed review of the zebrafish as a 
model organism, with particular focus on the gastrointestinal system and the 
wound healing response, is presented in Chapter 2.   
Mu-opioid receptor mediated signaling 
 This work explores the role of mu-opioid receptor activation in the wound 
healing response.  The opioid receptors, consisting of the mu, delta, and kappa 
subtypes, are G-protein coupled receptors (GPCRs) of the rhodopsin subfamily.  
These receptors were named for the opiate class of drugs which signal through 
them.  Opioids are widely used analgesics and have long been known to affect 
the development, differentiation and function in a variety of immune cells, 
typically in an immunosuppressive manner [51, 52].  Many of these effects have 
been linked to the mu-opioid receptor (MOR), while opposing effects by the delta 
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and kappa opioid receptors (DOR and KOR, respectively) are also observed [51-
55].  Opioid receptors are classic Gi/Go-coupled receptors, known to inhibit 
adenylate cyclase and increase intracellular [Ca2+] and [K+] [54], as well as to 
activate phospholipase C (PLC) [54, 56, 57].  Interesting, MOR has also been 
shown to induce cAMP by switching coupling from Gi to Gs, especially in the case 
of chronic morphine treatment [54, 58-60].  MOR has also been shown to 
activate the mitogen-activated protein kinase (MAPK) pathway through the 
extracellular-signal-related kinases (ERKs) [54, 61], a potential source of the 
receptor’s immunomodulary properties [62] and a pathway known to be 
protective against DSS-colitis [63].  Finally, MOR can activate the 
phosphoinositide 3-kinase (PI3K)/Akt pathway through the Gβγ subunit in 
multiple cell types [55, 64, 65], including  immune cells [66].  MOR activity is 
regulated in the canonical manner typical of GPCRs by down-regulation, 
desensitization and internalization of the receptor, often involving β-arrestin 
binding, which also induces downstream signaling events [54, 67, 68].  Hence, 
MOR affects numerous signaling cascades and likely impinges on a wide 
spectrum of cellular functions. 
 Due to the immunosuppressive properties of opioids, specific MOR 
agonists have recently been explored in murine systems as potential 
therapeutics for IBD.  Subcutaneous administration of the highly specific 
peripheral MOR agonist, DALDA, [69] reduces inflammation in two T-cell 
dependent models of murine colitis (TNBS-induced colitis and in T-cell transfer-
induced colitis [70]).  DALDA also reduced TNF mRNA production in cultured 
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colonic biopsies from CD and UC patients [71]. Other work showed that in a 
small, open-label clinical trial, low-dose therapy of the non-specific opioid 
antagonist Naltrexone decreased inflammation in the DSS murine model of acute 
colitis, and ameliorated Crohn’s Disease in patients [72, 73].  The activity of 
Naltrexone was postulated to work through DOR [72, 73], but the observations 
could be due to potentiation of endogenous MOR activity and prevention of Gs-
coupling [74].   
 Interestingly, MOR mRNA expression levels were shown to be modulated 
by cytokines important in IBD [15, 16, 75] such as interleukin-1β [54], IL-4 [76], 
IL-6 [77], and TNF [78], in both murine models of colitis and human IBD patient 
samples [71, 72, 79].  At least one study has shown that changes in MOR mRNA 
correspond to equivalent changes in functional receptor number and activity, as 
determined by radioligand binding assays of 3H-DAMGO and by [35S]GTPγS 
binding assays [80].  This suggests that MOR activity may be regulated in part at 
the mRNA level, which would be unique for a GPCR.  
 Altogether, the current literature supports the concept that MOR signaling 
modulates intestinal inflammation; however, the therapeutic effect of MOR 
activation in intestinal injury is still unclear and somewhat controversial.   
Moreover, the signaling pathways responsible for MOR-mediated therapeutic 
effect in the intestine are currently undetermined, although several candidates do 
exist (outlined in Figure 2). 
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Figure 2:  MOR signaling can impinge on a variety of signaling pathways.  
Activation of MOR can result in numerous downstream signaling events, a subset 
of which are shown here.  Ligand binding results in nucleotide exchange and 
dissociation of the Gα and Gβγ subunits.  The Gα unit (a Gi-subclass) inhibits 
adenylate cyclase, resulting in decreased levels of cAMP and diminished PKA 
(protein kinase A) activation.  The Gβγ subunit activates protein lipase C (PLC), 
the PI3K/Akt pathway, STAT3 (through Janus Activating Kinase 2—JAK2), as 
well as the outward rectifying K+ channel.  It inhibits influx Ca2+.  MOR activation 
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can also affect NF-κB activation, both positively and negatively.  Negative 
regulation has been demonstrated to involve β-arrestin signaling, which usually 
occurs as a result of chronic activation of the receptor, leading to internalization 
of MOR.    
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 MOR has numerous downstream secondary messengers that are known 
to be protective in the intestine.  NF-κB for example, has been shown to be both 
positively and negatively regulated by MOR-mediated signaling events [55, 81], 
sometimes in a concentration-dependent manner [82].  Similarly, Gi-coupled 
receptors have shown to activate STAT3 in other GPCR systems [83, 84], and 
DOR has specifically been shown to activate STAT3 [85].  Additionally, while 
MOR-activation is known to induce PI3K/Akt signaling [54], downstream 
activation of β-catenin is only presumed at this point.  More globally, opioids have 
been used to protect brain and cardiac tissue from ischemia/reperfusion injury 
[86-88], and in the heart this process requires PI3K/Akt-dependent activation of 
the JAK/STAT3 pathway [89].   
 Unfortunately, a paucity of information exists on MOR-specific activation, 
especially in the intestine.  Most work studying opioids in the intestinal system 
has focused on their alterations to gut motility [90].  Opiates in numerous 
mammalian systems decrease gut motility; in humans this results in increased 
tonic contractions of the intestine and increasing transit time of the lumenal 
contents [90].  This has been established as primarily an effect of the delta and 
mu receptors, while the kappa receptor has the opposite effect [90].  Opiates also 
decrease intestinal secretions by acting on both the enteric and central nervous 
systems [90].  In patients who experience both chronic pain and diarrhea 
(especially those with IBD), the use of opiates for these symptoms must be 
carefully managed, as colonic dyskinesia can predispose patients to toxic 
megacolon, a serious condition characterized by systemic toxicity and severe 
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colonic distension [91].  A second complication of chronic opiate use is narcotic 
bowel syndrome, characterized chronic or frequently occurring abdominal pain 
that worsens with continued or increasing opiate usage [91].  This is likely a 
result of chronic-opiate mediated desensitization and hyperalgesia [54, 91].   
 Due to the potential for serious complications, the role of opiates in 
enterocyte signaling has largely been ignored.  However, these admittedly 
serious side effects are usually the result of chronic opiate use.  In the studies 
presented here, we focus on the potential benefits of acute opiate use in the 
prevention of and recovery from acute intestinal injury.  The current lack of 
available therapeutics that target epithelial restitution requires the exploration of 
every possible therapeutic agent.  Furthermore, opiates are well-understood and 
available drugs, with consequently rapid bench-to-bedside potential.  The use of 
restitution enhancing drugs to treat intestinal pathologies such as IBD, radiation-
induced injury, and I/R injury remain a potent, but a relatively unexplored 
possibility due to the difficulty in finding non-opiate drugs outside of widely acting 
(and expensive) growth factors that can target this cellular response.   MOR-
specific agonists, particularly peripheral-only acting compounds such as those 
used in this dissertation work, could offer a new therapeutic avenue.  The work 
presented here establishes the presence of MOR-mediated protection from 
intestinal injury in three different models of acute intestinal injury across two 
species, and provides the bench-side justification for the pursuit of clinical trials 
exploring the use of MOR agonists in the treatment of a significant array of 
intestinal pathologies. 
  
 
CHAPTER 2 
  
THINK SMALL: ZEBRAFISH AS A MODEL SYSTEM OF HUMAN 
PATHOLOGY1
Introduction 
 
Although human pathologies have mostly been modeled using higher mammal 
systems such as mice, the lower vertebrate zebrafish has gained tremendous 
attention as a model system.  The advantages of zebrafish over classical 
vertebrate models are multifactorial and include high genetic and organ system 
homology to humans, high fecundity, external fertilization, ease of genetic 
manipulation, and transparency through early adulthood that enables powerful 
imaging modalities.  This review focuses on four areas of human pathology that 
were developed and/or advanced significantly in zebrafish in the last decade.  
These areas are 1) wound healing/restitution, 2) gastrointestinal diseases, 3) 
microbe-host interactions, and 4) genetic diseases and drug screens. Important 
biological processes and pathologies explored include wound-healing responses, 
pancreatic cancer, inflammatory bowel diseases, non-alcoholic fatty liver 
disease, and mycobacterium infection.  The utility of zebrafish in screening for 
novel genes important in various pathologies such as polycystic kidney disease 
is also discussed.    
                                            
1 Journal of Biotechnology and Biomedicine, In Press. 
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Background 
Investigators have long utilized reductionist systems and animal models to 
mimic and study basic processes regulating cellular biology, organ function and 
host homeostasis.  While much work has been accomplished and continues to 
be undertaken in higher mammalian systems such as mice, rats, and rabbits, 
important discoveries have also been made using invertebrate systems such as 
Caenorhabditis elegans and Drosophila melanogaster.  For example, RNA 
interference technology was first discovered in C. elegans [92], as was the initial 
caspase enzyme, caspase-1 (ced-3 in C. elegans) [93].  Similarly, it was in 
Drosophila melanogaster that the innate signaling Toll-like receptors (TLR) were 
first identified via the discovery of the Toll gene, as was its linkage to the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling cascade 
[94].  In the last ~15 years, there has been a growing appreciation for the 
vertebrate organism Danio rerio (zebrafish) as a tool to study human disease 
[95].  As opposed to C. elegans and Drosophila melanogaster, zebrafish is a 
vertebrate organism with physiological and anatomical characteristics of its 
higher organism counterparts (see Figure 3 for a diagram of larval zebrafish 
anatomy), while maintaining the ease of use of a lower organism.  The 
characteristics of zebrafish that make them desirable tools for the study of 
embryogenesis/development also make them useful for the study of human 
pathologies.  Zebrafish have a fully mapped genome 
(http://www.sanger.ac.uk/Projects/D_rerio/), which has significant homology with 
the human genome, including non-coding regions (~60 per gene globally across 
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all genes) [96] suggesting that numerous genes involved in human diseases 
could be matched in the zebrafish genome.  Reverse (morpholino knock-down, 
Targeting Induced Local Lesions in Genome—TILLING [97]) and forward genetic 
(mutagenesis, transgenic) approaches are well established and commonly used 
to manipulate and characterize zebrafish gene function.  
  
23 
 
 
Figure 3:  Diagram of zebrafish anatomy.  A representative image of a 
transparent, 6 dpf larvae captured with brightfield microscopy.  Organs and 
anatomical features are denoted in the figure.  SB = swim bladder.  Scale bar is 1 
mm.      
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Zebrafish are highly fecund and breed rapidly; a pair of zebrafish produces 
over 100 embryos per clutch that are usable for larval experiments as early as 3 
days post fertilization (dpf).  These larvae are transparent through 7 dpf, and this 
can be extended to up to 9-14 dpf with the addition of the melanocyte inhibitor 
phenylthiouria.  Moreover, the recent generation of transparent adult zebrafish 
such as the Casper line adds new imaging possibilities [98].   The transparency 
of zebrafish, in conjunction with sophisticated utilization of fluorescent technology 
to mark signaling proteins or cellular entities allows for powerful time-lapse 
imaging of biological and disease processes.  Additionally, the vertebrate 
zebrafish has many features commonly found in mammals, including an innate 
immune system composed of neutrophils, NK cells, and monocyte/macrophages 
with functionality by 48 hours post-fertilization (hpf) [99, 100], and an adaptive 
immune system that is fully functional at 4-6 weeks post-fertilization [101].  The 
adaptive immune system is highly analogous to that of mammals, with T-cells 
and B-cells that have Rag-dependent V(D)J recombination (reviewed extensively 
in [100]).   Finally, the zebrafish research community benefits from an up-to-date 
database of techniques, genetic strains and other useful resources at 
www.zfin.org.   
In this review, we focus our discussion on larval and adult zebrafish 
models that recapitulate human diseases, focusing on four separate branches of 
pathology: wound healing/restitution, gastrointestinal disease, microbe-host 
interactions and genetic diseases and drug screens.   
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Wound Healing/Restitution 
Wound healing represents a critical biological response of injured tissues 
and organs. Events causing epithelial injury and barrier breakdown initiate a 
biological response known as "restitution," which is aimed at resealing the 
damaged region and re-establishing host homeostasis.  This “wound healing” 
response involves migration of epithelial cells toward the injured regions as well 
as epithelial cell proliferation to replenish the cell pool.  Understanding the 
cellular and molecular mechanisms regulating this response could have profound 
translational impact for patients suffering from chronic inflammation, 
ischemia/hypoxia, burn injury and cancer.  The powerful imaging modalities 
available to zebrafish researchers alongside their ease of genetic manipulation 
makes this vertebrate system an ideal model for studying wound healing 
response to various injuries [49].  Additionally, the ability of zebrafish to 
regenerate both limbs and cardiac tissue [102] make them a powerful animal 
model for understanding the molecular mechanisms involved in regenerative 
signaling.   
The most popular zebrafish injury model is the larval tail wounding model, 
where a segment of the tail fin is resected.  Using this injury model with 
transgenic zebrafish expressing EGFP under the transcriptional controlled of the 
neutrophil-specific myeloperoxidase (MPO) promoter—Tg(BACmpx:GFP)i114—
investigators studied real-time neutrophil chemotaxis to the site of injury [48].  In 
this study, they observed retrograde chemotaxis of neutrophils towards the 
vasculature alongside where injury resolution was observed, suggesting for the 
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first time that retrograde chemotaxis may play an important role in the resolution 
phase of the inflammatory response [48].  To determine the function of the 
reactive oxygen species H2O2 in the wound healing response, investigators 
injected mRNA encoding for the hydrogen peroxide sensor HyPer to one-cell 
stage developing zebrafish embryos [103].  Upon tail wounding of 3 dpf larvae, 
the HyPer sensor demonstrated increased H2O2 production along a gradient 
decreasing away from the wound site, which signaled leukocyte chemotaxis to 
the injured location [49].  Using pharmacological and morpholino blockade, the 
authors showed that generation of the H2O2 gradient is dependent on the activity 
of the dual oxidase (duox) gene.  This HyPer reporter system has also been 
utilized in the study of neuronal regeneration, an important area of study for the 
treatment of many human diseases.  H2O2 produced by injured keratinocytes was 
shown to induce somatosensory axonal regeneration in zebrafish.  Similar to the 
tail fin wounding model, neuronal regeneration required activation of duox [50].  
Moreover, H2O2 administration promoted axonal regeneration following neuronal 
injury, even without accompanying keratinocyte injury [50].   These results 
expand the understanding of post-traumatic nerve injury and subsequent loss of 
limb function in humans.  The healing-enhancing properties of H2O2 have since 
been extended to studies in both rabbits [104] and horses [105], as well as one 
reported case study in a human patient [106].  
Beyond cutaneous wounds, zebrafish have been used for the ability to 
regenerate cardiac tissue.  Unlike mammals, which form scars and do not 
regenerate cardiac tissue following injury, zebrafish are able to fully regenerate 
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their heart within 2 months after 20% ventricular resection [107].  This ability for 
zebrafish to overcome scar formation requires activation of Mps1, a mitotic 
checkpoint kinase [107].  Additionally, cardiac regeneration involves up-
regulation of wound healing genes and proliferative factors including apoeb, 
vegcf and granulina (all of which have human analogs) and likely activation of 
platelet-derived growth factor B signaling [108]. Cardiac regeneration studies in 
zebrafish could produce novel paradigms and identify unique pathways/targets 
with profound translational impact for patients suffering from ischemic heart 
disease.    
Gastrointestinal Diseases 
The zebrafish gastrointestinal system is highly homologous to that of 
mammals, containing a liver, pancreas, gall bladder, and a linearly segmented 
intestinal track with absorptive and secretory functions [109, 110].  The intestinal 
epithelium displays proximal-distal functional specification, and contains many of 
same epithelial cell lineages found in mammals including absorptive enterocytes, 
goblet cells, and enteroendocrine cells [109, 110].  Enterocytes have a 
basolateral nuclei and form tight junctions, apical microvilli and an intestinal 
brush border [111].  In the last decade, numerous gastrointestinal pathologies 
have been modeled in the zebrafish, as summarized in Table 2. 
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Model Mechanism of 
pathology 
Human relevancy/key 
features 
Key references 
Pan-GI 
neoplasias 
Heterozygotic APC 
mutation 
APC mutations drive 
spontaneous and genetic 
intestinal adenocarcinomas. 
Haramis, 2006.  
[112] 
Hepatocellular 
carcinoma 
Thioactemide +/- HCV-
core-protein-zebrafish 
Human genetic overlap. 
Rising prevalence of HCV-
driven HCC in humans.  
Lam, 2006.  [113] 
Rekha, 2008. [114]   
Pancreatic 
cancer 
Transgenic ptf1a-KRAS 
zebrafish 
Recapitulates hedgehog 
signaling aberrations found in 
humans.  Elucidates a 
potential cellular origin for 
pancreatic cancers. 
Park, 2008. [115] 
Inflammatory 
bowel disease 
TNBS in the media of 
zebrafish larvae 
Model inflammatory and 
goblet cell hypertrophy.  
Responds to bacterial status 
and IBD medications 
Flemming, 2010. 
[116] 
Oehlers, 2011.  
[117] 
Inflammatory 
bowel disease 
Oxazolone enema in 
adult zebrafish 
Goblet cell depletion and 
eosinophil infiltration. 
Responds to antibiotic 
therapy. 
Brugman, 2009. 
[118] 
NAFLD 
 
 
 
Mutation in a novel 
gene: foigrhi1532b. 
Alternative model 
involves chemical 
induction with 
thiactemide 
Large lipid filled hepatocytes 
and cellular apoptosis; 
pathology linked to ER stress 
responses. 
Alternative model generates a 
fatty liver and hepatocyte 
apoptosis. 
Cinaroglu, 2011. 
[119] 
 
 
Amali, 2006. [120] 
(alternative model) 
Alcoholic liver 
disease 
2% ethanol to the water 
of 4 dpf zebrafish for 32 
days 
Hepatomegally and steatosis, 
with up-regulation of genes 
involved in toxic alcohol 
metabolism.  Model is 
sensitive to sterol regulatory 
binding protein, important in 
human disease.   
Passeri, 2009. 
[121] 
Table 2:  Zebrafish gastrointestinal models of pathology.  Abbreviations: GI, 
gastrointestinal; APC, adenomatous polyposis coli; HCV, hepatitis C virus; 
TNBS, 2,4,6-trinitrobenzene sulfonic acid; IBD, inflammatory bowel diseases; 
NAFLD, non-alcoholic fatty liver disease; ER, endoplasmic reticulum.   
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Interestingly, a forward genetic mutagenesis screen (N-ethyl-N-
nitrosourea (ENU), see Genetic Diseases and Drug Screens, below) generated 
zebrafish mutants that develop spontaneous intestinal, pancreatic and hepatic 
neoplasias [112].  These mutants were later found to be heterozygotic for a 
truncated form of APC, thereby leading to accumulation of nuclear β-catenin and 
increased expression of downstream genes such as cmyc and axin2 [112].  
Adding the carcinogen 7,12-dimethylbenz[a]anthracene to these mutant 
zebrafish increases the frequency of tumor development.  Since germ-line 
truncated APC mutations in both humans [122, 123] and mice [124] result in the 
spontaneous development of a large numbers of intestinal polyps, the APC 
zebrafish model could be useful in genetic, drug screening and toxicology 
studies.   
There are roughly 24,000 new cases of hepatocellular carcinoma (HCC) 
annually in the United States, resulting in over 18,000 deaths per year [125].  
World-wide, the disease incidence can be as much as 30-fold higher due to the 
increased prevalence of hepatitis infections [126]; globally an estimated 564,000 
new cases occur per year, accounting for 5.6% of all human cancers [126], and 
resulting in similar rates of mortality as seen in the US [126].  Oncogenomic 
profiling of liver tumors showed a significant overlap between human and 
zebrafish in 132 genes  [113].  These genes included those involved in β-catenin 
and Ras-MAPK signaling pathways, as well as genes implicated in cellular 
adhesion, apoptosis, and liver-specific metabolism found in both organisms 
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[113]. HCC can be induced in zebrafish with the liver toxin thioacetamide, 
resulting in HCC-related pathology within 12 weeks of exposure. The timeline of 
thioacetamide-induced HCC could be significantly accelerated (6 vs 12 weeks) 
by using transgenic fish expressing the hepatitis C virus (HCV) core protein 
(HCP-transgenic fish) [114].  The increasing prevalence of HCC in humans has 
been attributed to the rise of HCV infection [127], in particular through the 
oncogenic action of the HCV core protein [128], making this model particularly 
relevant to human disease.  
Pancreatic cancer represents the fourth most common cause of cancer-
related mortality in the western world, likely due to limited diagnostic tools and 
inability to survey the disease.  Exocrine pancreatic cells are responsible for 
more than 95% of pancreatic cancer [125]. The cell population in the pancreas 
that gives rise to human exocrine pancreatic cancer remains unknown and 
investigators have turned to zebrafish models to investigate this important 
question.  Transgenic zebrafish were generated using a bacterial artificial 
chromosome (BAC) approach that expressed EGFP-KRAS fusion protein under 
the control of the zebrafish pancreatic locus ptf1a (Tg(pft1a:EGFP-
Hsa.KRASG12V)jh7 [115].  Using these fish, investigators found that while normal 
pancreatic cell progenitors differentiated normally, KRAS-transgenic fish had 
blocked cellular differentiation, producing a pool of undifferentiated progenitors 
that progressed to invasive pancreatic cancer over a course of 3 to 9 months.   
These cancer cells also had increased expression of multiple hedgehog genes 
(shh, dhh, ihha, ihhb) as well as the downstream hedgehog targets Ptc2, ptc1 
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and gli1.  This aberrant signaling pattern seen in these pancreatic tumor cells 
was also typical of human pancreatic cancer [115].  This zebrafish model 
established for the first time that oncogenic exocrine pancreatic progenitor cells 
could be the cellular origin for pancreatic cancer.   
Outside of cancer models, one area of gastrointestinal disease that has 
received significant attention in recent years is the development of zebrafish 
models of Inflammatory Bowel Disease (IBD).  In humans, IBD is the result of 
dys-regulated interactions between a genetically susceptible host and their 
commensal gut microbiota [1, 10, 11].   IBD is primarily a disease of the Western 
world; it affects 1.4 million Americans and there is no cure for the disease [12].  
Outside of North America, similar disease burdens are seen in Europe but are 
~3-fold lower in Asia and the Middle East, with the exception of Japan [129].  
Pharmacological treatment centers around the use of anti-inflammatories and 
immunosuppressants, and surgical management of the disease is also possible 
though not always curative [13].  Numerous chemicals and genetic approaches 
are currently used by the IBD research community to study this pathology.  
These models mimic various aspects of the disease, such as disrupted barrier 
function and impaired innate and adaptive immune responses [35, 130].  Among 
the chemical models, the hapten oxazolone has been used for studies of acute 
intestinal inflammation.  This murine model consists of rectal administration of a 
single dose of oxazolone dissolved in ethanol, resulting in an acute colitis lasting 
up to 10 days, with peak inflammation at 2 days post-administration in mice 
[131].  The model is characterized by a strong Th2-dependent immune response 
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that can be abrogated by IL-4 neutralizing antibodies, and has similar 
characteristics to human ulcerative colitis [35].   
Investigators have tried to adapt the hapten oxazolone model of colitis to 
adult zebrafish.  Brugman et al. showed intestinal epithelial damage and goblet 
cell depletion in oxazolone-treated fish within 5 hours of treatment, which lasts for 
up to 7 days [118]. This was accompanied by eosinophil infiltration into the 
intestine with increased il1b, tnf, and il10 gene production compared to untreated 
zebrafish.  The inflammatory phenotype was reduced by the administration of the 
gram-positive specific antibiotic vancomycin, suggesting a role for commensal 
bacteria in the inflammatory process of this model.  The main constraint of this 
model is the need to use adult, non-transparent zebrafish which severely limits 
imaging capability.  In addition, the need to rectally administer each individual 
zebrafish with oxazolone represents a technical challenge.   
The hapten 2,4,6-trinitrobenzene sulfonic acid (TNBS) is another popular 
mammalian model of colitis characterized by a Th1-driven immune response [35] 
that is used for the study of both acute and chronic intestinal inflammation.  In the 
acute model, TNBS is dissolved in ethanol and rectally administered in a single 
dose, while the chronic model can have multiple administrations weekly over a 
period of months [132].  The ethanol is responsible for disrupting the intestinal 
barrier while the TNBS serves to activate the immune system [35].  Two research 
groups have developed a larval model of colitis by exposing 3 dpf zebrafish for 3-
5 days to TNBS in the fish media [116, 117].  Using the MPO reporter strain 
(Tg(BACmpx:GFP)i114) these investigators noticed neutrophil infiltration 
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throughout the zebrafish [48], gut-specific increases in il1b expression, altered 
intestinal lipid metabolism, goblet cell hypertrophy, and intestinal shortening.  
This larval TNBS model presents several advantages, including a dose-
dependent phenotype, a sensitivity to antibiotics treatment and a response to 
anti-inflammatory agents (5-ASA and prednisolone) widely used to treat human 
IBD  [117].  However, the intestinal histo-pathologies are poorly characterized in 
this model.  In addition, the inflammatory component appears mostly to be non-
intestine-specific.  Furthermore, no intestinal epithelial cell damage is observed 
histologically [117], suggesting a lack of significant intestinal injury.  Finally, it is 
unclear how a hapten could cause an inflammatory reaction in larvae missing a 
functional adaptive immune system.  
We have recently established a model of epithelial injury in zebrafish using 
the NSAID glafenine [133].  Administration of glafenine to 5 dpf zebrafish for 12 
hours results in a dramatic increase in intestinal epithelial cell apoptosis.  This 
intestinal-specific apoptotic response is mediated by induction of endoplasmic 
reticulum (ER) stress and is accompanied by attenuation of the unfolded protein 
response (UPR) coupled to an improper activation of downstream UPR 
mediators such atf6 and s-xbp1.  Interestingly, loss of XBP1 in IECs results in the 
development of spontaneous enterocolitis in mice [19] and polymorphisms of this 
gene are associated with human IBD [17]. 
Chronic liver disease is responsible for over 25,000 deaths annually in the 
United States and represents the tenth leading cause of death, with a prevalence 
of over 5.5 million patients in 1998 [134] and that has since been estimated to 
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affect up to 30% of the US population [135].  In the UK, the picture is grimmer, as 
it is the fifth leading cause of death [136]. Non-alcoholic fatty liver disease 
(NAFLD) is a highly prevalent form of severe chronic liver disease, affecting 3% 
of all adults in America [137].  It also has significant associated mortality, with a 
5-year survival of 67% and 10-year survival of 59% [137].  Additionally, up to 
one-third of all Americans have some level of NAFLD [136]. Outside of the US, 
where obesity is less prevalent, rates are also increasing.  In Italy, which is 
traditionally considered low risk, an incidence of NAFLD of 20-25% of the 
population has been recently been reported [136].  In China and Japan, the 
disease incidence has been reported at 15% and 14% of the population, 
respectively [136].  There is no identifiable cause of NAFLD, but the pathology is 
linked to obesity, diabetes, and hyperlipidemia.  Treatment involves managing 
these complex etiologies, and pharmacological therapies specific for NAFLD are 
not available for these patients [137].  Consequently, significant work has been 
invested to develop reliable zebrafish larvae models of liver pathology that could 
be easily utilized for drug targeting and screening.   
The most characterized zebrafish model of NAFLD involved a forward 
genetic screen using viral insertion and screening for hepatomegally.  In the case 
of the NAFLD model, a 172 bp gene trap cassette was found to be inserted in the 
intron between exons 11 and 12 of the recently discovered zebrafish gene foie 
gras (foigr) [138], which results in a frame shift mutation, and generation of a stop 
codon.  This mutation (foigrhi1532b) results in the development of steatosis (fatty 
liver disease) resembling human NAFLD, characterized by large lipid filled 
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hepatocytes and cellular apoptosis in larvae as young as 5 dpf [138].  However, 
the exact function of this gene, which is highly conserved across species 
including humans, is not yet determined.  Further studies with the foigr mutant 
have shown that the apoptosis observed involves increased ER stress and is 
regulated in part through the UPR gene atf6.  Morpholino blockade of atf6 
ameliorates liver injury during chronic ER stress in the foigr mutants [119].  
However, atf6 blockade potentiates steatosis during acute ER stress induced by 
the toxin tunicamycin [119], suggesting that atf6 may have variable effects in 
different phases (acute/chronic) of liver injury.  Hepatic steatosis has also been 
induced in zebrafish larvae using thioacetamide [120].  Investigators have 
showed that administration of 0.025% thioacetamide into the fish media at 3 dpf 
resulted in liver damage by 5 dpf, characterized by increased accumulation of 
fatty droplets, hepatocyte apoptosis and up-regulation of apoptotic genes such as 
bad, bax, p-38a, caspase-3 and 8, and jnk-1.  Overall, the availability of NAFLD 
zebrafish models is burgeoning, and they are poised to be screened for 
pharmacological compounds that could for the first time effectively treat this 
disease.   
Alcoholic fatty liver disease (ALD) is estimated to be involved in over 50% 
of all deaths due to liver failure secondary to liver cirrhosis, but accurate 
estimates for prevalence are unavailable [134].  Binge drinking leads to transient 
fatty liver disease, but chronic alcohol consumption can lead to fibrosis, cirrhosis, 
and steatohepatitis [139]. An ALD model has also been developed in zebrafish 
with administration of 2% ethanol to the water of 4 dpf zebrafish for 32 days.  
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This regimen results in hepatomegally and steatosis, alongside up-regulation of 
hepatic cyp2e1, sod, and bip gene expression—indicating hepatotoxic 
metabolism of the ethanol [121].  Importantly, ethanol-induced steatosis was 
prevented by morpholino blockade of the sterol regulatory binding protein 
(Srebps).  Because Srebps activation is important in chronic alcoholic liver 
disease [121] in humans, the zebrafish ALD model could be utilized to identify 
new therapeutic mechanisms and to screen for therapeutic agents.   
Microbe-Host Interactions 
The ability to generate germ-free and gnotobiotic zebrafish [140] has led 
to an increasing interest in understanding cellular and molecular mechanisms of 
microbial-host interactions using zebrafish.  Microbial-host interactions have 
received significant interested in recent years and have been implicated in a wide 
variety of human diseases, including CRC [141], IBD [1, 11], obesity and 
diabetes [142], intestinal healing [2], irritable bowel syndrome [143] and 
inflammatory nociception [144].  Zebrafish are host to gram-positive and gram-
negative bacteria, mycobacteria, protozoa, and viruses [145], also allowing for 
their use as a model for infectious diseases. In most cases, microorganisms 
associated with these pathologies are not intrinsically pathogenic, but are rather 
part of the normal, commensal biota.  The organ exposed to the highest amount 
of microorganisms in the human body is the gastrointestinal (GI) tract, especially 
the distal ileum and colon. Because of the high prevalence of bacteria and 
bacterial products in the GI tract, investigators have studied mechanisms 
controlling homeostasis in the face of such highly antigenic materials.  The 
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zebrafish GI tract also harbors the highest concentration of bacteria and as such 
represents an interesting model to study bacterial/host interactions.   
Bacteria and their associated products such as DNA, RNA and membrane 
structures (peptidoglycans, LPS--lipopolysaccharide) are typically detected by a 
series of innate sensors that are evolutionary conserved.  A survey of the 
zebrafish genome has identified numerous innate sensors from the TLR and the 
Nod-like receptor family, as well as their associated signaling pathways [146].  
An almost complete set of TLRs (TLR1-5, 7-9, 21 [147]) exist in zebrafish, as do 
the intracellular sensors Nod1 and Nod2 [148].  Associated innate signaling 
proteins have also been identified in zebrafish such as myeloid differentiation 
primary response gene (MyD88) [147, 149], TIR domain-containing adaptor 
inducing IFN-β (TRIF) [150] and NF-κB [151, 152].   
The most studied bacterial product is arguably the gram-negative derived 
LPS.  In mammals, LPS is detected by TLR4, in association with the co-receptors 
MD2 and CD-14 [153].  Once engaged, TLR4 recruits the adapter protein Myd88 
or TRIF to propagate the signal to NF-κB [154] and the interferon responsive 
factor (IRF) 3, respectively [155].  This signaling cascade plays a critical role in 
host response to microbes and microbial products.  As in humans, high doses of 
LPS are toxic to zebrafish [156]. Studies using commensal and germ-free 
zebrafish established that intestinal alkaline phosphatase (iap), known to detoxify 
the endotoxic lipid moiety A of LPS in mammals, is induced following microbial 
colonization [156].   Knockout of iap resulted in excessive intestinal neutrophil 
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infiltration, a process involving functional myd88 and tnfr as determined by 
morpholino blockade [156].   
Another important TLR system is TLR5, which detects flagellin and 
activates various signaling pathways including NF-κB [153].  Similarly to 
mammals, zebrafish detect flagellin (Salmonella-derived in these experiments) to 
induce multiple matrix metalloproteinase genes, as well as the inflammatory 
markers il1b, il8, ifn and cxcl-C1c  [157]. Morpholino blockade showed that 
flagellin-induced Il1b and metalloproteinase 9 (mmp9) were myd88 dependent 
whereas ifn and il8 were activated through another signaling system [157].       
The function of some of these TLR downstream signaling adaptors have 
also been studied in zebrafish.  Both red and green transgenic Myd88 reporter 
strains such asTg(myd88:EGFP)z163 and Tg(myd88-DsRED2)z164 have been 
developed [149]. These strains have been crossed to both macrophage 
(Tg(lyz:DsRED2)nz50 [158]) and neutrophil (Tg(BACmpx:GFP)i114 [48]) reporter 
strains to monitor myd88 signaling.  Studies with these dual-reporter fish 
demonstrated that MyD88 co-localized with both macrophages and neutrophils, 
and that these myd88-expressing leukocytes migrated to wound sites and were 
involved in bacterial phagocytosis [149]. 
 Another downstream mediator of LPS signaling, acting independently of 
MyD88, is TRIF.  While zebrafish TRIF shares only 32% homology with the 
human protein, like in mammalian systems it can induce IFN and NF-κB 
luciferase-reporter responses as seen using an over-expression system in 
human HEK293T cells [150].  Interestingly TRIF-dependent gene induction 
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through the TLR4 pathway was found to be non-functional in experiments with 
adult zebrafish stimulated with LPS [150]; however, this is to be expected given 
that zebrafish TLR4 paralogues (tlr4a and tlr4b) do not recognize LPS [159, 160].   
Outside of the TLRs, the intracellular sensors Nod1 and Nod2 are critical innate 
signaling systems in mammals.  Importantly, Nod2 was the first innate signaling 
molecule to be genetically linked to Crohn’s disease susceptibility [161].  The 
exact protective role of Nod proteins in mammals is not fully understood but 
defective bacterial killing appears to be an important factor [161-163].  Both nod1 
and nod2 genes are expressed in IECs and neutrophils of zebrafish.  Functional 
studies using morpholino blockade showed that Nod2 plays an important role in 
setting host anti-microbial properties [148].  Interestingly, Nod1 or Nod2 depletion 
resulted in increased susceptibility to Salmonella infection in a zebrafish 
embryonic infection model [148].  This study suggests that the anti-microbial 
properties of Nod2 are conserved in zebrafish.  
As mentioned above, NF-κB signaling is an important effector pathway 
downstream of numerous innate sensor systems [164].  Colonization of germ-
free NF-κB;EGFP reporter zebrafish Tg(NFkB:EGFP)nc1 with a commensal 
microbiota induced NF-κB activation and expression of NF-κB target genes 
including complement factor b (cfb) and serum amyloid a (saa) in intestinal as 
well as in extra-intestinal tissues of the GI tract [165].  Activation of NF-κB 
signaling in zebrafish indicates an important role of this transcription factor in 
maintaining host homeostasis that is conserved across species. The ability to 
longitudinally study NF-κB activation in a cell-type specific fashion in response to 
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various microbial stimuli makes the zebrafish a powerful system to decipher 
complex host-microbe interaction.  Overall, the recent development of the 
aforementioned technologies makes the study of microbial-host interactions in 
zebrafish a burgeoning area of research.   
Response to infection is another area of microbial-host interaction that has 
received significant attention in zebrafish.  The most studied and prominent 
zebrafish infectious model is the M. marinum model, which is highly analogous to 
the human infectious agent M. tuberculosis, the etiologic agent for Tuberculosis 
(TB).  TB is a growing epidemic worldwide, with over 83 million cases reported 
between 1990 and 1999, resulting in over 3 million deaths annually [166].  Many 
strains of the infectious bacteria are becoming drug resistant, resulting in an 
increase in global disease burden, including in the Unites States [167].  Finding 
new drugs to combat the ongoing threat of TB is consequently essential, as the 
disease can no longer be contained with current medications [168].  Co-
incubation of M. marinum with 5hpf embryos results in the formation of 
macrophage-driven granulomas within 5 dpf [169], a hallmark of TB pathology.  
In vivo imaging and macrophage depletion showed that granulomas, traditionally 
thought to be a host-protective mechanism, may in fact be a source of early TB 
tissue dissemination by passing M. marinum into uninfected macrophages during 
phagocytosis [170] [171].  Consequently, this system has provided novel insights 
into the pathological mechanisms of TB infection and its interactions with the host 
immune system, and is poised to be used as a drug screen to identify novel anti-
TB compounds.   
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Other pathogens have also been studied in zebrafish.  These include S. 
aureus, S. pyogenes, and S. typhimurium.  These and other infectious models in 
zebrafish have recently been reviewed in detail by Meeker, et al [100].  Although 
very informative, these studies were not performed using a natural route of 
infection but rather by using direct delivery (injection) into embryos at various 
developmental stages.  However, oral gavage technology in larvea would likely 
improve the physiological relevance of infectious models perform in zebrafish.  
Another limitation of zebrafish infection models is the difference in host 
temperature; zebrafish and their natural pathogens exist at a temperature of 
28°C, while many human-relevant pathogens are only infectious at 37°C [100].  
Finally, there is some evolutionary divergence in TLR signaling that must be 
taken into account when working with this organism.  Specifically, in contrast to 
mammals, LPS is not sensed by zebrafish TLR4 and the sensor negatively 
regulates MyD88 signaling [159].  Despite these limitations,  zebrafish remain a 
powerful tool for studying microbe-host interactions [146].    
Genetic Diseases and Drug Screens 
Because of their high fecundity, transparency and ease of imaging, 
zebrafish are particularly well suited for genetic screening approaches.  Forward 
and reverse genetic approaches can be undertaken to generate new zebrafish 
phenotypes and identify new genes of interest with potential relevance to human 
disease phenotypes.  Zebrafish disease models can also be screened in a cost- 
and time-effective manner to discover disease-suppressing compounds.  Using a 
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whole organism is a particularly appealing aspect of zebrafish-based screens, 
since complex cell-cell and organ-organ interactions are kept intact.   
There are two main approaches to forward-genetic screens in zebrafish 
that have been undertaken thus far.  The first involves exposing males to the 
mutagen ethylnitrosourea (ENU) and then screening for a phenotype [172, 173] 
shared by all mutants, such as renal cysts or heart failure.  ENU is an alkylating 
agent that typically induces AT base transversions.  Zebrafish are relatively 
resistant to the ENU toxic side effects, allowing for higher dosages and thus 
increased rates of mutation [47].  An alternative mutagenesis approach employs 
random retroviral insertion [174, 175].  While this retroviral method is only one-
ninth as efficient at generating a mutation as the ENU approach, it circumvents 
the need for positional cloning by tagging each insertion event, saving significant 
screening effort once a phenotype is found.   
Duchenne muscular dystrophy (DMD) affects 1 in 3500 males and causes 
progressive muscle degeneration that can lead to death.  DMD is the result of 
mutations in the sarcolemmal protein dystrophin located on the X-chromosome 
[176].  During an ENU screen of zebrafish [173], a mutation referred to as sapje 
[177] was discovered. This mutation was later found to be located in the 
zebrafish Duchenne muscular dystrophy (dmd) gene and causes progressive 
muscular degeneration in zebrafish larvae [178].  Electron microscopy showed 
that muscular degeneration was the result of failure to form proper muscle 
attachments at the myotendinous junction.  This pathological mechanism was 
hypothesized to occur in mammals but was lacking concrete evidence, making 
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the zebrafish a novel system for studying the pathophysiology of this devastating 
disease.   
The most common form of heritable polycystic kidney disease (PKD) is 
autosomal dominant PKD.  This disease affects more than 1 in 1000 live births  
and approximately 10% of patients with PKD will require kidney transplant due to 
renal failure [179].  PKD has been linked to defects in primary cilia formation and 
function in humans [179].  This disease has also been successfully modeled in 
zebrafish by using retroviral insertion mutagenesis and screening for cystic 
kidneys in 5 dpf larvae [180]. The screen discovered 12 genes whose loss 
formed cysts in the glomerular-tubular region, including two already associated 
with human disease (vhnf1 and pkd2), demonstrating genetic and phenotypic 
homology between humans and zebrafish.  Three of the 10 remaining genes are 
homologues of Chlamydomonas (a genus of green algae) genes, which encode 
components of intraflagellar transport particles involved in cilia formation [180], 
but have yet to be analyzed in human PKD patients.  The other 7 genes 
discovered provide completely novel targets for studying the underlying genetics 
and mechanisms of PKD, as many of the genes that can result in PKD remain 
unidentified in humans [179].  
Dilated cardiomyopathy (DCM) is the cause of at least half of the 5.8 
million heart failure cases in the US, typically resulting from prior heart damage 
due to a myocardial infarction or an infection [181].   World-wide, DCM is the 
leading indicator for heart transplant [182]; with incidences to be as high as 9.6 
per 100,000 person-years in Europe [182] and China [183]. DCM results in poor 
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heart function that eventually leads to death [181].  ENU zebrafish screens 
discovered numerous fish with cardiac abnormalities [172, 184, 185].  Two of 
these mutants, sih and pickwickm171, were found to have dilated hearts with thin 
walls and defective contractility [186, 187].  Further analysis showed that the sih 
(silent heart) mutants had a mutation in cardiac troponin T gene [186], while the 
pickwickm171 mutants had a mutation in the titin gene [187].  Since both of these 
genes are known to be important in human DCM, these mutants zebrafish 
represent interesting and complementary models to study this pathology. 
All of the aforementioned models demonstrate that forward genetic screens in 
zebrafish can generate specific phenotypes that are highly homologous to human 
diseases.  Further analysis of these mutants almost invariability lead to the 
identification of a gene with high homology and relevance to corresponding 
human disease.   
Targeted, reverse genetic approaches are also quite successful in 
generating models of disease, especially if a homolog exists between the human 
gene(s) driving the disease and the zebrafish.  One disease that has recently 
been modeled in zebrafish using a reverse-genetic approach is Hutchinson-
Gilford progeria syndrome (HGPS), a rare (1:4,000,000 people) premature 
senescence syndrome that generally results from sporadic mutations that 
disrupts conversion of prelamin A to mature lamin A [188].  HGPS patients have 
markedly aberrant development characterized by lipodystrophy, osteolysis that is 
most pronounced in the cranium, and coronary dysfunction [188].  The mean life 
expectancy for patients with HGPS is less than 13 years.  In zebrafish, 
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investigators were able to use a combination of directed loss of function 
mutations and morpholino knockdowns of prelamin and progerin to generate 
zebrafish that were able to live to adulthood (though with shortened lifespans).  
These fish had both phenotypic and molecular signs of early senescence, 
including lipodystrophy, aberrant musculature and craniofacial skeletal structure, 
increased cellular apoptosis, and cell-cycle arrest [189].  These phenotypic 
manifestations align remarkably well with those seen in human HGPS, 
demonstrating a proof of concept for reverse genetic approaches to developing 
zebrafish models of human diseases.     
Some of the mutants generated during forward-genetic screens have been 
subsequently subjected to drug screening methodologies.  The ability to rapidly 
and easily image large numbers of developing zebrafish makes them highly 
tractable as a pre-clinical system for drug screens [190].  A prototypical example 
of drug screening in mutant zebrafish discovered with the ENU forward-genetic 
approaches involves the gridlock (grl) mutant.  The grl mutant lacks blood flow to 
the posterior trunk and tail due to a localized block in caudal blood flow at the 
base of the dorsal aorta [191].  This model has many characteristics similar to the 
human congenital disease coarctation of the aorta, making it of significant clinical 
interest.  Coarctation of the aorta involves narrowing of the aorta that affects 1 in 
2,500 live births [192].  It is the fifth most common form of congenital heart 
defect, and without surgical treatment the mean age of survival is only 31 years 
of age [192].  Surgical intervention can prevent early death, but significant 
morbidity, usually in the form of hypertension, can persist and results in 
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decreased life expectancy [192].  Unfortunately, no clear etiology of the disease 
exists, and the grl model in zebrafish is the best animal model currently in 
existence for the study of this disease [192]. 
The grl zebrafish has a hypomorphic mutation in the hey2 gene, a basic 
helix-loop-helix protein involved in aortic development [193].  Gene titration 
studies using morpholino technology demonstrated that dose-dependent loss of 
this gene results in ablation of progressively larger sections of the aorta and 
expansion of the contiguous region of vein [194].  A pharmacological screen, 
assessing restoration of blood flood and survival of larvae using bright-field 
microscopy, found that two structurally related compounds (GS3999 and 
GS4012, unknown targets) promoted activation of the vascular endothelial 
growth factor (VEGF) pathway and were able to rescue the phenotype [195].  
Another unrelated screen found that phosphoinositide-3-kinase (PI3K) inhibitors 
were also able to rescue the phenotype by driving VEGF activation [83].  This 
included the uncharacterized flavone GS4898, a structurally similar compound to 
the PI3K inhibitor LY294002, and the PI3K inhibitor wortmannin.  This work also 
demonstrated for the first time that ERK signaling in embryos drives aortic 
differentiation, while activation of PI3K signaling produces a veinous fate.  These 
findings have since been recapitulated in a murine system and have provided 
new insights into arterial morphogenesis [196], as well as generated some of the 
first insights into the underlying mechanisms behind coarctation of the aorta in 
humans. 
47 
 
A pair of robust screens has also been performed to evaluate compounds 
known to induce prolonged QT intervals in humans in the hopes of developing a 
pre-clinical cardiac toxicity screen.  Cardiac QT elongation, which can cause the 
fatal heart arrhythmia known as Torsade de Pointes, is required to be evaluated 
in clinical drug trials [197] and thus these screens are of great clinical 
importance.  Two such screens to evaluate bradycardia, atrioventricular blockade 
and arrhythmias in zebrafish have been performed thus far [198, 199].  In the first 
study 100 biologically active compounds were screened and 18 of the 23 that 
caused arrhythmias in humans were also positive in the zebrafish, while post-
screen analysis showed that poor absorption explained 4 out of 5 of the false-
negatives [199].  Additionally, the combination of erythromycin and cisaperide 
was also positive during screening while each drug alone was not, recapitulating 
a known drug-drug interaction that causes arrhythmias in humans.  
Consequently, the zebrafish holds significant promise to be used as a screen to 
evaluate new drugs for their potential to generate this serious and often fatal side 
effect.   
Overall limitations  
The use of zebrafish as a model organism for studying human disease is a 
relatively new and emerging field of research.  Consequently, the number of 
available zebrafish strains and facilities that house zebrafish is much smaller 
than for well-developed model higher vertebrate organisms such as the mouse.  
Additionally, very few validated zebrafish reagents such as antibodies and cell 
lines are available to the research community.  This significantly curtails the in-
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depth investigation of molecular and cellular details implicated in a given 
phenotypes.  
Zebrafish also have numerous duplicate genes [200], which significantly 
complicate generation of knockout strains using either forward or reverse-genetic 
approaches.  Forward-genetic approaches that disrupt one gene copy likely will 
not disrupt the second copy, and duplicate genes also make targeted knockout 
strategies more difficult as both copies must be deleted.  Additionally, while the 
zebrafish genome has been fully sequenced, the annotation is still limited and 
more of a work in progress.  Furthermore comparative genomic analyzes 
between zebrafish and the human or murine genome counterparts have yet to be 
performed.    
Zebrafish also have environmental conditions that differ substantially from 
humans.  They must be raised in water with specific ionic concentrations and 
temperature (28°C).  Consequently, some water-insoluble small molecules 
cannot be administered to zebrafish because carrier solvents (such as EtOH or 
DMSO) would reach toxic levels before solubility is achieved.  Additionally, since 
drugs are administered directly to the fish media, bathing the entire fish in the 
test compound can result in non-desired toxic side effects.  An example in our 
hands was the attempt to use dextran sodium sulfate (DSS) to induce colitis in 
larval zebrafish.  At concentrations as low as 0.01% (v/v) the surfactant 
properties of the DSS choked the gills of the zebrafish, resulting in their death 
before an intestine-specific effect could be observed (Goldsmith and Jobin, 
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unpublished observation).  As discussed in a previous section, the development 
of an oral gavage approach could circumvent this important limitation.  
Perspectives  
Animal models have been used since the inception of medical research.  
For most models of human disease, the preferred and most utilized animal 
system of human disease is overwhelmingly the murine system.  Despite the 
tremendous gain of knowledge provided by using murine experimental systems, 
the long gestation time (18-20 days), and sexual maturation rate (6-8 weeks) 
combined with high cost of housing and breeding represent significant limitations. 
Furthermore, experiments with mice are labor-intensive and not particularly well 
suited for high-throughput screening. These limitations have spurred the need to 
develop other model organisms that could be used to provide initial gene or drug 
targets information before beginning investigations in more expensive systems.   
Transparent, larval zebrafish models have the potential to fill this important niche 
in the study of human disease, enabling rapid, physiologically-relevant in vivo 
screening.  The transparent nature of zebrafish also allows for real-time imaging 
of pathogenesis, which has already provided key insights into the molecular 
mechanisms of metastasis [201-204] and tuberculosis dissemination [169-171].  
The recent advent of the Casper fish promises to extend the imaging capacity 
beyond larvae to adult fish, permitting studies in fish with a functional adaptive 
immune system.  The zebrafish has already demonstrated profound bench-to-
bedside power, as evidenced by the rapid translation time (~2-years) from the 
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initial reports of the role of H2O2 in neutrophil chemotaxis during wound healing in 
zebrafish [49] to the first utilizations of such knowledge in human patients [106].   
The zebrafish remains a relatively underdeveloped model organism with large 
amounts of untapped potential.  As more is understood about the comparative 
genome, anatomy and physiology of zebrafish to that of humans, the relevance 
and utility of this vertebrate model will only grow and provide a powerful 
complement to the murine system.  Two decades of research has demonstrated 
the power and relevancy of the zebrafish in modeling human disease.  Its unique 
properties make it an ideal in vivo system for initial use in the interrogation of a 
given pathology before translating the observations made in the model organism 
to more expensive murine systems.   
 
  
 
CHAPTER 3  
 
ZEBRAFISH GLAFENINE-INTESTINAL INJURY IS AMELIORATED BY MU-
OPIOID SIGNALING VIA ENHANCED AUTOPHAGY2
Introduction 
 
Beside their analgesic properties, opiates exert beneficial effects on the intestinal 
wound healing response. In this study, we investigated the role of mu-opioid 
receptor (MOR) signaling on the unfolded protein response (UPR) using a novel 
zebrafish model of NSAID-induced intestinal injury.  The NSAID glafenine was 
administered to 5 days-post-fertilization (dpf) zebrafish larvae for up to 24h in the 
presence or absence of the MOR-specific agonist DALDA.  By analysis with 
histology, transmission electron microscopy, and vital dye staining, glafenine-
treated zebrafish showed evidence of endoplasmic reticulum (ER) and 
mitochondrial stress with disrupted intestinal architecture and halted autophagy, 
alongside accumulation of apoptotic intestinal epithelial cells in the lumen.  While 
the early UPR marker BiP was induced with glafenine-injury, downstream atf6 
and s-xbp1 expression were paradoxically not increased, explaining the halted 
autophagic responses.  The mu-opioid agonist DALDA protected against 
glafenine-induced injury through induction of atf6-dependent UPR and 
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autophagy. Our findings show that DALDA prevents glafenine-induced epithelial 
damage through induction of effective UPR and autophagy.   
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Background 
Intestinal homeostasis is achieved in part by the maintenance of a 
functional barrier composed of a single layer of intestinal epithelial cells (IEC), 
which separates the host from the highly antigenic lumenal milieu [1]. Events 
leading to compromised barrier function are associated with various intestinal 
disorders including inflammatory bowel diseases (IBD) [1, 5]. Conditions leading 
to an impaired mucosal barrier function are diverse and include medications 
(non-steroidal anti-inflammatory drugs or NSAIDs [4]), radiation exposure[2], 
ischemic episodes [3], and genetic predisposition [1].  Notably, genes that disrupt 
the unfolded protein response (UPR) and autophagy following cellular stress 
have recently been implicated in the pathogenesis of IBD [17, 18].  The disease 
etiology remains unclear, however genetic evidence and experimental models 
suggest that intestinal cell death due to improper responses to ER stress leads to 
impaired barrier function [19].  Because of the importance of the epithelium in 
maintaining intestinal homeostasis, understanding mechanisms involved in 
intestinal epithelial healing and autophagy responses, and the identification of 
compounds that promote these processes, could lead to new therapeutic 
strategies for IBD.  
Epithelial barrier damage triggers a host response termed 
restitution/wound-healing [10].  In this response, cells at the wound edge migrate 
into the wounded area, undergo cytoskeletal rearrangement, and finally re-
establish tight junction barriers with their neighboring cells [10, 29].  This initial 
phase does not require epithelial proliferation, but renewal of cells are needed to 
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replenish the decreased enterocyte pool after injury [10]. Various pathways 
including NF-κB, MAPK, STAT3, GSK3β/β-catenin [33] and PI3K/Akt [10] are 
involved in the wound healing response through a combination of pro-migratory, 
proliferative and/or anti-apoptotic activities. The mu opioid receptor (MOR) ligand 
DALDA has also recently been shown to activate the intestinal wound healing 
response in mice [205].  However, the mechanism of MOR-mediated protection 
is largely unknown at this point. 
The wide array of upstream signals and downstream pathways has made 
the study of restitution/wound healing a complex and difficult area of research 
[10, 164]. The vast majority of our information on this complex process is derived 
from rodent models, which have limited capacity for imaging techniques and 
therapeutic investigation [35].  Zebrafish (Danio rerio) possess several features 
that make it an attractive model for in vivo investigation of intestinal injury.  
Zebrafish are transparent through early adulthood, allowing for the use of live, in 
vivo imaging techniques.  Furthermore, the anatomy and physiology of their 
digestive tract is similar to mammals, with a pancreas, liver, gall bladder, and 
intestine [109, 110].  The zebrafish intestinal epithelium displays proximal-distal 
functional specification, and contains most of same cell lineages found in 
mammals including absorptive enterocytes, goblet cells, and enteroendocrine 
cells [109, 110].  The zebrafish digestive tract develops rapidly to permit feeding 
and digestive function by 5 days post fertilization (dpf).  Zebrafish also possess 
innate and adaptive immune systems homologous to those of mammals [146, 
206].  Previous studies have attempted to establish models of intestinal injury in 
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zebrafish larvae by immersion in the hapten TNBS; however, these models lack 
overt pathological changes to the intestinal tract based on histology, and the 
inflammation and injury produced is not intestine-specific [116, 117].   
Here, we developed a novel larval zebrafish model of acute intestinal 
injury using the NSAID glafenine.  NSAIDs are known to disrupt the intestinal 
epithelium, leading to ulceration and inflammation in both humans and in mice [4, 
207].  Additionally, zebrafish have homologs for both cyclooxygenase (COX) 
isoforms (the targets of NSAIDs) that function similarly and display the same 
responses to prototypical pharmacological inhibitors as seen in mammals [208].  
Our work establishes that administration of glafenine larvae for 1-12h results in 
profound intestinal injury, with limited evidence of damage in extra-intestinal 
location.  Immersion in glafenine resulted in intestinal epithelial cell (IEC) 
apoptosis and sloughing due to induction of ER stress combined with inhibition of 
appropriate compensatory UPR and autophagic responses.  In contrast to 
previous reports of 2,4,6-trinitrobenzene sulfonic acid (TNBS) injury in the 
zebrafish [116, 117], the glafenine injury model shows profound pathological 
changes to the intestine, and appears to be specific to the gastroenterological 
system.  We demonstrate for the first time that MOR signaling induces the UPR 
and autophagic signals to enhance restitution, thereby protecting against 
glafenine-induced intestinal injury.     
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Materials & methods 
Fish husbandry, zebrafish lines and drugs 
All experiments using zebrafish were performed using protocols approved 
by the Animal Studies Committee of the University of North Carolina at Chapel 
Hill.  Zebrafish were maintained as previously described[209] All experiments 
were performed on zebrafish at 5.5-6 days post-fertilization (dpf).  Fish were 
plated into 10cm diameter petri dishes, with 20mL gnotobiotic zebrafish medium 
(GZM)[140], to a maximum of 20 fish/plate the day of the experiment, and all 
drugs (glafenine plus any therapeutics) were administered simultaneously to the 
water for the indicated period of time.  Isovolumetric vehicle controls were used 
for all experiments.  Wild-type TL zebrafish were used for most assays in these 
studies.  Blood flow analysis was performed with 
Tg(gata1:dsRed)sd2;(kdr1:EGFP)s843 [210, 211] zebrafish, and NF-κB activation 
was assessed with Tg(NFkB:EGFP)nc1 zebrafish[165].  Glafenine (Sigma-Aldrich, 
St. Louis, MO) was dissolved in DMSO, and administered at 25μM final 
concentration for all experiments unless otherwise noted.  DALDA (US Biological; 
Swampscott, MA) administered at 10μM.  Indomethacin and Naloxone were 
obtained from Sigma Aldrich.  Sc-560, Ns-398 and dmPGE2 were obtained from 
Cayman Chemicals (Ann Arbor, MI); R-spondin1, hIGF1 and mEGF were 
obtained from R&D Systems (Minneapolis, MN); Q-VD-Oph was obtained from 
BioVision (Mountain View, CA). 
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Acridine orange tube assay 
Fish were submerged in a 1μg/mL solution of acridine orange (AO) 
(Sigma-Aldrich) and were then anesthetized in 0.017% tricaine, and mounted in 
3% methylcellulose for visualization using a Leica MZ16F fluorescence 
stereomicroscope with a dsRed filter.  Larvae were scored for the presence of an 
AO-positive tube extending from the intestine out of the cloaca, or for the 
presence of a strong, red signal in intestinal segment 2. Zebrafish with one of 
these two characteristics were deemed “positive”.   
Fish imaging and fluorescence quantification 
Live zebrafish were anesthetized with 0.017% tricaine (MS-222; Sigma-
Aldrich, St. Louis, MO), mounted on 3% methylcellulose, and imaged with a 
Leica MZ16F fluorescence stereomicroscope. Within a given experiment, 
exposure times and magnifications were held constant.  Relative fluorescence 
intensity was determined with ImageJ [212], using equal-sized boxes for the 
region of interest (ROI). 
Histology and immunohistochemistry 
Larvae were collected and fixed in 4% paraformaldehyde/PBS overnight, 
then transferred to 70% ethanol for another 24 hours.  Fish were then embedded 
axially in 1% agarose and paraffin embedded. Fish were serially sectioned axially 
and the distance from the cloaca of each section was established based on 
section thickness and section number, to determine the section being viewed.  
We developed a histological scoring system in conjunction with a veterinary 
pathologist (see Figure 6A), using only segment 2 sections due to their more 
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consistent histological presentation.  Histological scores were verified by a 
blinded pathologist.  IHC for activated caspase 3 (R&D Systems, Minneapolis, 
MN) was performed as described[213].  5-ethynyl-2'-deoxyuridine (EdU) staining 
was performed using the Edu Click-iT® kit (Invitrogen; Carlsbad, CA), according 
to manufacturer’s protocol, with a final EdU concentration of 15 μg/mL.  Fish 
were exposed to EdU for the same duration as glafenine and any other 
treatments (12 hours).  Bright-field histological images were taken on an 
Olympus IX70 (Olympus; Center Valley, PA) with the default Olympus DP 
Controller software.  An Olympus, UpLan Fl 40X, 0.75 NA objective was used.  
For fluorescence images, a Zeiss 710 microscope with an oil immersion, 40X, 1.4 
NA objective was used (Carl Zeiss; Thornwood, NY).  Zeiss Zen 2009 software 
was used for image acquisition.  All images were acquired at room temperature. 
Electron microscopy  
 Zebrafish were collected, euthanized with tricaine (0.083%), and 
immersion-fixed in 2% formaldehyde/2.5% glutaraldehyde/0.1M sodium 
cacodylate buffer, pH 7.4, overnight to several days at 4˚C. Following post-
fixation for 1 hour in potassium ferrocyanide-reduced osmium[214], specimens 
were dehydrated through a graded series of ethanol and embedded in Polybed 
812 epoxy resin (Polysciences, Warrington, PA). Transverse 1µm sections were 
cut at several locations along the gut, stained with 1% toluidine blue/1% sodium 
borate and examined by light microscopy to confirm region of interest. Ultrathin 
sections were cut with a diamond knife (70-80 nm thickness), mounted on 200 
mesh copper grids and stained with 4% aqueous uranyl acetate for 15 minutes 
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followed by Reynolds’ lead citrate for 8 min[215]. The sections were analyzed 
using a LEO EM-910 transmission electron microscope (Carl Zeiss SMT, Inc., 
Peabody, MA), operating at an accelerating voltage of 80 kV.  Digital images 
were taken using a Gatan Orius SC 1000 CCD Camera and DigitalMicrograph 
3.11.0 software (Gatan, Inc., Pleasanton, CA).  All images were acquired at room 
temperature.   
Oral micro-gavage and barrier function assay 
Wild-type TL zebrafish larvae at 6dpf were pre-treated in a petri dish 
containing 20mL of GZM plus 0.1mM PTU (to inhibit melanin synthesis) with 
Glafenine (25µM) or the equivalent amount of the DMSO vehicle control (0.025% 
v/v) for 1 or 3 hrs at 25oC. Following treatment, larvae were gavaged as 
previously described (Cocchiaro and Rawls, in preparation) with 1% TxR-dextran 
(10,000 MW, D1863; Invitrogen/Molecular Probes) or 1% TxR-dextran plus 
20mM EDTA (positive control). Briefly, larvae were anesthetized in 0.026% 
tricaine, and mounted in 3% methylcellulose layered on an agarose injection 
mold to position the larvae for gavage and hold them gently in place. Borosilicate 
glass capillary needles specifically designed for gavage were clipped as bluntly 
as possible. Using a Drummond Nanoject II microinjection apparatus and 
stereomicroscope, gavage needles were carefully maneuvered into the mouths 
of anesthetized larvae, through the esophagus, and just inside the anterior bulb 
of the intestine by gently depressing the esophageal sphincter. The dextran 
gavage solution (4.6 nl on the slow setting) was administered into the anterior 
bulb. Following gavage, fish were moved to fresh GZM/PTU media, washed 
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gently to remove methylcellulose, and revived from anesthesia.  At 15-20 min 
post-gavage, larvae were re-anesthetized, mounted in 3% methylcellulose on top 
of a 3% agarose block (to reduce reflection glare), and imaged on a Leica 
M205C fluorescence stereomicroscope. The same magnification and gain 
settings were used for all images.  ImageJ software was used to quantitate mean 
relative fluorescence in a region of interest in the larvae trunk above the posterior 
intestine (trunk ROI) and an ROI outside of the fish (background ROI). To ensure 
consistency in measurement, the posterior side of the trunk ROI was always 
aligned with the end of cloaca just above the intestine.  GraphPad Prism 5.0 was 
used for graphs and statistical analysis. The assay was also performed for larvae 
pre-treated for longer at 12-14h (data not shown). 
RT-PCR 
 Total RNA was isolated from either whole zebrafish larvae or 
microdissected digestive tracts using an Ambion Purelink Kit (Invitrogren) 
according to manufacturer’s protocol and RT-PCR was performed as 
described[165], using a ABI Prism HT7700. Specificity and linearity of 
amplification for each primer set was determined by melting curve analysis and 
calculation of the slope from serial diluted samples. Relative fold-changes were 
determined using the ΔΔCT calculation method. Values were normalized to the 
internal control 18S RNA.  Primers: atf6 (5’-CTGTGGTGAAACCTCCACCT-3’ 
and 5’-CATGGTGACCACAGGAGATG-3’), xbp1 (5’-
GGGTTGGATACCTTGGAAA-3’ and 5’-AGGGCCAGGGCTGTGAGTA-3’), xbp1-
s (5’-TGTTGCGAGACAAGACGA-3’ and 5’-CCTGCACCTGCTGCGGACT-3’), 
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18S (5’-CACTTGTCCCTCTAAGAAGTTGCA-3’ and 5’-
GGTTGATTCCGATAACGAACGA-3’ were previously described [119, 165]).  
PCR for analysis of atf6 morpholino efficacy was performed using specific 
primers for atf6 (5’-TAGCCTACACTTTTCACCAG-3’ and 5’-
ATGTCGTCGAATTTAATGTTAG-3’) and final products visualized on a 3% 
agarose gel[119]. 
Morpholino knockdown 
Zebrafish embryos at the 1- to 2-cell stage were injected with splice-
blocking Morpholinos (MOs; GeneTools LLC) targeting atf6 (4.6 pmol/embryo, 
GAGTGGGGTAAGATACACGTTCTAG; generously provided by Dr. Kirsten 
Sadler Edepli, Mount Sinai School of Medicine); or standard control MO (4.6 
pmol/embryo; Gene Tools LLC) using a Drummond Nanoject II microinjector. 
Efficacy of atf6 knockdown was measured by PCR. 
 
Cell Culture 
Zebrafish Pac-2 cells (passages 20-25, American Type Culture Collection, 
Manassas, VA) were grown in L15 (Lebovitz) media supplemented with 15% fetal 
bovine serum (FBS) [216] and pen/strep antibiotic solution.  Cells were housed in 
an incubator kept at 28°C, without humidification or supplemental CO2. Cells 
were starved overnight in 1% FBS without the antibiotics before experiments 
were performed.   
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Protein isolation and Western blot analysis 
Whole 6 dpf zebrafish were euthanized with 0.083% tricaine and 
homogenized for 15 sec with a polytron (IKA Works Inc., Wilmington, NC) in cold 
RIPA buffer containing proteinase inhibitors (Complete Mini; Roche Diagnostics 
GmbH, Penzberg, Germany), phosphatase inhibitor cocktail no. 2 at a 1:100 
dilution (Sigma-Aldrich) and 1 mM phenylmethanesulfonyl fluoride (PMSF, 
Sigma-Aldrich). Afterwards, lysates were diluted 1:1 with 2X Laemmli buffer.  
Proteins from Pac-2 cells were isolated with direct lysis using 1x Laemmli buffer.   
Proteins (30 µg, quantified by Bradford assay) were separated using 10% 
or 13% (for LC3) SDS-PAGE and transferred to nitrocellulose membranes. Blots 
were then probed with antibodies to BiP (1:3000) (Sigma-Aldrich), LC3 (1:600) 
(Novus Biologicals, Littleton, CO), and β-actin (1:1000) (MP Biomedical; Solon, 
OH).  Antibodies were diluted in 5% milk/0.1% TBS-Tween. Blots were then 
washed 3 times for 5min in 5% milk/TBST and then incubated with an 
appropriate HRP-conjugated secondary antibody (1:5000) (GE Healthcare, 
Piscataway, NJ) for 30min.  Proteins were detected by chemiluminescence.   
 
Statistical analyses 
Statistical analyses were performed using GraphPad PRISM version 5.0 
(GraphPad, La Jolla, CA).  Assessments between groups of fish were done with 
a two-way analysis of variance (ANOVA).  Histology post-tests and further 
comparisons made between zebrafish were analyzed using a Mann-Whitney U 
test at a 95% confidence interval, unless otherwise noted in the figure legend.  
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Relative fluorescence data and EdU cell counting were compared with Student t-
tests, at a 95% confidence interval.  All graphs depict mean ± SEM.  Experiments 
were considered statistically significant if P<.05.  For all figures * denotes P<.05, 
** denotes P<0.01, and *** denotes P<.001, unless otherwise noted specifically 
in the figure legend.   
Results 
Glafenine administration produces cellular sloughing comprised of 
apoptotic IECs 
NSAIDs induce gastrointestinal damage in both humans and mice through 
COX blockade [4, 207].  In an effort to develop a zebrafish model of 
gastrointestinal injury, we exposed zebrafish larvae at 5.5 days post-fertilization 
(dpf) to a panel of NSAIDs for 12h (Figure 4A). Administration of Sc-560 (COX-1 
[217]), Ns-360 (COX-2 [208]), or indomethacin (non-specific [208]) all failed to 
generate a visible intestinal phenotype, using maximum tolerable dosages that 
did not result in a rate of death ≥50% (data not shown).  Furthermore, combined 
administration of Sc-560 and Ns-360 resulted in 100% death (data not shown).  
However, administration of the non-specific NSAID glafenine induced the 
formation of an opaque, impacted intestinal lumen extending from the distal part 
of segment 1 through segment 3, with the production of a visible “tube” of 
material extending from the cloaca (Figure 5A, white arrowheads).  Dose titration 
studies revealed that administration of 25 μM glafenine for 12h produced the 
highest level of “tube” formation with minimal zebrafish death (Figure 4B).  
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Figure 4:  Only the NSAID glafenine induces apoptotic tubes at non-lethal 
dosages.  A) Studies with COX inhibitors demonstrate that the effects of 
glafenine are specific to the drug.  *** denotes P<.001 relative to control; ### 
denotes P<.001 relative to glafenine.  N≥10 per condition.  B) Dose -dependent 
survival studies with glafenine.  Pooled  results of 3 or more independent 
experiments, N ≥20 for time points through 12h; N ≥10 for longer time points. 
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Because of the documented role of prostaglandins in IEC survival [4], we 
speculated that the impacted lumen was composed of expulsed dead IECs.  To 
test whether cells in the lumenal mass were still alive, we exposed untreated and 
glafenine-treated zebrafish to the apoptosis reporter dye acridine orange (AO) for 
30 min and imaged them by fluorescence microscopy.  An intense streak of AO 
positive cells in the lumen of glafenine-exposed fish could be observed by wide-
field (Figure 5B, left panel) and by confocal microscopy analysis, suggesting the 
presence of cellular entities (Figure 5B, right panel).  The mass extending from 
the cloaca observed by brightfield microscopy was also AO-positive (Figure 5B), 
suggesting that dead cells are expelled from the distal intestine through the 
cloaca.  Analysis of relative AO fluorescence in the intestinal lumen revealed a 
2.2-fold increase in glafenine-treated fish compared to untreated controls (Figure 
5C).  Histological assessment of serial sections revealed marked intestinal 
sloughing into the lumen in segment 1, while segment 2 was characterized by an 
impacted lumen with pyknotic epithelial nuclei, cellular hypertrophy/hyperplasia, 
and apical/sloughing nuclei (Figure 5D and Figure 6B-E).  All of these 
phenotypes are signs of cellular damage and apoptosis.  Blinded, histological 
scoring of segment 2 sections showed a statistically significant increase in 
cellular damage in glafenine-treated fish compared to control (8.8 vs 2.6, Figure 
5E).  In addition, an increase in activated caspase-3 positive cells was observed 
in the epithelium (segment 1) and lumenal debris (segments 1 and 2) of 
glafenine-treated fish but not untreated fish (Figure 5F).  This staining was not 
seen using IgG control antibody (Figure 6F).  In contrast, caspase-3 staining  
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Figure 5: Glafenine results in apoptotic cell death with sloughing and 
dysmorphic cellular architecture.  All studies at 12h glafenine exposure.  A)  
Lumenal sloughing is apparent on bright-field microscopy.  Bar represents 1 mm; 
segments of the intestine are bracketed and labeled.  Arrow heads show 
sloughing from the intestine.  B) AO staining shows apoptotic lumenal and 
sloughing debris.  Blue arrowheads point to enterocytes that auto-fluoresce red; 
white arrowheads point to apoptotic lumenal and extruded debris.  Bar 
represents 1 mm for wide-field images; bar represents 50 μm for confocal 
images.  C) Apoptotic mass can be detected by differences in relative AO 
fluorescence. Representative of 4 independent experiments, N≥4 per 
experiment.   D) H&E sections of glafenine-induced injury.  The edge of IECs are 
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outlined in white in segment 2 images.  Arrows point to sloughed cellular debris 
and nuclei.  Regions of liver are encircled with white dashes.  Bar represents 50 
μm.  E) Segment 2 histological scores, pooled from 3 independent experiments. 
N as portrayed.  F) Activated caspase-3 IHC.  Lumenal edges are outlined in 
white.  Arrowheads point to positively staining IECs, M denotes staining 
melanocytes.  Regions of liver are encircled by a solid white line (denoted with 
Liv).  Bars represent 50μm for segment 1, 12.5μm for segment 2.  
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Figure 6: Details of the segment 2 histological scoring system.  A)  
Histological criteria used in the intestinal damage assessment.  B-F) Bars 
represent 50μm.  B)  Example of pyknotic nuclei. Pyknosis score of 6, total score 
of 10. C) Example of sloughing, arrow points to an apical nucleus.  Sloughing 
score of 4, total score of 10.  D) Example of proliferation/hypertrophy.  
Proliferation score of 4, total score of 12.  E) Control fish, total score of 1.  F) IgG 
(rabbit) control IHC for Caspase-3 studies, which show that the Caspase-3 
staining observed is enterocyte and lumenal debris-specific.  
69 
 
was virtually absent in the liver of glafenine-treated zebrafish (Figure 5F, 
encircled in white).  Together, these findings suggest that glafenine treatment 
induces cellular apoptosis in the intestine.    
We next performed kinetic analysis of glafenine-induced intestinal injury.  
To facilitate this, we developed a rapid apoptosis/injury assay (see Methods) 
using AO staining. We observed that glafenine induced epithelial injury and 
apoptotic tubes in about 50% of zebrafish as early as 3h, which increased to 
~90% of fish at 12h of exposure (Figure 7A).  Histological analysis of segment 2 
after 3h of glafenine exposure confirmed the presence of injured epithelial cells 
(Figure 7B).  Additionally, marked intestinal sloughing was found in segment 1 at 
3h (Figure 7C) and this feature persisted through 12 h of treatment (Figure 5D).  
Histological analysis of the liver at 3, 6, and 12h of glafenine exposure showed 
minimal cellular damage that could be at best described as hydropic changes, 
maximally seen at 6h (Figure 7D).  To determine whether glafenine is still 
bioactive after long-term treatment (12h), media-swapping studies were 
performed where a new, untreated cohort of zebrafish were introduced into 
media in which a different group of zebrafish was exposed to 12h of glafenine.  
The conditioned media did not lead to AO-positive tubes in the new group of fish 
(data not shown).  These data demonstrate that glafenine-induced injury occurs 
acutely and that the drug is no longer active after 12h.   
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Figure 7: Progressive glafenine-induced injury over 0-12h is centered on 
the intestine.  A) AO-positive tube formation, N≥13.  B) Segment 2 histological 
score, N ≥ 9. 0 & 12h time points recapitulated from Fig 1. C) 3h histology. Bars 
represent 50μm.  D) Scale bars for all images are 50 μm.  H&E sections of livers 
of zebrafish exposed to 0, 3, 6, and 12h of glafenine.  Mild hydropic changes are 
seen at 6h. 
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To identify the cellular origins of the damaged cells, we performed TEM 
ultrastructural analysis of glafenine-treated fish.  The apoptotic tubes observed 
macroscopically in glafenine-exposed fish were comprised of cellular debris and 
multiple, distinctively apoptotic IECs within the epithelium of segments 1 and 2 
and in the lumen of segment 2 (Figure 8A), confirming that the Caspase-3 and 
AO signals described earlier were due to apoptosis.  Debris consistent with 
microvilli vesiculation, a hallmark of apoptotic cell shedding [29], was also 
observed only in injured zebrafish (Figure 8B).  In addition, IECs of glafenine-
exposed zebrafish showed features of ER stress with pitted ER in intestinal 
segments 1 and 2, which was most pronounced at 3h of glafenine exposure 
(Figure 8C).  Further kinetic analysis revealed increasing signs of ER and 
mitochondrial stress over time, from 1-12h of exposure (Figure 9A&B).  Early 
signs of ER stress peak at 3h, while organelle stress (along with apoptosis) 
steadily increases up to 12h after initial exposure; however, despite the fact that 
autophagy is initiated, most organelles are not fully enveloped by ER, indicating 
the process is in its early stages (Figure 9A&B).  
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Figure 8:  TEM identifies the apoptotic cells as intestinal epithelial in origin.  
TEM images, representative of 2 separate fish, across multiple sections at 12h 
glafenine exposure.  5000x magnification, bars represent 2μm.   A&B fixed at 12h 
of exposure; C taken at 3h exposure to glafenine.  A) Ultrastructure architecture 
of control and glafenine-injured fish in segment 1 and segment 2 of the intestinal 
epithelium.  Apoptotic IECs (white arrows) and lumenal cellular debris (seg 2, 
white arrows) can be observed.  Brush border is indicated by black arrows.  B) 
Lumenal debris seen with glafenine injury in segment 1, which is consistent with 
microvesiculation of intestinal brush border.  C) ER stress in segment 2, with 
characteristic pitting marked by black arrows.    
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Figure 9: Glafenine leads to ER stress and arrested autophagy. 5.5-6 dpf 
zebrafish larvae were exposed to glafenine for the indicated times.  Black arrows 
point to ER stress evidenced by pitting.  Dashed circles outline stressed 
organelles being enveloped by ER.  Solid circles outline dead organelles.  
Dashed, white arrows point to stressed mitochondria, while solid, white arrows 
74 
 
point to basement membrane invagination. Scale bars are 1 μm for all images.  
A) Lower magnification images.  B) Higher magnification images. 
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To determine if glafenine-induced IEC apoptosis was associated with 
reductions in epithelial barrier function, we gavaged zebrafish with TxR-labeled 
10kD dextran and monitored extra-intestinal fluorescence. Strikingly, extra-
intestinal fluorescence in zebrafish treated with glafenine for 1 or 3 hours was low 
and indistinguishable from untreated controls (Figure 10A-B).  Conversely, 
positive control treatment groups co-gavaged with TxR-dextran and 20mM EDTA 
displayed infiltration of TxR-dextran into intersomitic spaces and circulation 
(Figure 10A).  These results suggest that glafenine treatment alone does not 
robustly compromise epithelial barrier function during acute damage when the 
drug is most active.  TxR-dextran gavage after 12 h of glafenine exposure 
exhibited similar results (data not shown).   
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Figure 10: Intestinal epithelial barrier leakage does not occur with acute 
glafenine treatment.  Wild-type TL zebrafish larvae at 6dpf were pre-treated 
with glafenine or vehicle control for the indicated times, followed by gavage with 
1% TxR-dextran or 1% TxR-dextran plus 20mM EDTA (positive control).  ImageJ 
was used to quantitate the relative mean fluorescence in an region of interest 
(ROI) in the zebrafish larvae trunk above segment 2 and 3 of the intestine (trunk 
ROI; small white dashed rectangle in A), and normalized to an ROI outside of the 
fish as an internal control to account for background glare (an ROI outside of the 
fish was used).  A) Dextran leaks into circulation and intersomitic spaces when 
co-gavaged with EDTA.  Representative images of larvae from the 1hr pre-
treatment group are shown. In larvae gavaged with dextran only, the dextran 
remains in the intestinal lumen.  When co-gavaged with dextran plus EDTA, 
fluorescent signal is observed in circulation (dorsal aorta, white arrow) and 
intersomitic vessels and spaces (white arrowheads). Scale bars equals 200µm. 
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(TxR= Texas Red; BF=brightfield).   B) Treatment with glafenine does not lead to 
acute intestinal barrier disruption. Mean normalized TxR fluorescence in the trunk 
was determined following 1h or 3h of pre-treatment with glafenine or control. 
Graph represents data averaged from 2 experimental replicates taking into 
account the mean, SD, and N (16-19 larvae/condition/experiment). Two-way 
ANOVA with Bonferroni post-test was performed to compare each column to all 
other columns.  
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Because glafenine has been reported to cause anaphylaxis in humans, as 
well as liver damage [218, 219], we determined impact of glafenine in extra-
intestinal sites. Importantly, no changes were observed in the skin or 
musculature of glafenine-treated fish, suggesting a predominantly gastrointestinal 
phenotype (Figure 11). This was confirmed by AO staining which revealed no 
effects of glafenine treatment, with the exception of the liver (Figure 12).  
However, histological analysis and caspase 3 staining failed to document 
evidence of cellular damage/death (Figures1-2).  Together, these data suggest 
that glafenine causes minimal liver damage.  Additionally, we noticed no gross 
bleeding into the intestine in control and glafenine-exposed 
Tg(gata1:dsRed)sd2;(kdr1:EGFP)s843 fish, with all dsRed-labeled red blood cells 
overlapping the EGFP-labeled vasculature (Figure 13A-B).  Altogether, these 
data suggest a gastroenterological-specific phenotype, with damage most 
specific to the intestinal track.  
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Figure 11: TEM studies show that glafenine-induced injury (12h) keeps the 
skin and musculature intact.  Representative of 3 separate fish per condition. 
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Figure 12: Glafenine-induced injury is specific to the gastroenterological 
system.  Acridine orange staining marks apoptotic cells throughout the fish.  
Studies were performed at 12h glafenine exposure.  Representative control and 
glafenine-treated fish are shown, with the regions analyzed shown on the 
glafenine image.  Bars equal 1mm.  Representative of 3 independent 
experiments, N≥4. SB = Swim bladder, Liv = Liver, DF = Dorsal fin.  
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Figure 13: Glafenine-treatment does not result in gross intestinal bleeding.  
Double-reporter Tg(gata1:dsRed)sd2;(kdr1:EGFP)s843 zebrafish track both 
blood cells (red channel) and vasculature (green channel).  Images 
representative of 5 individual fish, taken at 12h glafenine exposure.   Bars are 
1mm in length.  A) The zebrafish show no gross bleeding into the intestinal 
lumen.  B) The zebrafish show no gross vascular defects.  
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The mu-opioid agonist DALDA protects against glafenine-induced injury  
Since apoptosis is an important feature of our model, we investigated the 
impact of anti-apoptotic, pro-proliferative, and/or pro-migratory compounds on 
glafenine-induced injury using the formation of AO positive tubes as a rapid 
screening assay.  We identified several compounds that conferred protection 
against glafenine-induced injury when added to the housing media.  R-spondin1 
(a β-catenin activator), the MOR agonist DALDA, the COX-2 derivative product 
dmPGE2, and the pan-caspase inhibitor Q-VD-OPh all afforded significant 
protection (Figure 14A).  These compounds all share the characteristic of 
engaging anti-apoptotic or pro-survival signaling pathways [205, 220-222].  In 
contrast, the mitogenic factors hIGF1 and mEGF failed to protect against 
glafenine-induced injury.  Together, these data suggests that only a subset of 
pro-survival, anti-apoptotic signals are protective in this model.  We hypothesized 
that mitigation of ER stress was the common factor of the drugs that reduced 
glafenine-mediated AO tube formation. 
Given the recent discovery of the intestinal-protective effects of mu-opioid 
signaling [205], we decided to further investigate the effect of this opiate on 
intestinal injury in this zebrafish model.  Co-administration of the opioid inhibitor 
Naloxone (1mM) alongside DALDA treatment abolished DALDA-mediated 
protection as determined by the tube assay (data not shown), demonstrating that 
DALDA-protection was mediated through MOR signaling.  Histological 
assessment of DALDA-treated, glafenine-exposed fish showed a ~45% decrease 
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in intestinal damage compared to untreated glafenine-exposed animals (Figure 
14B).  In addition, glafenine-induced zebrafish mortality was improved by ~2-fold 
by DALDA treatment (Figure 14C).  Because apoptosis plays a central role in this 
injury model, we determined the level of activated caspase-3 staining in the 
intestinal tissues of zebrafish co-treated with Glafenine and DALDA.  In 
accordance with decreased AO tube formation and improvement of animal 
survival, DALDA sharply reduced the amount of activated caspase 3 staining in 
the intestine compared to fish exposed only to glafenine (Figure 14D).  
Additionally, DALDA treatment enhanced epithelial cell proliferation during 
glafenine injury ~2-fold as measured by EdU incorporation (Figure 14E).  
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Figure 14: Glafenine-injury can be prevented with a subset of anti-
apoptotic/pro-survival drugs, including the MOR agonist DALDA. All studies 
performed at 12h drug(s) exposure.  A) Rapid apoptosis assays show that 
glafenine-induced injury can be prevented by drugs that engage pro-survival 
and/or anti-apoptotic signaling, but not solely proliferative signaling.  N≥15 per 
group.  Control, glafenine, and glafenine + DALDA results are all representative 
of 3 or more independent experiments.  dmPGE2 representative of 2 
independent experiments.  Other drugs representative of replicate experiments 
performed on the same day with different groups of larvae.  Significance shown 
is relative to glafenine treatment alone.  P<.001 between control and glafenine 
groups (not shown on graph).  Dosages: 10μM dmPGE2, 250ng/mL hIGF1, 
10nM mEGF and R-spondin, 50μM Q-VD-Oph. B) Segment 2 histological scores.  
N for each group is represented on the graph. Control and Glafenine groups 
recapitulated from Figure 1, for ease of comparison with DALDA treatment. C) 
DALDA enhances zebrafish survival from glafenine-induced injury.  N=50, pooled 
from 3 independent experiments.  Glafenine at 50μM final concentration.  D) 
Activated caspase-3 IHC staining in the intestinal epithelium.  Representative of 
4 fish per group. Scale bar equals 12.5μm.  The lumenal edge is outlined in 
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white. E) Proliferation in segment 2 in response to drug treatment. EdU staining 
of zebrafish with 12h of drug exposure for each group.  N≥8, except for control 
group, where N=4.  Scale bar equals 50μm.   
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Opioid signaling overcomes glafenine-induced blockade of ER stress 
response genes, allowing for cell survival 
Since DALDA amelioration of glafenine-induced intestinal injury is 
associated with decreased apoptotic markers, we speculated that DALDA-
protection is mediated by either preventing the observed ER stress and/or by 
increasing compensatory responses such as autophagy that can ward off 
apoptosis in the presence of cell stress.  Interestingly, ER stress was present 
(although diminished) and autophagy was enhanced in zebrafish treated with 
DALDA compared to glafenine-injury alone (Figure 15A).  DALDA-treated 
zebrafish maintained an organized epithelium without basement membrane 
invagination, and organelles did not appear swollen or lacking in sub-organelle 
architecture.  ER stress, based on pitting white lesions, was not prominent in 
DALDA-treated fish.  Also, increased smooth ER was apparent, presumably the 
result of resolving autophagy and the re-establishment of subcellular structures 
consumed during autophagy (Figure 15A).  IECs in the DALDA-treated group 
also displayed enhanced rough ER (Figure 15B), a typical sign of resolving 
autophagy as resolution requires increased protein synthesis. 
Given the presence of ER stress, we investigated downstream 
protein/genes of the UPR and autophagy cascades.  Protein levels of the early 
UPR mediator BiP were similar in lysates from whole fish exposed to glafenine 
with or without DALDA (Figure 15C).  In contrast, eIF2a phosphorylation, which is 
downstream of PERK activation, could not be detected (data not shown).  
Quantitative RT-PCR assays using microdissected digestive tracts demonstrated 
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that two UPR genes normally up-regulated downstream of BiP accumulation, 
spliced-xbp1 (s-xbp1) and atf6 [119, 223], were atypically not up-regulated in 
glafenine-exposed compared to untreated fish, although these genes were 
induced in DALDA-treated fish (Figure 15D).  These results were recapitulated 
using whole larvae lysates (Figure 16A), and DALDA was able to drastically 
induce these genes in the absence of glafenine-injury and inhibition (Figure 16B).  
Since atf6 is a key mediator of the ER stress response, leading to the UPR and 
autophagy, we next determined the functional role of this gene in DALDA-
mediated protection from injury.  Zebrafish injected with atf6-morpholino (MO) 
displayed abrogation of DALDA-mediated rescue of glafenine-induced injury 
compared to animals injected with control MO (Figure 15E, knockdown confirmed 
via PCR), suggesting that enhancement of the UPR and autophagy responses 
mediates DALDA rescue of glafenine injury.  
  
88 
 
 
Figure 15:  DALDA reverses Glafenine-induced organelle stress, restores 
proper UPR/autophagy responses.  All studies shown at 12h glafenine 
exposure.   A) TEM with and without DALDA treatment demonstrates a lack of 
ER stress and resolved autophagy.  White arrowheads show pitting from ER 
stress.  Black arrows indicate the brush border.  Dashed arrows demark 
apoptotic IEC.  Scale bars equal 2 μm.  B) Same conditions as in A, showing 
granularity in the cytoplasm of segment 1 IECs, indicative of rough ER.  Scale 
bar is 0.5 μm.  C) Glafenine-injury induces BiP protein accumulation, an early 
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signal in the UPR and autophagy cascades. Western blot representative of 4 
independent experiments, each consisting of protein lysate from  ≥10 pooled 
fish/condition.  D) Real-time PCR for UPR/autophagy response genes: u-xbp1 
(unspliced), s-xbp1(spliced), and atf6.  Each replicate for each condition was 
generated from 10 pooled micro-dissected fish gastrointestinal tracks, N ≥ 
4/group.  E) Fish were injected with 5 pmol of control or atf6 morpholino in 4.6 nL 
of water and subjected to our standard AO tube assay.  Pooled from 2 
independent experiments, N≥29/group.  RT -PCR for atf6 in morpholino-injected 
fish, at 6 dpf.  WT band is at 180 BP, the morphant with an intron-1 inclusion is at 
314 BP.  Representative of triplicate groups of 2 independent experiments.  F) 
Western blot of lysate from Pac-2 cells exposed to 10 μM DALDA for the 
indicated time.  Representative of 2 independent experiments.   
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Figure 16:  Autophagy response genes spliced xbp1 (s-xbp1), and atf6 
expression following glafenine and/or DALDA exposure.  Fish were treated 
as indicated and RNA extracted from whole animals at 12h glafenine exposure.  
s-xbp1 and atf6 expression was determined using ABI Prism HT7700.  Samples 
are from whole tissue lysates of 10 fish per sample, N ≥ 2 per group.   
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To determine if DALDA is sufficient to stimulate autophagy in zebrafish 
cells, we examined the effect of DALDA on the production and processing of the 
autophagy marker LC3.  Zebrafish larvae at 5 dpf showed high baseline levels of 
LC3-II (data not shown), therefore we tested this question using the zebrafish 
Pac-2 fibroblast cell line. Cells were treated with DALDA for 0-2 h and LC3 
conversion was evaluated by Western blot.  DALDA treatment progressively (0-
90m) enhanced LC3-I production, as well as processing to generate LC3-II 
(Figure 15G).  Together, these findings demonstrate that glafenine induces 
cellular organelle stress in the intestine while retarding downstream, pro-survival 
and autophagic signals atf6 and s-xbp1, resulting in enhanced apoptosis and 
intestinal injury.  Activation of MOR signaling rescues proper autophagy 
response through induction of atf6 and allows cellular survival and maintenance 
of intestinal homeostasis (Figure 17).  
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Figure 17:  Schematic of glafenine-induced intestinal injury in zebrafish and 
MOR-mediated protection. Glafenine induces ER stress and UPR response.  
However, this process is halted with loss of downstream gene induction, leading 
to inefficient autophagy response and induction of IEC apoptosis.  In presence of 
DALDA, glafenine-mediated blockade of the UPR process is restored and 
autophagy is successfully completed, resulting in reduced IEC apoptosis and 
maintenance of epithelial layer.      
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Discussion 
Recent studies in mice and in human patients have implicated improper 
IEC autophagy and UPR in the face of ER stress as a potential etiology for IBD 
[17-19]. In this study, we recapitulate this IEC apoptosis in the zebrafish using 
the NSAID glafenine, an inhibitor of both COX isoforms that was pulled from the 
market after Phase IV studies showed that the drug results in anaphylaxis and 
gastrointestinal disturbances in human patients [218].  Current murine models for 
studying ER-stress induced IEC damage require the production of genetic 
knockouts.  This zebrafish model provides several advantages over those 
systems, including the use of chemical induction and the ease of live imaging 
and screening for intestinal damage phenotypes.  This is also the first larval 
zebrafish model to demonstrate marked intestinal pathology, namely IEC 
apoptosis. Previous reports only presented vague systemic inflammatory 
infiltration without overt changes in the intestinal epithelium [116, 117].   
We present several lines of evidence indicating that the NSAID glafenine 
induces IEC apoptosis by enhancing ER stress, while interfering with 
compensatory rescue UPR and autophagic responses (Figure 17).  First, TEM 
revealed ER pitting shortly after glafenine exposure (1-3h), a hallmark of ER 
stress.  After extended glafenine exposure (12h), IECs displayed features which 
indicated an arrested autophagic response including partially enveloped 
organelles and numerous swollen, stressed organelles in living epithelial cells 
alongside many distinctively apoptotic cells.  Secondly, induction of UPR-
associated genes atf6 and s-xbp1 are impaired in glafenine-exposed fish.  
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Finally, the presence of activated caspase-3-positive apoptotic cells in both 
intestinal epithelium and the lumenal compartment of glafenine-treated fish are 
consistent with a failure to adequately respond to cellular stress [17, 19, 224, 
225].  These findings suggest that glafenine induces a strong IEC stress 
phenotype that translates into increased cellular apoptosis and epithelial 
damage.  While some liver damage likely exists, the intestinal-cell phenotype is 
far more pronounced.  Additionally, our TEM analysis and AO staining studies, 
alongside the use of an NF-κB reporter strain to assess tissue-specific NF-κB 
activity (Figure 18), showed a gastroenterological-specific phenotype, another 
strength of this model.  
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Figure 18:  Tg(NFkB:EGFP) fish show increased segment 2 NF-κB 
activation in zebrafish after injury with glafenine.  Tg(NFkB:EGFP)nc1 reporter 
zebrafish were used to assess NF-κB activation at 12h of glafenine exposure.  
Representative of 3 independent experiments, N as portrayed.  Bar represents 1 
mm.  The same regions as in Figure 12 were used, as marked on the fish.  SB = 
Swim bladder, Liv = Liver, DF = Dorsal fin. 
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Interestingly, despite the observed IEC apoptosis, the epithelial barrier 
remains intact.  Using TxR-labeled dextran and oral gavage, we observed that 
the dextran does not leak out of the intestine in glafenine-treated zebrafish.  This 
suggests that glafenine-induced apoptosis is highly controlled, and results in cell 
shedding with maintenance of the epithelial barrier.  Our TEM results support 
these findings, demonstrating the presence of shedding apoptotic IECs in the 
epithelial border with maintenance of the barrier by cells basal to the dying cell—
together forming the characteristic Y-pattern of controlled cell shedding [29].  
Additionally, glafenine treatment of zebrafish larvae has previously been shown 
to cause increased activity of digestive enzymes phospholipase and protease 
within the intestinal lumen [226].  Our results provide a potential physiologic 
explanation for this observation: that these and other enzymes may be released 
promiscuously from apoptotic IECs after glafenine exposure. 
While our kinetic and media-swapping studies suggest that glafenine-
injury is rapid and acute, the mechanism by which glafenine induces epithelial-
specific stress responses and damage is uncertain.  Intestinal epithelium damage 
is a well-known effect of COX inhibitors [4, 207].  NSAIDs decouple mitochondrial 
oxidative phosphorylation within 1h of administration [227], resulting in ER and 
general cell stress that in the highly energy-dependent enterocyte can lead to 
cellular death.  In our model, TEM showed characteristic mitochondrial 
vacuolization typical of NSAID-induced mitochondrial injury, suggesting that this 
may be the mechanism of injury in our model.  Previous, in vitro only, studies 
demonstrated that other NSAIDs induce apoptosis through improper ER stress 
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responses [225], also suggesting that the effects of glafenine observed here are 
a result of its COX-inhibitory properties.  The fact that dmPGE2 rescues 
zebrafish from IEC apoptosis in this model lends credence to this theory.  The 
observation that other NSAIDs were unable to recapitulate the injury caused by 
glafenine suggest that these inhibitors, as opposed to glafenine, mainly cause 
non-intestinal mediated mortality over intestinal injury. This is compatible with our 
observation that zebrafish treated with other NSAIDs died before development of 
any intestinal apoptosis.  In aggregate, we postulate that IECs are unable to 
appropriately response to glafenine-induced ER stress and as a result undergo 
rapid and but orderly apoptosis.  
Neuropeptides have attracted interest as a means to modulate intestinal 
inflammation and to promote epithelial restitution [70].  We recently showed that 
the MOR agonist DALDA protects against DSS-induced intestinal injury through 
wound healing and proliferative responses in mice[205].  DALDA promoted 
intestinal proliferation in glafenine-exposed fish consistent with the previously 
reported properties of the drug [205].  However, other zebrafish bioactive 
proliferative factors (mEGF and hIGF1) [228, 229] failed to prevent glafenine-
injury, suggesting that proliferation is not the primary protective mechanism of 
DALDA in this model.  Interestingly, our study identifies a novel means by which 
mu opioid signaling may protect against acute epithelial injury.  TEM analysis of 
DALDA-treated fish showed decreased ER stress and enhanced autophagy, 
leading to reduce cellular apoptosis and maintenance of epithelial layer integrity. 
Our studies showed that DALDA enhances atf6 and s-xbp1 mRNA expression in 
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zebrafish both in the presence and absence of glafenine, and that the protective 
effects of DALDA were lost in zebrafish lacking atf6 function.  Furthermore, we 
were able to establish that DALDA can induce LC3 accumulation and processing 
in vitro.  We therefore conclude that MOR signaling enhances proper UPR 
responses and autophagy, a previously unknown mechanism of neuropeptide-
mediated intestinal protection.  At least one important autophagy pathway, the 
PI3K pathway [224], is directly activated by MOR signaling [54], providing a 
potential mechanism for DALDA’s action in this zebrafish model.  To support this 
hypothesis, addition of the PI3K inhibitor wortmannin resulted in complete loss of 
DALDA-mediated protection (data not shown).  Together, our findings show that 
the zebrafish represents a powerful model to study cellular and molecular events 
associated with the intestinal injury response and that human relevant drugs 
(DALDA, NSAIDs) have bioactive effects in this vertebrate system.   
In summary, we established a novel zebrafish larvae model of epithelial 
damage through chemical induction of ER stress and impairment of autophagic 
responses.  We further demonstrated that the MOR agonist DALDA rescues this 
intestinal damage by potentiating the appropriate adaptive responses, including 
the UPR and autophagy.  This novel model of intestinal injury in zebrafish can be 
utilized to explore the burgeoning field of ER stress-induced intestinal 
inflammation, and identify novel targets applicable to human disease.   
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CHAPTER 4  
 
MU OPIOID SIGNALING PROTECTS AGAINST ACUTE MURINE INTESTINAL 
INJURY IN A MANNER INVOLVING STAT3 SIGNALING3
Introduction 
 
Opiates have long been used as analgesics to relieve pain associated with 
various medical conditions.  Here we evaluated the effect and mechanism of mu-
opioid signaling on the intestinal wound healing response, and assessed 
downstream pathways known to be protective against intestinal injury.  Mice 
(C57BL/6) were exposed to 3% dextran sodium sulfate (DSS) for 7 days or 4% 
DSS for 5 days followed by 7 days of water.  The MOR specific agonist DALDA 
and the antagonist cyprodime were injected subcutaneously (s.c) daily for in vivo 
studies or used for in vitro analysis.  We found that MOR activation attenuated 
DSS-induced histological and gross intestinal injury and weight loss, diminished 
Ifng, Tnf and Il6 mRNA expression and promoted intestinal healing during 
recovery.  DALDA also enhanced colonocyte proliferation (Ki-67 staining) by 
350%.  MOR activation increased STAT3 phosphorylation in both DALDA-treated 
mice and the CMT-93 cell line.  Importantly, DALDA induced colonocyte 
migration was completely ablated by shStat3 knockdown.  Together, this work 
                                            
3 Published in The American Journal of Pathology.  2011; 179(2): 673-83.  
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shows that MOR activation protects against and enhances recovery from DSS-
induced intestinal injury.  This is associated with an increase in STAT3 activation.  
Furthermore, STAT3 is required for DALDA-induced colonocyte migration.  
Consequently, manipulation of MOR signaling may represent a novel means to 
promote mucosal healing and maintain intestinal homeostasis following intestinal 
injury.   
Background 
A critical component of intestinal homeostasis is the presence of an 
intestinal mucosal barrier, comprised of a single monolayer of intestinal epithelial 
cells (IEC) that isolates highly antigenic luminal contents from an immunologically 
rich and underlying stromal compartment [1].  A wide body of research has 
shown that loss of intestinal barrier function leads to the development of various 
gastrointestinal inflammatory disorders, including inflammatory bowel diseases 
(IBD) [1, 5].  Conditions leading to an impaired mucosal barrier function are 
diverse and include genetic predisposition, medications (NSAIDS[4], antibiotics), 
radiation exposure [2] and ischemic episodes [3].  Overt damage to the epithelial 
barrier caused by these injuries triggers a host response termed 
restitution/wound-healing [10].  In this response, cells at the edge of the wound 
undergo a dedifferentiation process and migrate into the wounded area.  They 
then undergo cytoskeletal rearrangement [28], re-differentiate, and finally re-
establish tight junction barriers with their neighboring cells [10].  This process 
does not require epithelial proliferation, but renewal of cells are needed to 
replenish the decreased enterocyte pool after injury [28].  Numerous proliferative 
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signals such as epidermal growth factors (EGF) [7], transforming growth factors 
(TGF-β) [30, 31], and cytokines such as IL-22 [32] are implicated in the 
maintenance of the mucosal barrier.   At the molecular level, these proliferative 
signals utilize various pathways including NF-κB, MAPK, STAT3 and PI3K/Akt 
[10] pathways.  Identifying factors that engage these signaling pathways and 
promote wound healing is of great therapeutic interest for diseases such as IBD.   
Wound healing promoting factors include the various neuropeptides produced by 
the enteric nervous system.  Of strong relevance to IBD, several neuropeptides 
modulate immune cell function and could consequently impact the development 
of intestinal inflammation [230].  Opioids are a class of neuropeptides that have 
traditionally been used as analgesics; however, an emerging literature associates 
this class of neuropeptide with intestinal proliferation and inflammation [231].  
Vertebrates traditionally express three types of opiods receptors: mu, delta, and 
kappa, all of which are G-protein coupled receptors that preferentially bind to Gi 
proteins.  Binding of ligand to these receptors leads to the prototypical 
inactivation of neural pain fibers [54, 232, 233]. Interestingly, recent studies have 
shown opioids to protect against ischemia-reperfusion (I/R)-induced cardiac 
injury[86, 89].  Furthermore, the peripheral mu specific-agonist DALDA ([D-
Arg2,Lys4]dermorphin-(1,4)-amide) [69] reduces inflammation in two 
experimental models of murine colitis: 2,4,6-trinitrobenzene sulfonic acid (TNBS) 
and adoptive transfer of CD45RBhiCD4+ T-cells [70].  Conversely, experimental 
colitis is exacerbated in mu-opioid receptor (MOR) knockout mice, [70] and MOR 
expression is up-regulated in mucosal samples from human IBD patients 
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compared to controls [71].  Together, these data implicate an important role for 
MOR signaling in regulating gut homeostasis.  Although these studies have not 
fully addressed the mechanism by which MOR signaling ameliorates intestinal 
inflammation, it appears that down-regulation of cytokine production and 
modulation of T-cell function contributes to MOR’s beneficial effect.   
Based on its beneficial impact in other models of colitis [70], as well as in 
ischemia-induced cardiac injury [86, 89], we hypothesized that MOR signaling is 
cytoprotective in the context of intestinal barrier damage.  Using a chemical 
model of acute injury and wound-healing that is T-cell & B-cell independent[234], 
we observed that the mu-opioid agonist DALDA protects against DSS-induced 
intestinal injury and promotes healing through activation of STAT3 and induction 
of cytoprotective factors regulated in part by STAT3. Our findings suggest that 
MOR agonists could represent a novel means to modulate tissue injury and 
enhance intestinal restitution and proliferation. 
Materials and Methods 
DSS-induced acute injury 
Wild-type and transgenic NF-κBEGFP reporter mice (C57BL/6 background) 
were maintained in standard housing cages in specific pathogen free (SPF) 
conditions.  Mice (n=7), were given 3% DSS (MP Biomedicals; Aurora, OH) in 
their drinking water for 7 days while control mice received water alone. Water 
consumption was comparable between the different experimental groups.  
Throughout DSS administration, vehicle (10% DMSO/90% saline), the peripheral 
(does not cross the blood-brain barrier) MOR agonist DALDA[69] (100% saline, 
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50 µg/kg) (US Biological; Swampscott, MA), or the MOR antagonist cyprodime 
[235] (10% DMSO/ 90% saline, 10 mg/kg) (Tocris Bioscience; Ellisville, MI) was 
injected (s.c.) daily on the mid-dorsal surface of the mice. Mice were monitored 
daily for weight loss and visible signs of rectal bleeding.  Occult bleeding was 
evaluated at day 4 of the experiment (Hemoccult, Beckmann Coulter Inc.; 
Fullerton, CA), in accordance with internal pilot studies that showed occult 
bleeding to be reliably observable in this model from Day 4 onwards.  Clinical 
score, assessing weight loss, occult blood, and stool consistency was calculated 
as previously described [236].  All animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of North Carolina 
at Chapel Hill.   
DSS recovery studies 
C57BL/6 mice (n=6) were administered 4% DSS in their drinking water for 
5 days, followed by water for a recovery period for 7 days.  DALDA or vehicle 
was injected s.c. daily during the water recovery phase, as described above. 
Occult bleeding was evaluated at day 12.  Mice were euthanized at days 8 and 
12.  Colonoscopies were performed as described previously [237], on days 5, 8 
and 12. 
Sample collection and histological evaluation 
Mice were sacrificed at the indicated time points by CO2 asphyxiation 
followed by cervical separation.  The colon was dissected and flushed with ice-
cold PBS, longitudinally splayed, swiss rolled, fixed in 10% formalin for 24 hrs, 
and then embedded in paraffin.  Colitis severity was evaluated using 
105 
 
Hematoxylin-Eosin-stained sections by a blinded investigator on a scale from 0 to 
40, as described previously [238-240]. 
IHC staining for pSTAT3(Y705) (Cell Signaling Technology Inc.; Beverly, 
MA) was performed according to the manufacturer’s specifications, at a 1:50 
dilution as previously described [237].  Ki-67 staining performed as previously 
described [237]. All sections were counterstained with Hematoxylin.  Two 
different sections (per animal), approximately 200 µm apart, were assessed for 
staining, and representative images are shown.    
For protein analysis, distal colons were dissected, flushed with ice-cold 
PBS and homogenized for 15 s with a polytron (IKA Works Inc; Wilmington, NC) 
in cold RIPA buffer containing proteinase inhibitors (Complete Mini, Roche 
Diagnostics GmbH; Penzberg, Germany) and phosphatase inhibitor cocktail #2 
at a 1:100 dilution (Sigma-Aldrich).  After incubation at 4°C for 30 minutes, 
samples were sonicated and cleared. Lysates were then diluted 1:1 with 2X 
laemmli buffer.   
Confocal analysis of EGFP expression 
Colons were fixed in 4% paraformaldehyde for 40 minutes at room 
temperature, and permeabilized in 2% Triton X-100 for 18-22 hrs at 4°C.  Tissues 
were rinsed in 1X PBS, counterstained with propidum iodide (PI) 
(Invitrogen/Molecular Probes; Eugene, OR) for 30 minutes, and then placed in 
custom imaging chambers and immersed in Focus Clear (Cedar Lane Labs; 
Burlington, NC).  Tissues were imaged with an Olympus Fluoview FV1000MPE 
microscope, with a 25x long-working distance water immersion objective.  EGFP 
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was excited with a 495 nm laser, and PI was excited with a 559 nm laser.  Tissue 
was imaged from the surface to a depth of 120 µm with a standard scale for laser 
power, offset, and gain based on depth that was maintained between samples.  
Images were analyzed using BioImage XD and Imaris (Bitplane AG; Zurich, 
Switzerland).   
CMT-93 cell culture and stimulation 
Murine rectal carcinoma cells (passage 33-59) (American Type Culture 
Collection (ATCC); Manassas, VA) were cultured in DMEM-high-glucose as 
described previously [241].  Cells were starved for 18-22 hrs in Opti-MEM and 
then treated with DALDA (10 µM) or naloxone (10 mM, Sigma-Aldrich; St. Louis, 
MO) for the times indicated.  Cells were directly lysed in 1X laemmli buffer and 
protein concentration was measured using Bio-Rad quantification assay (Bio-Rad 
Laboratories; Hercules, CA).  
Luciferase Assays 
CMT-93 cells were infected with Ad5κB-Luc vector[242] for 12 hours in 
Opti-MEM, and then were stimulated with LPS (10 μg/mL) in presence or 
absence of 10 μM DALDA. Luciferase assay were performed on a Monolight 
2010 luminometer for 20 s (Analytical Luminescence, San Diego), 
Western blot analysis 
Proteins (30 µg) were separated using 10% SDS-PAGE and transferred to 
nitrocellulose membranes and then probed with antibodies to pSTAT3(Tyr705) 
(1:2000), ERK1/2 (1:1000), pERK1/2 (1:2000) (Cell Signaling Technologies), 
STAT3 (1:1000) (Santa Cruz Biotechnologies; Santa Cruz, CA) and β-actin 
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(1:1000) (MP Biomedical; Solon, OH), were used with 5% milk in TBS-Tween 
(0.1%) or 5% BSA in TBS-Tween (0.1%) (for Cell Signaling Technologies 
antibodies), followed by the appropriate HRP-conjugated secondary antibody 
(GE Healthcare, Piscataway, NJ) and detected by chemiluminescence.  
Densitometry analysis for pSTAT3 was performed with NIH ImageJ software 
(http://rsbweb.nih.gov/ij/), to determine the ratio of pSTAT3 to STAT3, where 
indicated. 
Immunofluorescence 
CMT-93 cells were grown to 50% confluence in Opti-MEM media on glass 
cover slides.  Cells were fixed in ice cold methanol, blocked with normal goat 
serum, and incubated with 1:100 anti-pSTAT3(Y705) (Cell Signaling 
Technologies) followed by anti-rabbit TRITC (1:100) (Jackson Immunoresearch 
Laboratories; West Grove, PA) for 30 minutes.  Cells were then counterstained 
with Hoechst dye and mounted with Fluoromount-G (Southern Biotech, 
Birmingham, AL).  Images were captured with a Zeiss LSM 710 confocal 
microscope (Zeiss; Jena, Germany).   
RNA isolation and real-time PCR 
RNA isolation from colonic tissues and CMT-93 cells and  subsequent 
mRNA analysis was performed as previously described[237], using a ABI Prism 
HT7700.  Specificity and linearity of amplification for each primer set was 
determined by melting curve analysis and calculation of the slope from serial 
diluted samples. Relative fold-changes were determined using the ΔΔCT 
calculation method. Values were normalized to the internal control GAPDH.  
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Primers: Tnf (5’-ATGAGCACAGAAAGCATGATC-3’ and 5’-
TACAGGCTTGTCACTCGAATT-3’)[237], Il6 (5’-
CGGAGGCTTAATTACACATGTT-3’ and 5’- CTGGCTTTGTCTTTCTTGTTATC-
3’)[243], Il1b (5’- GCCCATCCTCTGTGACTCAT-3’ and 5’- 
AGGCCACAGGTATTTTGTCG-3’), GAPDH (5’-
GGTGAAGGTCGGAGTCAACGGA-3’ and 5’-
GAGGGATCTCGCTCCTGGAAGA-3’)[243], Cox2 (Ptgs2) (5’- 
TGAGTACCGCAAACGCTTCTC-3’ and 5’- TGCAGCCATTTCCTTCTCTCCT-
3’)[244].  Cyclin D (Ccnd1), Ifng, Myc, and Reg3b are QuantiTect primers 
(Qiagen; Valencia, CA).   
Migration and proliferation assays  
Migration assays were performed as described previously[245].  Briefly, 
CMT-93 cells were plated to confluency in Opti-MEM and then were scratched 
with a P1000 pipette tip.  10 µM DALDA in PBS or PBS alone was then 
immediately added.  4 different regions per plate were demarked and images 
were taken at the specified time points using an Olympus IX7 microscope.  
Images were analyzed with NIH ImageJ software.  Each experiment was 
measured at 4 individual points, and was repeated independently at least 2 
times. 
Reproductive proliferation assays [246] were performed by plating CMT-
93 cells at a known cellular density, and 2 hours after plating, cells were switched 
to 1% serum media and stimulated for 8 hours with 10 µM DALDA in PBS or PBS 
alone.  Cells were then trypsinized and counted using trypan blue.  Each plate 
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was counted 4 different times, and the experiment was repeated independently 
at least 2 times.   
shRNA knockdown 
A stable shStat3 knockdown CMT-93 cell line was created using a 
lentivirus provided by the UNC-CH Lentiviral shRNA Core with a mixture of 4 
different shStat3 constructs.  Open Biosystems TC1 library numbers 
TCRN0000071453-7 were employed (pLKO.1 vector) [247].  Control shRNA 
virus SHC-002 (Sigma-Aldrich) was used to create a stable control knockdown 
line.  Cells were maintained in selection media containing 2 µg/mL puromycin, to 
which the lentiviral vectors conferred resistance but completely killed uninfected 
cells.  
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism version 5.0a 
(GraphPad, La Jolla, CA). Comparisons of weight between mouse groups and 
over time were done with a two-way analysis of variance (ANOVA).  Weight post-
tests and further comparisons made between mice were analyzed using a Mann-
Whitney U test at a 95% confidence interval.  In vitro data and Ki-67 and pSTAT3 
cell counting were compared with student t-tests, at a 95% confidence interval.  
All graphs depict mean ± S.E.M.  Experiments were considered statistically 
significant if P<.05.  
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Results 
DALDA ameliorates DSS-induced intestinal injury  
To investigate the impact of MOR signaling in intestinal injury response, 
we employed the mu-specific agonist DALDA in a DSS model of acute intestinal 
injury.  Mice were administered 3% DSS for 7 days, along with sterile s.c. 
injections of saline (vehicle), mu-specific agonist DALDA (50 μg/kg) [69], or the 
mu-specific antagonist cyprodime (10 mg/kg) [235].  We found that DALDA 
significantly attenuated DSS-induced weight loss (Figure 19A).  Clinical scores, 
which factors in weight loss, diarrhea and bloody stool, showed that DALDA-
treated mice displayed a significant reduction in disease compared to untreated 
mice (mean of 5.92 vs 3.93, P< .01), while MOR antagonism exacerbated 
disease (mean of 5.92 vs 7.92, P<.01) (Figure 19B).  Histological scores (Figure 
19C) showed that DALDA significantly reduced intestinal inflammation as 
compared to vehicle-treated (mean of 24.2 to 10.8, P<.01), while cyprodime 
worsened inflammation (mean of 24.2 to 33.5, P<.05).  In addition, DSS-induced 
histological crypt damage was attenuated by DALDA treatment, while cyprodime 
exacerbated damage (Figure 19D).  The extent of the pathological changes of 
DALDA and cyprodime on DSS-induced intestinal injury are shown in Figure 
19E.   
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Figure 19:  MOR activation protects against DSS-induced intestinal injury.  
Mice were given 3% DSS for 7 days concurrent with opioid treatment.  DALDA 
(50 µg/kg), cyprodime (10 mg/kg) or vehicle were injected s.c. daily.  All graphs 
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depict mean ± SEM. A) Percent weight loss from starting weight. N=7 for all 
groups. P<.001 by 2-way ANOVA between treatment groups and over time.  
P<.05 for DALDA-treated vs. vehicle-treated at day 7.  B) Clinical score.  N=7 for 
all groups.  P<.01 for DALDA-treated vs. vehicle-treated. C) Histological score.  
N≥5 for all groups.  D) Crypt damage score.  N>4 for all groups.  E) 
Representative H&E photomicrographs.  Bar = 100 µm for all sections.  F)  Fold 
change Tnf and Il6 distal colonic mRNA expression.  N≥4 for all groups.  
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After establishing that MOR activation protected against DSS-induced injury, we 
assessed the effects of DALDA on inflammatory cytokines.  We found that 
DALDA significantly reduced colonic Tnf and Il6 mRNA expression (Figure 19F).  
As these cytokines are induced in part through immune-derived NF-κB signaling 
during experimental colitis [248], we next explored the impact of daily s.c. 
injections of DALDA on NF-κB activity using fresh-fixed tissues sections obtained 
from NF-κBEGFP reporter mice and confocal microscopy imaging. As previously 
reported, EGFP expression in the lamina propria increased in DSS-exposed NF-
κBEGFP reporter mice [243, 249].  Interestingly, lamina propria-derived EGFP 
expression (NF-κB activity) was strongly reduced in DALDA-treated mice (Figure 
20A).  Moreover, DALDA failed to block LPS-induced NF-κB transcriptional 
activity in CMT-93 cells (Figure 20B). These findings indicate that DALDA 
protects against DSS-induced acute intestinal injury in mice, and is associated 
with reduced immune cell-derived NF-κB activation and pro-inflammatory gene 
expression without directly inhibiting NF-κB signaling. 
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Figure 20:  DALDA prevents DSS-induced EGFP expression in DSS-
exposed NF-κBEGFP mice. NF-κBEGFP mice were administered 3% DSS for 7 
days, concurrent with DALDA (50 µg/kg), cyprodime (10 mg/kg) or vehicle 
treatment. Colonic EGFP expression was assessed in whole tissue mounts using 
confocal microscopy. Propidium iodide (red) was used to visualize nuclei.  4 mice 
per condition were visualized macroscopically (data not shown), and 2 per 
condition were visualized further by confocal microscopy.  A) 25x magnification.  
B) 60x magnification of the same tissues as shown in A.  C)  LPS induced NF-κB 
transcriptional activity is not blocked by DALDA.  CMT-93 were infected with 
Ad5κB-Luc for 12 hours, and then stimulated with 10 μg/mL LPS in the presence 
or absence of 10 μM DALDA for 12 additional hours. 
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MOR activation enhances recovery from DSS-induced intestinal injury 
As wound-healing is a critical process during tissue repair, we evaluated 
the impact of DALDA on recovery from DSS-induced intestinal injury.  Mice were 
administered 4% DSS for 5 days, followed by 7 days of s.c. injections of saline or 
50 μg/kg DALDA.  Gross mucosal damage visualized by colonoscopy showed 
attenuation of macroscopic lesions by day 7 in DALDA-treated mice (Figure 
21B). Furthermore, DALDA enhanced weight loss recovery and DALDA-treated 
mice returned to near-normal weight by day 7 of the recovery phase (Figure 
21A).  DALDA similarly reduced clinical scores after 7 days of recovery (mean of 
5.3 vs 2.3, P<.05, Figure 21C), while histological scores were noticeably lower 
after only 3 days of therapy (mean 29.2 vs. 15.6, P<.01 at day 3, 23.2 vs. 11.3, 
P<.01 at day 7, Figure 21D), with initial improvements associated with decreased 
crypt damage (mean 9.7 vs. 3.7, P< .05 at day 3, Figure 21E).  In accordance 
with histological and clinical decreases in disease, Tnf, Il6, Il1b and Ifng mRNA 
levels were significantly reduced in DALDA-treated compared to vehicle-treated 
mice (Figure 21F).  These findings indicate that DALDA protects against DSS-
induced intestinal injury and promotes wound healing. 
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Figure 21:  MOR activation enhances recovery from DSS-induced intestinal 
injury.  Mice were administered 4% DSS for 5 days, followed by 7 days of water 
recovery concurrent with treatment: 50 µg/kg DALDA or vehicle were injected s.c. 
daily.  All graphs depict mean ± SEM.  A) Percent weight loss from starting 
weight. N>6 for all groups.  B)  Representative colonoscopies for each group on 
the final day of the experiment.  C) Clinical score.  N=6 for all groups.  D) 
Histological score.  N>4 for all groups.  E) Crypt damage score.  N>4 for all 
groups.   F)  Fold change Tnf, Il6, Il1b, and Ifng mRNA accumulation was 
determined by RT-PCR.  N≥4 for all groups.   
117 
 
 
DALDA enhances colonocyte proliferation and STAT3 activation in vivo 
As proliferation is an important feature of the healing response that occurs 
after migration/restitution, we measured proliferation in DALDA-treated mice by 
Ki-67 staining.  We observed a modest 38% increase in proliferative activity 
(P<.01) in DALDA-treated mice compared to control (Figure 22).  Importantly, 
proliferation index increased by almost 2-fold (P<.05) in DSS-exposed, DALDA-
treated mice compared to DSS alone (Figure 22).  
Because STAT3 signaling is also a critical proliferative response in the 
DSS acute model of intestinal injury[32],  we next determined the impact of MOR 
agonism on STAT3 activation.  Compared to untreated controls, DSS-exposed 
mice showed a 5-fold increase in colonic pSTAT3.   DALDA therapy alongside 
DSS injury increased pSTAT3 10-fold (P<0.001) over that of untreated controls 
(Figure 23A); surprisingly, mice given DALDA alone without DSS-injury did not 
have increased levels of pSTAT3 over control (N=4, data not shown), suggesting 
that STAT3 activation by MOR is tightly regulated, and that MOR-mediated 
activation occurs only in the presence of injury.  IHC indicated that DALDA-
induced STAT3 phosphorylation appears predominately in colonocytes (Figure 
23B-C), resulting in a 2.7-fold increase in pSTAT3-positive colonocytes per 20 
crypts (P<0.05) in DALDA-treated vs. vehicle-treated mice exposed to DSS.  We 
next assessed expression of cytoprotective genes regulated in part by STAT3, 
using real-time PCR.  As anticipated, DALDA significantly enhanced expression 
of Cox2 (Ptgs2), Myc, Reg3b, and Cyclin D (Ccnd1) mRNA levels in DSS-
exposed mice compared to vehicle-treated mice (Figure 23C).  These specific 
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cyto-protective genes were selected because their expression decreased in 
DSS-exposed STAT3ΔIEC mice compared to wild-type [32], demonstrating that 
they are regulated by STAT3 in colonocytes.  
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Figure 22:  Enhanced colonocyte proliferation in DALDA-treated mice.  All 
graphs depict mean ± SEM.  A) Representative photomicrographs.  Bar = 100 
µm.  B) Ki-67 positive cells were counted in 50 crypts across multiple fields of 
view.  N≥4 for all groups except DALDA alone, for which N=3.   
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Figure 23:  DALDA enhances STAT3 activation in DSS-induced intestinal 
injury.  Mice were administered 3% DSS + vehicle or 3 % DSS + DALDA (50 
µg/kg, injected s.c. daily) for 7 days.  All graphs depict mean ± SEM.  A)  Levels 
of STAT3 phosphorylation (Y705) in distal colonic tissue measured by Western 
blot.. Relative level of pSTAT3 over total STAT3 was determined by 
densitometry. Representative of 4 individual mice.  B&C) pSTAT3 
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immunohistochemistry analysis.  Representative images of 4 mice per group.  
Bars represent 100 µm in all images.  White boxes outline higher magnification 
images of each section.  Bar graph shows pSTAT3 positive colonocytes per 20 
crypts.  D) Expression of STAT3-dependent genes (Ptgs2, Myc, Reg3b, Ccnd1) 
in distal colonic tissue.  N≥3 per group.   
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DALDA enhances STAT3 phosphorylation in vitro 
To gain more insight into the role of STAT3 in MOR-mediated protective 
effect, we utilized an in vitro cell system. CMT-93 cells were exposed to DALDA 
(10 μM) for 1 hour after which STAT3 phosphorylation was measured by Western 
blot.  Densitometric analysis showed that pSTAT3 levels increased by ~3-fold in 
DALDA-treated cells compared to unstimulated cells (P<0.05 compared to an 
assumption of a 0-fold change, Figure 24A).  In addition, immunofluorescence 
assays showed an increased level of pSTAT3 in DALDA-treated cells compared 
to unstimulated cells (Figure 24B).  We determined whether the general opioid 
antagonist naloxone could inhibit DALDA-induced pSTAT3 activation, and indeed 
we see that 30 minute pretreatment with naloxone (Figure 25C) blockades 
STAT3 phosphorlyation.  We then investigated the impact of DALDA on cyto-
protective genes regulated in part by STAT3 using real-time PCR.   Expression of 
Myc, Cox2 (Ptgs2), Cyclin D (Ccnd1) and Reg3b mRNA were significantly 
induced in DALDA-stimulated CMT-93 cells (Figure 24C).  These studies indicate 
that colonocytes respond to a mu-opioid receptor agonist by activating STAT3 
signaling and downstream cyto-protective mediators. 
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Figure 24:  DALDA induces STAT3 phosphorylation in CMT-93 cells. A-C) 
CMT-93 cells were treated for 1 hour with 10 µM DALDA or vehicle.  A) Western 
blot and densitometry comparing pSTAT3 to STAT3 within the same sample.  
Representative of 8 independent experiments.  B) pSTAT3 immunofluorescence 
staining,  representative of triplicate samples, from 2 independent experiments.  
C)  Activation of STAT3 dependent genes (Ptgs2, Myc, Ccnd1, Reg3b). N≥4 for 
both groups, in two independent experiments. 
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ERK phosphorylation is a well established downstream consequence of 
Gi-coupled GPCR activation and a classic effector of MOR activation [250].  We 
detected ERK1/2 phosphorylation in the distal colonic tissue of DALDA-treated 
mice and in DALDA stimulated CMT-93 cells (Figure 25A and C).  To confirm the 
specificity of DALDA-induced ERK1/2 phosphorylation, CMT93 cells were 
pretreated (30 min) with the mu-opioid receptor competitive antagonist naloxone 
(10 mM) and then stimulated with DALDA.  Interestingly, levels of pERK1/2 are 
slightly augmented in naloxone treated cells, a phenomenon previously reported 
[251, 252]. Importantly, naloxone attenuated DALDA-induced pERK1/2 in CMT93 
cells (Figure 25B). 
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Figure 25:  DALDA induces ERK1/2 phosphorylation by an opioid-
dependent pathway. A) Western blot for pERK1/2 in CMT-93 cells stimulated 
with 10 µM DALDA for 0-60 minutes.  Representative of 3 individual experiments.  
B) Western blot for pSTAT3 and pERK1/2 in CMT-93 cells stimulated with 
DALDA for 1 hr with or without 30 minute pre-treatment with 1 mM of the opioid 
antagonist Naloxone.  Representative of 3 individual experiments.  C) DALDA 
induces colonic ERK1/2 phosphorylation in vivo.  Western blot for pERK1/2 from 
distal colonic protein extracts from individual control mice or mice injected with 50 
µg/kg DALDA daily s.c. for 7 days. 
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DALDA enhances colonocyte migration in a STAT3-dependent manner 
Since DALDA promoted proliferation in vivo and activated 
protective/proliferative signaling in vitro, we next explored the effect of MOR 
activation on cellular restitution/migration using an in vitro wound healing/scratch-
assay model.  Immediately following wounding, cells were incubated with DALDA 
(10 μM) and 8 hours later the distance migrated into the scratch was measured 
with ImageJ.  Migration increased by 67% (P<.001) in DALDA-treated compared 
to untreated cells (Figure 26A-B). Furthermore, reproductive cellular proliferation 
assays showed that DALDA enhanced CMT-93 proliferation by 45% over the 
same time period (Figure 26C; P<0.05).  Since DALDA enhanced STAT3 
phosphorylation in vivo and in vitro, we determined the functional impact of this 
signaling event on CMT-93 migration using an shRNA knockdown approach. 
CMT-93 cells were infected with a lentiviral vector containing shStat3 and a 
puromycin resistance gene, allowing for the selection and maintenance of a 
stable knockdown line. STAT3 expression was efficiently inhibited in shStat3 
infected cells compared to scramble controls (Figure 26D).  Moreover, DALDA-
induced pSTAT3 was strongly blocked in shStat3 infected cells compared to sh 
control (Figure 26E).  Most importantly, DALDA-induced cellular migration was 
completely abrogated in shStat3 infected cells compared to control-infected cells 
(Figure 26F).  These findings demonstrate that DALDA drives colonocyte 
migration in a STAT3-dependent manner, and combined with our in vivo studies 
shows that MOR activation enhances intestinal wound healing by both enhancing 
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restitution/migration and cellular proliferation, in a manner involving STAT3 
signaling. 
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Figure 26: DALDA enhances colonocyte migration in a STAT3-dependent 
manner. A) CMT-93 monolayers were scratched and treated with 10 µM DALDA 
or vehicle.  Migration was observed over a 24h period.  A) Representative 
photomicrographs of cell migration.  Shaded area shows initial wound area.  Bars 
represent 100 µm in all images.  B) Quantification of migration distance after 8 
hours.  Mean results of 3 independent experiments, N=4 for each experiment.   
C) Reproductive cellular proliferation assays.  CMT-93 cells were treated with 10 
µM DALDA or vehicle for 8 hours and direct cell quantification was performed.  
Mean results of 2 independent experiments, N=4 for each experiment.  D-F) 
Cells were infected with a shStat3 lentivirus to reduce Stat3 expression or control 
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scrambled shRNA (shScramble)  D) Western blot representative of 3 
independent experiments illustrate Stat3 knockdown in shStat3 cells. E)  Western 
blots show reduced DALDA-induced STAT3 phosphorylation in shSTAT3 
infected CMT-93 cells.  Representative of 2 individual experiments.     F) 
Quantification of migration over an 8-hour period.  Representative of 2 separate 
experiments, N=4 per experiment. 
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Discussion 
As a result of their ability to promote intestinal repair, increasing clinical 
interest has focused upon the use of trophic factors to treat diseases associated 
with chronic epithelial injury such as IBD [5, 25, 253].   Here we have 
demonstrated that peripheral activation of the mu-opioid pathway protects 
against DSS-induced intestinal injury and enhances wound healing.  We have 
shown that the MOR-specific agonist DALDA activates proliferative signaling in 
the intestine, a response associated with enhanced colonocyte-derived STAT3 
activation and induction of cytoprotective genes.    In contrast, the MOR-specific 
antagonist cyprodime worsens DSS-induced intestinal injury, suggesting that this 
opioid pathway plays an essential role in the intestinal wound-healing response.  
Interestingly, previous reports have shown that low-dose therapy of the non-
specific opioid antagonist naltrexone protects against both DSS-induced injury in 
mice and ameliorates Crohn’s disease in a small, open label patient study [72, 
73].  In these studies, naltrexone was deliberately administered at levels below 
the dose needed to pharmacologically blockade receptor function. Because the 
MOR-specific antagonist cyprodime exacerbates DSS-induced colitis, it is likely 
that low-dose naltrexone therapy acts to potentiate endogenous opiate signaling 
[58, 72, 73].  However, such a mechanism remains controversial and has never 
been truly established.   
Our work provides significant new insights into the mechanisms behind 
DALDA- mediated amelioration of intestinal injury and inflammation.  Chronic 
opiate administration is known to be immunosuppressive clinically, and 
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specifically inhibits T-cell, B-cell, and natural killer cell function [230, 254, 255].  
Moreover, DALDA has been shown to be protective in two T-cell driven models 
of murine colitis: the TNBS and adoptive transfer of CD45RBhiCD4+ T-cell models 
[70].  This implies that MOR-mediated immunosuppression may provide a 
potential mechanism for MOR-mediated protection from intestinal injury.  
However, DSS-induced acute colitis has been shown to be T-cell, B-cell, and NK-
cell independent [234], and hence DALDA cannot be solely operating through 
inhibition of adaptive immune responses.  While we observed decreased 
activation of NF-κB (EGFP expression) and inflammatory gene expression in 
DALDA-treated mice, these observations are likely a secondary effect of the drug 
since genetic ablation of IEC-derived NF-κB signaling [23, 40, 256-258] and 
blockade of the pathway [243, 249, 259] are both known to exacerbate injury 
response in the intestine.  In addition, in vitro NF-κB transcriptional activity in IEC 
was not inhibited by DALDA treatment. 
We show that DALDA operates in part through the enhancement of wound 
healing and cellular proliferation in response to DSS-induced epithelial damage.  
Indeed, an early effect of DALDA therapy is improvement of crypt damage score 
and enhanced epithelial proliferative responses (Ki-67 staining).  These 
observations suggest that DALDA acts by enhancing both epithelial proliferation 
and damage repair responses.  This concurs with our in vitro data showing that 
DALDA enhanced IEC proliferation/migration following wounding,.  We postulate 
that the enhanced wound-healing afforded by DALDA limits luminal antigenic 
activation of lamina propria immune cells (NF-κB activation, cytokine expression) 
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and inflammation through epithelial restitution/migration and enhanced 
colonocyte proliferation.   
The novel finding that DALDA induced IEC STAT3 phosphorylation both in 
vivo and in vitro is particularly relevant to the wound healing response.  IEC-
derived STAT3 signaling has been shown to confer protective responses against 
DSS-induced intestinal injury through the promotion of wound healing responses 
[32, 260], and furthermore, STAT3 signaling is a known driver of enterocyte 
proliferation [261, 262].  IHC staining demonstrated that colonocytes are the 
predominant cells exhibiting pSTAT3 in DALDA-treated, DSS-exposed mice. 
DALDA enhanced expression of cyto-protective genes (Reg3b, Ccnd1, Cox2, 
myc) that are lost in STAT3ΔIEC mice known to be sensitive to DSS injury [32].  
The up-regulation of these genes only in the presence of DALDA suggests that 
while DSS alone can up-regulate colonocyte STAT3 activation to an extent, only 
the presence of DALDA and subsequent exogenous MOR signaling is sufficient 
to generate protective responses, through higher elevated pSTAT3 levels, 
increased cyto-protective gene expression and proliferation (Ki-67 staining).    
Our gene expression observations could also be recapitulated in vitro with CMT-
93 colonocytes, where we also saw DALDA increase pSTAT3 levels in CMT-93 
cells and enhance cellular migration in response to a wound, as well as enhance 
cellular proliferation.  Knockdown of STAT3 demonstrated the importance of 
STAT3 signaling in DALDA-mediated enhanced migration, as this response was 
abrogated in shStat3-infected CMT-93 cells compared to control.   
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These observations strongly suggest that DALDA promotes protective 
function in the intestine through a mechanism involving STAT3 activation. 
Although IECs are the predominant cells exhibiting pSTAT3 in response to 
DALDA treatment, it is unclear whether these cells are the main target of the 
opioid.  Tissue-specific MOR gene deletion will be necessary to evaluate the 
cellular compartment implicated in DALDA-induced protective response.  
Additionally, while STAT3ΔIEC mice are available, previous work has shown that 
these mice are extremely sensitive to DSS-colitis and have severe defects in 
epithelial restitution[32], making exploring the role of DALDA on such a sensitive 
background untenable.   
ERK1/2 is a canonical downstream effector of Gi-coupled signaling and 
represents a classical read-out of opioid signaling.  Interestingly, while we 
observed persistent in vivo activation of ERK1/2 in DALDA-injected mice, STAT3 
phosphorylation was observed only in the context of DALDA administration 
during an injury response.  This suggests that MOR-mediated STAT3-driven 
proliferation in vivo is tightly regulated and activation depends on the injury status 
of the epithelium.  A previous study has identified IL-22 as a key cytokine 
involved in DSS-induced pSTAT3 and injury response [32].  Interestingly, we 
observed enhanced colonic IL-22 mRNA expression in DALDA-treated, DSS-
exposed mice (Goldsmith and Jobin, unpublished observation).  Further studies 
will be required before establishing the functional role of IL-22 in DALDA-
mediated cytoprotective effect in the intestine.   
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Our work highlights a potential new therapeutic class of compounds for 
the treatment of diseases involving intestinal barrier damage, including ischemic 
injury, radiation-induced damage, and IBD.  One could envision the use of 
opioids as an adjunct therapy in IBD by helping to induce or maintain remission 
through promoting re-epithelialization of the intestine.  In particular, opioids could 
be used as an adjunct in helping to induce remission in IBD by lowering the 
amount of prednisone needed, or as a mainline therapy in steroid-refractory 
patients.  Use of opioids for IBD therapy needs to be pursued cautiously, 
however, as our work shows that opioids likely act through increased colonocyte 
proliferation and IBD patients already have an increased risk of malignant 
transformation.  Consequently, MOR-targeted therapy would likely be best suited 
towards short-term use for remission induction, similar to prednisone.  Other, 
non-IBD, applications could include enhancing recovery from radiotherapy-
induced injury and use as a gut-saving agent in cases of ischemic injury. 
In summary, this report establishes mu-specific opioids as promoters of 
colonocyte migration/restitution and proliferation in the intestine involving the 
activation of STAT3-dependent pathways.  Since opioids are already available on 
the market and have well-known safety profiles, this class of compounds could 
represent a novel therapeutic approach to gastrointestinal therapy, once clinical 
trials validate their beneficial impact in patients.  
  
135 
 
Acknowledgements 
 The authors would like to thank Dr. Joseph Galenko in the CGIBD at 
UNC-CH for his assistance with statistical analysis.  The authors would also like 
to thank the Dr. Scott Plevy of UNC-CH for his generous donation of the lentiviral 
constructs generated by the UNC Lenti-shRNA core and Dr. Taku Kobayashi of 
UNC-CH for his help generating the knockdown lines.  We would also like to 
thank Mr. Greg Gipson for technical assistance with mouse experiments, as well 
as Dr. Janelle C. Arthur and Dr. Javier Rivera-Guzman of UNC-CH for critical 
reading of the manuscript.  We would also like to thank Dr. Robert Bagnell 
(Director, Microscopy Services Laboratory) and Mr. Robert Currin (Manager, Cell 
& Molecular Imaging Facility and UNC-Olympus Center), both of UNC-CH, for 
their assistance with the fluorescent microscopy experiments.  Finally we would 
like to thank Dr. Arlin Rogers (UNC-CH, Department of Pathology) for his blinded 
confirmation of our histological assessment of intestinal injury.   
 
  
 
CHAPTER 5  
 
INTESTINAL EPITHELIAL CELL (IEC)-DERIVED MU-OPIOID SIGNALING 
PROTECTS AGAINST ISCHEMIA REPERFUSION (I/R) INDUCED INJURY 
THROUGH PI3K SIGNALING4
Introduction 
 
Intestinal ischemia has a wide variety of etiologies, including but not limited to 
atherosclerosis, blood clots, hypotension, and chronic inflammation.  Here we 
evaluated the role of intestinal epithelial cell (IEC)-derived mu-opioid receptor 
(MOR) signaling in host response to ischemia/reperfusion injury.  Ileal ischemia 
was accomplished through obstruction of the distal branches of the superior 
mesenteric artery (60min) and reperfusion for 90min (ischemia-reperfusion, I/R).  
Surgery was performed under isofluorane/ketamine combined anesthesia.  
Floxed-MOR mice were crossed to villin-cre transgenic mice to selectively delete 
the MOR gene in IECs (MORIEC-/-).  Radio-ligand binding assays demonstrated 
selective functional loss of MOR signaling in IECs of MORIEC-/- mice, while brain 
cortex control tissue retained signaling capacity.  Administration of the MOR 
agonist DALDA significantly protected against both ischemia and reperfusion 
phases of intestinal I/R injury, an effect completely ablated in MORIEC-/- mice.  
This cyto-protective effect was associated with activation of enterocyte-mediated 
                                            
4 Under review at The American Journal of Pathology 
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PI3K/GSK3β signaling and decreased cellular apoptosis. Pharmacological 
blockade of PI3K activation resulted in loss of MOR-mediated cyto-protective 
function.  In vitro experiments showed that DALDA-mediated IEC migration was 
dependent upon PI3K signaling.   Together, these data shows that IEC-derived 
mu-opioid signaling utilizes PI3K pathway to protect cells against the damaging 
effect of I/R.  Targeting MOR signaling may represent a novel mean to alleviate 
intestinal injury and promote the wound healing response.  
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Background 
The gastrointestinal epithelium performs a wide array of functions for the 
host including secretion/absorption of nutrients, innate immune surveillance, and 
physical barrier against the rich, diverse and potentially immunogenic luminal 
contents. Therefore, preserving the integrity and maintaining intestinal barrier 
function is critical for host homeostasis.  At the forefront of the intestinal barrier 
lies a single monolayer of intestinal epithelial cells (IECs) [1], which form a tight 
network of cells through the formation of tight junctions between IECs.  These 
tight junctions are a critical component of the epithelium, and are necessary for 
the maintenance of the barrier during epithelial injury [27, 29]. The epithelium is a 
very dynamic system with highly migratory and proliferative IECs that help 
maintain and replace the barrier [27].  These active cells require constant high 
levels of blood flow to maintain their function, which is supplied by the superior 
mesenteric artery for the small intestine and proximal two thirds of large bowel, 
and the inferior mesenteric artery for the last third of the colon [8, 9, 21].  These 
arteries are supplemented by significant collateral blood flow to ensure proper 
intestinal function [8, 9, 21].  
Various events such as chronic inflammation [263], infection [1], 
medications [207, 264], and ischemia can all result in the loss of the intestinal 
barrier [3, 8], with deleterious consequences for the host.   Among these various 
conditions, intestinal ischemia has been associated with severe disruption of 
small intestinal function and integrity.  Intestinal ischemia results in tissue 
hypoxia, which can cause induction of cellular apoptosis and loss of the 
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protective epithelial layer.  Beside ischemia, the intestine can experience various 
level of hypoxia due to atherosclerotic blockade, hemorrhage, veinous emboli, 
surgical clamping, and cardiac tamponade [3].  In all of these cases, enteric 
blood supply must be reduced by at least 50% to overcome compensatory 
mechanisms [8].  Ischemia represents one of the driving factors in the 
pathogenesis of the newborn disease necrotizing enterocolitis (NEC) [21].  
Paradoxically, the restoration of blood flood (reperfusion) enhances the damage 
to the intestine through the introduction of oxygen free-radicals and increased 
immune cell activation [3].  In severe cases, ischemia/reperfusion (I/R) injury can 
result in multiple organ dysfunction syndrome (MODS), with a mortality rate of 
approximately 30% [6].    
I/R induced injury occurs in a multistep fashion.  In the first phase, the 
impaired blood flow to the epithelium generates an adaptive response involving 
the activation of protective signaling events that induce activity of different 
transcription factors such as hypoxia-inducible factor (HIF) [22] and nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) [23].   In the 
second phase, the adaptive response is generally overwhelmed by the rapid re-
introduction of blood flow/oxygen (reperfusion), which enhances and sustains the 
inflammatory response  [3].  Finally, the sustained intestinal immune response 
compromises the intestinal barrier function of the epithelium—allowing bacterial 
translocation across the mucosa, leading to bacteremia and sepsis, and creating 
a positive feedback loop of inflammation and intestinal damage [3].  In I/R injury, 
the consequences of this positive feedback loop are typified by NEC [21], where 
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this sustained response results in progressive loss of a newborn’s intestinal 
track, resulting the death of 2-4% of all very low birth weight infants [24].   
Unfortunately, current treatment of I/R injury is completely supportive, and no 
treatments focus on restoring the epithelial barrier defects that can lead to 
MODS.  Recently, we have found that mu-opioid receptor (MOR) signaling is 
protective against chemical-induced acute intestinal injury [205].  Rodent studies 
have demonstrated that opioid signaling is cardio-protective during ischemic 
episodes [86, 89], and these observations have been successfully extended to a 
randomized, double-blind clinical trial [265].  MOR is a G protein-coupled 
receptor, and the cardio-protective effects of MOR signaling are believed to act 
through the Gβγ-subunit of the Gi protein coupled to MOR.  Specifically, the Gβγ 
subunit activates phosphoinositide 3-kinase (PI3K) [54], which can result in 
numerous pro-survival downstream signaling events, predominately mediated 
through Akt activation [266].  Additionally, studies have shown that opioid-
mediated cardio-protection involves integrated signaling between the 
PI3K/Akt/GSK3β pathway and the JAK2/STAT3 pathway [89].  However, the role 
and cellular source of MOR signaling during I/R mediated intestinal injury remain 
to be defined.  
In these studies, we establish that MOR signaling is protective against both the 
ischemic and reperfusion phase of intestinal I/R injury.  Genetically deficient 
MOR-derived IEC signaling demonstrated that IEC cells are the source of the 
cyto-protective responses.  The MOR-mediated protective effect was in part 
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attributed to PI3K signaling as pharmacological inhibition of the pathway 
abrogated DALDA-induced beneficial impact.     
Materials and methods 
Generation of MORIEC-/- mice 
All mice were on the C57BL/6 background.  Villin-Cre mice were crossed 
to MORf/f mice which contain loxP sites in introns 1 and 3, to generate mice 
lacking exons 2 and 3 of the mu opioid receptor (Figure 27A).  MORf/f mice were 
generated by Xenogen Biosciences (Hopkinton, MA) using homologous 
recombination. Tail snips were collected from all pups generated from crosses, 
and genomic DNA was isolated using a Qiagen Blood and Tissue Kit (Qiagen; 
Valencia, CA).  Mice were bred to generate homozygote MORf/f allele and Villin-
Cre gene.  Primers used for genotyping:  Villin-Cre promoter (5’-
TAAGAAAGGATCATCATCAAAGCCGG-3’, and 5’-
GTGAAACAGCATTGCTGTCACTT-3’) Flox-Oprm1 (5’-
GTGTTTAAACATAGGTACAAGATATTCCCAAGCGAGA-3’ and 5’-
GTCTCGAGCTGAGATTTAGGAAAGGTGTCGAATTATTG-3’).   
For phenotypic analysis, RNA was isolated from enterocytes and 
splenocytes as previously described [237], and expression of MOR, Oprm1 and 
Gapdh was determined by RT-PCR.  Amplicons were resolved on a 2% agarose 
gel and visualized using a Kodak Gel Logic Imager 200 series (Kodak; 
Rochester, NY). Primers used: Oprm1 (amplicon 569 bp, 5’-
ACCTGGCTCCTGGCTCAACT-3’ and 5’- TGGACCCCTGCCTGTATTTTG-3’), 
Villin1 (amplicon 330 bp, 5’-CCCCCATCTTCCA-3’ and 5’-
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TGCCCTGCCAGATATATAACA-3’), CD45 (Ptprc) (amplicon 70 bp,5’- 
ATGGTCCTCTGAATAAAGCCCA-3’ and 5’-TCAGCACTATTGGTAGGCTCC-3’), 
Gapdh (amplicon 240 bp, 5’-GGTGAAGGTCGGAGTCAACGGA-3’ and 5’-
GAGGGATCTCGCTCCTGGAAGA-3’) [243].   
Ischemia/reperfusion induced injury 
MORf/f and MORIEC-/- mice (C57BL/6 background) were maintained in 
standard housing cages in specific pathogen free (SPF) conditions.  Mice (n=4-6) 
were anesthetized under 1% isofluorane, supplemented by 10 mg/kg ketamine 
injected subcutaneously (s.c.). Vehicle (saline) or the MOR agonist DALDA [69] 
(100% saline, 50 µg/kg) (US Biological; Swampscott, MA), was injected s.c. ten 
minutes prior to surgery. The PI3K inhibitor Ly294002 (0.25 mg/kg) (Calbiochem; 
Darmstadt, Germany), was injected i.p. 10 minutes before administration of 
DALDA.  A mid-line laparotomy was made and peripheral branches of superior 
mesenteric artery were occluded with aneurysm clips (Kent Scientific; Torrington, 
CN), to create a 2-3 cm region of ischemic ileum adjacent to the cecum.  
Collateral blood flow through the intestine was blocked using aneurysm clips 
across the intestine and collateral vessels, demarking the region of ischemic 
intestine.  Haematoxylin was administered to the edges of ischemic tissue to 
mark them, and then the incision was closed with surgical staples.  Ischemia was 
maintained for 60 minutes, and then the incision was re-opened and the clamps 
were removed and the incision was re-closed.  The mice were maintained in a 
heated room for a variable amount of time (0, 1.5, or 4 hours) without anesthesia 
for the reperfusion phase of injury.  All animal experiments were approved by the 
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Institutional Animal Care and Use Committee of the University of North Carolina 
at Chapel Hill.   
Murine sample collection and histological evaluation 
Mice were anesthetized using isoflurane, and then sacrificed by cervical 
dislocation.  The colon was dissected and flushed with ice-cold PBS, 
longitudinally splayed, swiss rolled, fixed in 10% formalin for 24 hrs, and then 
embedded in paraffin.  Damage severity was evaluated using Haematoxylin and 
Eosin (H&E)-stained sections by a blinded investigator. The scoring system is 
based on an IEC apoptosis/necrosis system [267], where a score of 1 signified a 
loss of only the villus tips; a score of 2 corresponded to loss of 50% of the villus; 
a score of 3 indicated a loss of the entire villus, but with maintenance of the crypt; 
and a score of 4 signified complete loss of the epithelial layer.  Fractional (to the 
nearest 0.5) scores were given, and the score was based on the average 
damage of the entire tissue section. 
Cell membrane fraction isolations 
Primary intestinal epithelial cells were isolated as described previously 
[268]. Briefly, small intestines and colons were opened longitudinally, washed, 
and intestinal epithelial cells were separated from the underlining tissue by 
shaking the intestines in a solution containing 1.5mM EDTA (with 0.5mM DTT for 
colon sections) and proteinase inhibitors (Complete Mini, Roche Diagnostics 
GmbH; Penzberg, Germany) for 30min at 37°C. The remaining tissue was filtered 
with a 0.45 μm cell culture filter to remove the underlying stroma and samples 
from three mice were pooled and spun at 1300 rpm for 5 minutes.  Cells were 
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lysed in chilled, hypotonic 50 mM Tric-HCl, pH 7.4 solution for 30 minutes.  Cell 
membrane isolates were then prepared by washing the lysate 3 times in standard 
binding buffer (50 mM Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, pH 7.4) followed 
by centrifugation at 20,000 rpm.  The lysate was then resuspended in the binding 
buffer and passaged through a 26 gauge needle to ensure homogenization; 
forming the final membrane suspensions used in the radioligand binding assays. 
Brain membrane homogenates were made using cortex tissue.  Brains were 
harvested from mice and their cortexes were dissected.  The tissues were 
homogenized in standard binding buffer with proteinase inhibitors using a 
polytron (IKA Works Inc; Wilmington, NC), and then prepared in the same 
manner as the IECs in standard binding buffer.  Protein concentration of each 
membrane suspension was determined by Bio-Rad quantification assay (Bio-Rad 
Laboratories; Hercules, CA).   
Radioligand binding assay 
Radioligand binding assays were performed by the Psychoactive Drug 
Screening Program at UNC-CH, using a modification of previously described 
procedures [269]. 50 μL of membrane suspensions were incubated with 0.3, 0.6, 
1.25 2.5, 5, or 10 nM H3-DAMGO (GE Healthcare; Piscataway, NJ) with or 
without 10 μM naltrexone (Sigma-Aldrich; St. Louis, MO) for 1 hour at room 
temperature, shielded from light. Samples were then harvested by rapid filtration 
onto Whatman GF/B glass fiber filters pre-soaked with 0.3% polyethyleneimine 
using a 96-well Brandel harverster. Four rapid 500-μl washes were performed 
with chilled standard binding buffer to reduce non-specific binding.  The filter 
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mats were dried and scintillant was melted onto the filters and the radioactivity 
was counted using a Microbeta scintillation counter.  Radioactivity of H3-DAMGO 
was quantified by liquid scintillation counting, using EcoScint scintillation cocktail 
(National Diagnostics; Atlanta, GA).  Raw data (decays per minute) was 
converted to fmols of ligand binding per mg of total tissue, using a detection 
efficiency of 0.5 to convert from decays per minute to counts per minute.  
Immunohistochemistry and immunofluorescence  
IHC staining was performed according to the manufacturer’s specifications, as 
previously described [237].  Primary antibodies and dilutions were: 
pGSK3β(Ser9), 1:400 (Cell Signaling), and pAKT(Ser473), 1:50 (Cell Signaling 
Technology Inc.; Beverly, MA). IHC for activated caspase 3, 1:400 (R&D 
Systems; Minneapolis, MN) was performed as described [213].  All sections were 
counterstained with Hematoxylin.  During analysis of IHC, only crypts that had 
two or more positively staining cells per 10 total crypts in a field of view were 
counted for IHC analysis.   
Fluorometric TUNEL (terminal deoxynucleotidyl transferase dUTP nick 
labeling) assay was performed using a DeadEnd Kit (Promega; Madison, WI) 
according to manufacturer protocols.  Images were acquired using a Zeiss 710 
microscope with a 20X, 1.4 NA objective (Carl Zeiss; Thornwood, NY).  Zeiss 
Zen 2009 software was used for image acquisition.  All images were acquired at 
room temperature. 
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RNA isolation and real-time PCR 
RNA isolation from ileal tissues and subsequent subsequent cDNA 
amplification was performed as previously described [237], using a ABI Prism 
HT7700.  Specificity and linearity of amplification for each primer set was 
determined by melting curve analysis and calculation of the slope from serial 
diluted samples. Relative fold-changes were determined using the ΔΔCT 
calculation method. Values were normalized to the internal control GAPDH or β-
actin.  Primers: Il6 (5’-CGGAGGCTTAATTACACATGTT-3’ and 5’- 
CTGGCTTTGTCTTTCTTGTTATC-3’) [243], Il1b (5’- 
GCCCATCCTCTGTGACTCAT-3’ and 5’- AGGCCACAGGTATTTTGTCG-3’) 
[205],Gapdh (5’-GGTGAAGGTCGGAGTCAACGGA-3’ and 5’-
GAGGGATCTCGCTCCTGGAAGA-3’) [243], b-actin (5'-
TTACCAACTGGGACGACATG-3' and 5'CTGGGGTGTTGAAGGTCTC-3') 
Bacterial ribosomal 16S DNA and cultures 
For all bacterial translocation assays, mice were subjected to 60 minutes 
of ischemia followed by 4 hours of reperfusion in the presence or absence of 
DALDA as described above.  Mice were sacrifice and their livers harvested and 
weighed.  To determine bacterial 16S rDNA loads, livers were incubated in lysis 
buffer (200 mM NaCl, 100 mM Tris-HCl pH 8, 20 mM EDTA, 20 mg/ml lysozyme) 
for 30 minutes at 37°C, and then in 1% SDS and 0.35 mg/mL Proteinase K for 30 
minutes at 60°C. The homogenates were further lysed in a 60% volume of 
phenol:choloforom:isoamyl alcohol mixture (25:24:1) using a Mini Bead Beater 8 
(Biospec; Bartleville, OK).  DNA was isolated using a choloform:isoamyl alcohol 
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(24:1) solution and precipitated with 2.5X volumes of ethanol with 3 M sodium 
acetate pH 5.2 overnight at -20°C.  The pellet was resuspended in Tris buffer (10 
mM, pH 8) and a Qiagen DNAease Blood and Tissue kit (Qiagen) was used 
according to manufacturer protocol.  Isolated DNA was subjected to real-time 
PCR as described above, using the following primers:  universal 16s rDNA (5’-
GTGSTGCAYGGYTGTCGTCA-3’ and 5’-ACGTCRTCCMCACCTTCCTC-3’), 
normalized to murine Gapdh (as above).   
For bacterial cultures, harvested and weighed tissues were immediately 
homogenized with a polytron in sterile PBS.  10 μL of lysate was plated on sheep 
BHI plates (Remel; Lenexa, KA) in triplicate, and incubated overnight at 37°C.  
For anaerobic studies, plates were preconditioned overnight in an anaerobic 
chamber, and incubation of the plates was also done in an anaerobic chamber.  
CMT-93 cell culture and stimulation 
Murine rectal carcinoma cells (passage 33-59) (American Type Culture 
Collection (ATCC); Manassas, VA) were cultured in DMEM-high-glucose as 
described previously[241].  Cells were starved o/n in Opti-MEM and then treated 
with DALDA (10 µM) for the times indicated.  Cells were directly lysed in 1X 
laemmli buffer and protein concentration was measured using Bio-Rad 
quantification assay.  
Western blot analysis 
Proteins (30 µg) were separated using 10% SDS-PAGE, transferred to 
nitrocellulose membranes and then probed with antibodies specific to 
pGSK3β(Ser9), GSK3β, pAKT(Ser473), Akt (all diluted at 1:1000 dilution, Cell 
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Signaling Technologies), and β-actin (1:10,000) (MP Biomedical; Solon, OH) in 
5% BSA in TBS-Tween (0.1%), followed by the appropriate HRP-conjugated 
secondary antibody (GE Healthcare, Piscataway, NJ).  The immune complexes 
were detected using chemiluminescence. 
Migration and proliferation assays  
Migration assays were performed as described previously[245].  Briefly, 
CMT-93 cells were plated to confluency in Opti-MEM and then were scratched 
with a P1000 pipette tip.  10 µM DALDA or PBS-vehicle alone was then 
immediately added to the plates. Wortmannin (1 μM; Sigma-Aldrich) or DMSO 
vehicle was added 5 minutes before addition of DALDA.  4 different regions per 
plate were demarked and images were taken at 0 and 8 hours post-wounding 
using an Olympus IX7 microscope.  Images were analyzed with NIH ImageJ 
software.  Each experiment was measured at 4 individual points, and was 
repeated independently at least 2 times. 
Statistical analyses 
Unless specifically noted, statistical analyses were performed using 
GraphPad Prism version 5.0a (GraphPad, La Jolla, CA).  Comparisons of mouse 
studies were made with non-parametric, one-way analysis of variance (ANOVA), 
Kruskal-Wallis test with Dunn’s Multiple Comparison post-test. Further 
comparisons made between mice were analyzed using a Mann-Whitney U test at 
a 95% confidence interval.  In vitro migration data and cell counting were 
compared with student t-tests, at a 95% confidence interval.  Radioligand binding 
assays were analyzed using a non-linear fit (single-binding site) function, built 
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into Prism. All graphs depict mean ± S.E.M.  Experiments were considered 
statistically significant if P<.05.  P<.05 denoted by *, P<.01 denoted by **, P<.001 
denoted by ***.  
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Results 
Generation of IEC-specific MOR gene deleted mice  
To define the role of intestinal epithelial cell-derived MOR signaling in the 
intestine, we crossed floxed-MOR mice (MORf/f) to Villin-Cre mice to generate 
specific IEC gene deleted mice (MORIEC-/-, Figure 27A).  PCR analysis showed 
MOR (Oprm1) mRNA accumulation in purified IECs and splenocytes from MORf/f 
mice, whereas the transcript was absent in the IECs of MORIEC-/- mice (Figure 
27B). MOR mRNA accumulation was detected in splenocytes isolated from 
MORIEC-/- mice, showing the specificity of MOR gene deletion (Figure 27C).  
Radioligand binding assays revealed a lacked of detectable binding of the MOR-
specific ligand 3H-DAMGO in IEC cells isolated from MORIEC-/- mice compared to 
MORf/f mice (Table 3).  3H-DAMGO binding to brain (cortex) cell membrane 
extracts was not significantly altered in MORIEC-/- mice. These findings confirmed 
that MOR signaling is functionally ablated in IEC in MORIEC-/- mice.   
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Figure 27.  Generation of IEC-specific MOR gene deleted mice.  A)  
Schematic representation of the exon-flanked loxP sites of MORf/f mice.  B) RT-
PCR analysis of MOR (oprm1) mRNA accumulation from IECs and splenocytes 
obtained from MORf/f and MORIEC-/- mice.  Villin and CD45 are used as marker of 
enterocytes and immune cells respectively.  Gapdh is used as a loading control.  
Biological duplicates are shown.   
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Mouse Strain Cortex DAMGO Bmax Enterocyte DAMGO Bmax 
MORf/f 165.6 +/- 16.10 fmol/mg 11.55 +/- 4.397 fmol/mg 
MORIEC-/- 108.5 +/ 13.10 fmol/mg No binding detected 
 
Table 3:  MORIEC-/- enterocytes do not bind mu ligand.  Radioligand binding 
assays using the MOR-specific agonist 3H-DAMGO demonstrated an absence of 
intestinal binding in MORIEC-/- mice.  No statistically significant difference between 
MORf/f and MORIEC-/- binding was observed (P = 0.0705) in the cortex (brain) 
samples used as a positive control. N = 4 or 6 per group.  
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IEC mu-opioid signaling protects against ischemia/reperfusion injury 
To address the cell-type specific role of MOR signaling in intestinal injury 
response, we subjected mice to episode of ischemia-reperfusion (I/R) where 
peripheral branches of the SMA were clamped for 60 minutes (ischemic phase),  
followed by 90 minutes of reperfusion.  As seen in Figure 28, I/R induced 
epithelium denudement, with partial to complete ablation of the crypts, alongside 
immune cell infiltration into the lamina propria.  Interestingly, administration of 
DALDA (50 μg/kg) dramatically reduced I/R mediated tissue damage compared 
to untreated mice, as shown by histological damage assessment (2.5 vs 0.6, 
P<0.05; (Figure 28A-B). However, DALDA was unable to protect MORIEC-/- mice 
from I/R induced injury compared to MORf/f mice (1.75 vs 2.58 P =0.2920) 
(Figure 28A-B).   
Due to hypoxic conditions, I/R leads to increased IEC apoptosis with 
associated disruption of intestinal barrier function [3, 8, 9].  A fluorescent TUNEL 
assay showed enhancement of fragmented DNA indicative of apoptosis/necrosis 
in mice subjected to I/R injury, which was absent in mice treated with DALDA 
(Figure 28C).  DALDA-mediated reduction of DNA fragmentation was ablated in 
MORIEC-/- mice (Figure 28C).  To specifically address the role of apoptosis in 
DALDA-mediated protection, we investigated the level of caspase-3 activation 
using IHC.  Interestingly, caspase 3 activation was strongly reduced following 
DALDA treatment, an effect abrogated in MORIEC-/- mice (Figure 28C).  These 
findings indicate that IEC-derived MOR signaling is critical for the DALDA-
mediated protective effect on the epithelium.   
154 
 
 
Figure 28.  DALDA administration protects against ischemia-reperfusion 
induced injury. 50 μg/kg of DALDA was administered s.c to MORf/f and MORIEC-
/- mice 10 minutes before ischemia/reperfusion (I/R) exposure. Healthy tissues 
(H) represent a non-ischemic region of the small bowel adjacent to the damaged 
area.  A)  Representative H&E images of ileal swiss rolls.  Scale bars are 200 
μm.  N =5-6 per group.  B)  Histological damage scores show DALDA mediated 
protection from I/R injury only in mice with functional IEC-derived MOR signaling 
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(MORf/f).  N =5-6 per group.  C) TUNEL assay demonstrates decreased 
apoptotic/necrotic IECs in DALDA-treated mice with functional IEC-derived MOR 
signaling.  Cells with fragmented DNA are stained green while DAPI 
counterstained marked all intestinal cells.  Scale bars are 200 μm.  
Representative of 3 sections per group, from two different mice.  IHC analysis of 
activated caspase 3 from ileal section of DALDA-treated MORf/f and MORIEC-/- 
mice showed decrease caspase 3 staining in mice with functional IEC-derived 
MOR signaling.  Images are representative of two different mice.  Scale bars are 
100 μm.  
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Interestingly, I/R induced Il1b and Il6 mRNA accumulation was not 
modulated by DALDA administration, nor was it affected by the status of MOR 
expression (Figure 29).  A similar, but less robust pattern of induction, was 
noticed with Tnf mRNA (data not shown). 
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Figure 29.  MOR-mediated cyto-protective effect does not correlate with 
decreased cytokine production.  Mice were treated with DALDA and exposed 
to I/R as described in Figure 28.  Il1b, Il6, and Tnf mRNA ileal tissue levels were 
determined using ABIPrism7900HT.  Data was processed using the ΔΔCt 
method, normalized to b-actin and set relative to sham operated mouse tissue.  
No statistical significance was noted between any of the ischemic tissue groups. 
Comparing between sham and all ischemic groups, P <0.0317 for Il1b, P<0.0159 
for Il6.  N ≥3 per group. 
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Because I/R induced injury is a multi-phase process, we next investigated 
the role of MOR signaling during the early ischemic phase of intestinal injury. 
Administration of DALDA protected against the induction of intestinal damage 
during the ischemic phase (2.7 vs 1.5, P<0.01), an effect dependent on the 
presence of functional IEC-MOR signaling Figure 30A&B). These data suggest 
that IEC-derived MOR signaling protect against the deleterious effect of 
ischemia.  TUNEL (data not shown) and IHC analysis of activated caspase-3 
demonstrates that IEC-MOR signaling confers protection during the ischemic 
phase of injury through up-regulation of pro-survival/anti-apoptotic signals (Figure 
30D). 
One potentially serious outcome of intestinal ischemia is multi-organ dysfunction 
syndrome [6], which results from bacterial translocation and dissemination after 
loss of the intestinal barrier function [23].  To assess for the presence of extra-
intestinal bacteria during I/R injury, we measured the bacterial 16S rDNA in the 
liver.  Increased bacterial 16S rDNA (~4 fold) in the liver of I/R-exposed MORf/f 
mice was significantly decreased in DALDA treated mice, while this beneficial 
effect was lost in MORIEC-/- mice (Figure 30C).  These findings indicate that 
DALDA prevented initial ischemia induced epithelial damage and prevent 
bacterial translocation to extra-intestinal organs.  
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Figure 30.  DALDA administration protects against ischemia induced injury 
and attenuates bacterial translocation.  50 μg/kg of DALDA was administered 
s.c to MORf/f and MORIEC-/- mice 10 minutes before ischemia (I) exposure 
(60min). Healthy tissues (H) represent a non-ischemic region of the small bowel 
adjacent to the damaged area.  A)  Representative H&E images of ileal swiss 
rolls.  Scale bars are 200 μm.  B)  Histological damage scores show DALDA 
mediated protection from ischemia injury only in mice with functional IEC-derived 
MOR signaling (MORf/f).  N =5-6 per group. C)  PCR quantification of total 
bacterial 16S DNA at 4 hours of reperfusion shows that MOR-mediated 
protection results in decreased bacterial dissemination to the liver.  Data was 
analyzed by the ΔΔCt method, normalized to murine Gapdh, and compared to 
control.  N = 4 per group.  D)  IHC analysis of activated caspase 3 from ileal 
section of DALDA-treated MORf/f and MORIEC-/- mice shows that enterocyte MOR 
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signaling confirms protection from apoptosis during the ischemic phase of injury.  
Images are representative of three different mice.  Scale bars are 200 μm.  
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MOR-mediated protection involves PI3K-mediated GSK3β phosphorylation  
We previously showed in vitro that IEC wound healing responses are 
dependent on PI3K/GSK3β signaling [270].  To test the role of the PI3K/GSK3β 
pathway in MOR-mediated protective effect, we stimulated murine rectal-
carcinoma CMT-93 cells with DALDA (10 μM) for variable period of time.  
Interestingly, DALDA increased GSK3β phosphorylation with a peak activation of 
60 minutes (Figure 31A).  DALDA-mediated GSK3β phosphorylation was 
dependent on PI3K/AKT signaling since the pan-PI3K inhibitor wortmannin 
blocked both AKT and GSK3β phosphorylation (Figure 31B). To functionally link 
PI3K/GSK3β activation to cellular restitution, we then performed migration 
scratch assays. DALDA mediated cellular migration was blocked by PI3K 
inhibition (Figure 31C).   
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Figure 31.  MOR signaling induces GSKβ phosphorylation and cell 
migration in a PI3K-dependent manner in CMT-93 cells.  CMT-93 cells were 
stimulated DALDA (10 μM) for the indicated time in presence or absence of the 
PI3K inhibitor wortmannin (1 μM).  Proteins were extracted and subjected to 
Western blot analysis.  A)  Kinetic analysis of GSK3β phosphorylation.  
Representative of 2 independent experiments.  B)  DALDA-mediated Akt/GSK3β 
phosphorylation is blocked in wortmannin treated cells.  Representative of 3 
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independent experiments.  C)  DALDA-induced cell migration require PI3K 
signaling.  CMT-93 cells were grown in a monolayer, treated with DALDA (10 
μM) in presence or absence of Wortmannin (Wort; 1 μM).  Cells were then 
scratched with a pipet tip and cellular migration from the wound-edge was 
measured 8 hours later. Four separate wounds were measure per group; data 
representative of 2 independent experiments.    
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To expand these observations in vivo, we performed IHC analysis on 
DALDA-treated mice.  Interestingly, IEC-specific Akt and GSK3β phosphorylation 
is enhanced in DALDA-treated MORf/f mice compared to the vehicle-treated mice 
(Figure 32A-B).  We further quantified the pGSK3β staining, and found increased 
staining in the crypts of DALDA-treated MORf/f mice compared to the vehicle-
treated mice (7.2 vs 3.9, P<.01, Figure 32C).  Finally, we observed that activation 
of these signaling pathways was abrogated in DALDA-treated MORIEC-/- mice 
(Figure 32A-C), demonstrating that these effects were a result of direct 
enterocyte-mediated MOR signaling. 
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Figure 32.  DALDA induced protection from I/R injury correlates with 
enterocyte AKT and GSK3β phosphorylation.  Mice were treated with DALDA 
and exposed to I/R as described in Figure 28.  Healthy tissues (H) represent a 
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non-ischemic region of the small bowel adjacent to the damaged area.  A) 
Representative IHC of ileal swiss rolls stained for pAkt.  Scale bars are 200 μm.  
N = 2 per group.  B)  Representative IHC of ileal swiss rolls stained for p-GSK3β.  
Scale bars are 200 μm.  N = 3 per group.  C) Number of p-GSK3β positive crypts 
per 10 crypts.  N = 3 mice per group, with three random fields of view per mouse.  
Analysis by one-way ANOVA with Tukey’s post-test.   
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To determine the functional role of PI3K signaling in DALDA mediated protective 
effect, MORf/f mice were treated with the PI3K inhibitor Ly294002 (0.25 mg/kg, 
i.p).  Interestingly, DALDA-mediated protective effect against I/R-injury was lost 
in mice treated with Ly294002 (Figure 33A&B).  Additionally, the administration of 
Ly294002 resulted in decreased DALDA-mediated induction of GSK3β 
phosphorylation (Figure 33C&D), and reduction in baseline GSK3β 
phosphorylation levels (Figure 33D).  These findings indicate that the DALDA-
mediated cyto-protective effect in the intestine is mediated by IEC-dependent 
MOR signaling to the PI3K pathway, including downstream targets Akt and 
GS3K3β. 
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Figure 33.  DALDA-mediated cyto-protection is PI3K-dependent. The PI3K 
inhibitor Ly294002 was administered to MORf/f and MORIEC-/- mice at 0.25 mg/kg 
i.p. 10 minutes before injection of vehicle or DALDA and then exposed to I/R as 
described in Figure 28.  A) Histology (scale bars are 200 μm) and B) histological 
damage scores show that DALDA mediated protection from I/R injury requires 
functional PI3K signaling. N = 4-11 per group. C)  DALDA-induced pGSK3β 
phosphorylation is ablated in mice treated with Ly294002.   Scale bars are 200 
μm. Positive staining pGSK3β crypts per 10 total crypts.  Results are from 5-6 
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mice/group, with two random fields of view per mouse.  Analysis by one-way 
ANOVA with Tukey’s post-test.   
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Discussion 
Intestinal ischemia/reperfusion injury is a serious pathology with potentially lethal 
sequelae, including necrotizing enterocolitis [21] and MODS [6].  Unfortunately, 
no therapeutic strategies are currently available to treat the underlying intestinal 
injury that drives many of these sequelae.  Although opioid agonists have been 
shown to protect various organs against injury, including the intestine and heart, 
the cellular compartment(s) mediating these effects have remained elusive.  
Since IEC responses to various injurious insults including inflammation, radiation, 
and I/R are critical for the maintenance of intestinal barrier function [2, 23, 32, 
40], we speculated that these cells drive DALDA-mediated protective effect.  
Indeed, selective genetic removal of MOR signaling in IECs abrogated the cyto-
protective action of DALDA following I/R exposure.  Since the extent of intestinal 
injury following I/R exposure is similar between MORf/f and MORIEC-/- mice, we 
conclude that MOR signaling is protective only in the presence of an exogenous 
ligand (e.g DALDA).  Additionally, adjacent healthy tissue in mice subjected to I/R 
showed no alterations in villus length or crypt numbers in MORIEC-/- mice.   
Furthermore, administration of DALDA did not result in increased villus length or 
crypt numbers in the healthy tissue of MORf/f mice.  These findings suggest that 
DALDA/MOR-mediated protection is a direct result of tightly-regulated MOR 
signaling that occurs only in injured tissue.  
Interestingly, DALDA administration had no significant modulatory effect on I/R-
induced Il6, Il1b, and Tnf mRNA expression levels.  Since MORIEC-/- mice have 
functional MOR in the immune compartment, these findings suggests that 
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DALDA/MOR primary therapeutic targets are not at the immune cell response 
level.  Also, this suggests that the induction of inflammatory cytokines in the 
intestine in the early stages of I/R injury is driven by the presence of hypoxic 
conditions more than the extent of injury to the tissue itself.  This is compatible 
with the reported effect of hypoxia on inflammatory gene expression observed in 
the intestine and may represent an adaptive response to promote IECs 
resistance to apoptosis [271] [272]. Together, these findings indicate that DALDA 
likely mediates its protective function by enhancing IEC resistance to cell death 
during hypoxic conditions and/or by enhancing the recovery of the intestinal 
barrier by increasing IEC restitution. The pro-migratory effect of DALDA on injury 
CMT-93 cells in conjunction with decreased epithelial apoptosis in both ischemic 
and ischemia/reperfusion phase are supportive of this mechanism.    
Previous reports showed that MOR activates the pro-proliferative and survival 
signaling pathway PI3K/Akt/GSK3β in numerous in vitro systems [54] and during 
cardiac ischemia [89].  Here, we showed that DALDA enhanced AKT and GSK3β 
phosphorylation in the intestine both in vivo and in vitro, which correlated with 
protection from intestinal ischemia.  The pharmacological agent Ly294002 
demonstrated that MOR-mediated protection from I/R injury requires activation of 
PI3K signaling.  PI3K is a heterodimer comprised of a catalytic (p110α, p110β, 
p110δ, or p110γ) and regulatory (p85, p55, or p50—or p101 for p110γ) subunit 
[273, 274].  Although Ly294002 is a fairly selective inhibitor of PI3K signaling, its 
inhibitory effect is not directed toward any specific subunit and therefore one 
cannot identify the PI3K subunit mediating the beneficial effects observed.  
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However, since IECs express the ubiquitous p110β catalytic subunit (known to 
couple to GPCRs [275]) and the regulatory p85α subunit, these subunits may be 
the target of DALDA effect.  The regulatory p85α subunit has shown to be central 
to enterocyte PI3K signaling both at baseline and upon stimulation with 
parathyroid hormone [276, 277], and has been shown to promote mitogenic 
signals in enterocytes [278].  Further investigation would be necessary to identify 
the PI3K subunit responsible for DALDA-mediated protection.  
Interestingly, we observed the protective effect of DALDA in the ischemic phase 
of injury where IECs typically undergo massive apoptosis due to prolonged 
hypoxia [3, 8, 9], suggesting that anti-apoptosis may be the primary mechanism 
of protection conferred by DALDA.  The anti-apoptotic role of the PI3K signaling 
pathway has been observed in enterocytes [279], as well as in endothelial cells 
subjected to hypoxic conditions [280].  Downstream, phospholipid-dependent Akt 
pathway activation has been implicated in the anti-apoptotic effects of PI3K 
activation [266].  Akt activation can lead to enhancement of pro-survival signaling 
through IKK-mediated increases in NF-κB activity [266].  Akt activation can also 
directly inhibit apoptotic signals such as Fas-L, Bax, and p53 and promotes anti-
apoptotic signals such as Bcl-XL, Bcl-2 [266].  Additionally, Akt activation results 
in GSK3β phosphorylation, which leads to inhibition of apoptotic signals mediated 
by MCL-1 and Bax, and enhancement of pro-survival signals  such as β-catenin 
[266].  Since DALDA failed to directly activate NF-κB signaling in IECs [205], the 
Akt/GSK3β pathway is likely the candidate pathway activated in the intestine by 
this opioid agonist.   
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Regardless of the PI3K-dependent mechanism(s) involved, the functional impact 
of DALDA-mediated intestinal barrier enhancement through increased PI3K 
activity is clearly illustrated in the bacterial translocation assay.  Presence of 
bacterial 16S rDNA in the liver of I/R exposed mice was strongly decreased by 
DALDA administration.  This is an important finding, as bacterial translocation in 
the face of a damaged barrier is the main source of multi-organ failure in patients 
suffering from intestinal ischemia [6, 8, 9].   
Overall, these studies demonstrate for the first time that activation of IEC-
specific, PI3K-dependent MOR signaling is able to result in protection from 
ischemia/reperfusion-induced intestinal injury.  The current lack of therapies for 
treating intestinal ischemia, combined with the wide availability of FDA-approved 
MOR-specific agonists to clinicians, makes this work of particular clinical 
relevance.  
  
 
CHAPTER 6  
DISCUSSION AND CONCLUSIONS 
Mu opioid receptor signaling protects against intestinal injury 
A significant strength of this work lies in its use of multiple models of acute 
intestinal injury across two species.  Numerous GI pathologies including IBD [1, 
11], I/R injury [3, 8, 9] and radiation injury [2, 7] involve loss of the intestinal 
barrier.  The studies presented in this dissertation establish the ability of MOR-
mediated signaling to protect against and enhance recovery from a variety acute 
intestinal injury events.  Using the peripheral acting, highly specific MOR agonist 
DALDA, we demonstrated that MOR signaling can protect against glafenine-
mediated injury in zebrafish, protect and enhance recovery from DSS-induced 
injury in mice, and prevent I/R-mediated injury in mice.   
The ability for MOR signaling to affect a wide array of models is perhaps 
related to the fact that it is a GPCR, and can thus interact with numerous cellular 
signaling cascades.  A good portion of the work in this dissertation focused on 
establishing some of these events.  In these studies, we found that MOR-
mediated protection affects enterocyte signaling.  Our work in zebrafish 
demonstrated that administration of DALDA can restore proper UPR and 
autophagic responses that are blocked by glafenine administration, enhancing 
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cellular survival.  S-XBP1, a gene that we demonstrated is up-regulated by 
DALDA-administration in zebrabfish, has recently been implicated in IBD 
pathogenesis due to an increased susceptibility to IEC apoptosis in the presence 
of ER stress [17, 19].  Genetic ablation of s-XBP1 in mice results in increased 
susceptibility to DSS colitis [19]—a model of acute injury treated by DALDA, 
which suggests a linkage and possible common mechanism of action across 
these various studies.  The fact that MOR activation enhances s-XBP1 mRNA 
levels suggests that opioid therapy could be used to treat IBD patients with low-
transcription polymorphisms of this gene [19], assuming that MOR activation 
could overcome the low basal transcription of s-XBP1; which remains to be 
determined.   
Our murine studies demonstrated two further IEC-protective pathways 
driven by MOR signaling.  Our DSS studies in mice demonstrated that DALDA 
enhances enterocyte STAT3 activation, which is known to be protective in 
enterocytes [32, 281-283].  Surprisingly, our I/R studies did not show increased 
STAT3 activation during the course of MOR-mediated protection; however, we 
did observe PI3K activation and AKT and GSK3β-phosphorylation.  This 
suggests another pathway through which MOR can act to enhance epithelial 
restitution.  Together, these works provide a picture of MOR-signaling as a 
broadly acting agent that enhances multiple enterocyte-protective pathways.  
These broad-based effects could account for its ability to protect against multiple 
models of injury.  The work presented here establishes both the viability and 
molecular basis for MOR-mediated protection from intestinal injury.   
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Limitations, future directions and proposed mechanisms 
One area that remains untouched in this research is the study of MOR-
mediated protection from chronic colitis.  In particular, it would be interesting to 
study the effect of DALDA on Il10-/- colitis.  These mice develop spontaneous 
colitis within four weeks of being transferred from germ-free to specific pathogen 
free (spf) conditions, as a result inappropriate immune activation to commensal 
gut flora [284].  DALDA therapy has already been shown to abrogate other 
immune-mediated models of murine colitis [70, 71], and so it would be interesting 
to see if DALDA administration could protect against this human-disease-relevant 
[163, 285, 286] murine model of colitis.  Specifically, DALDA would be 
administered concurrently with transfer of the germ-free mice to SPF conditions 
via osmotic pump, with conditions of the pump such that only a low dose (<50 
μg/kg/day) would be administered (to ward off receptor desensitization).    This 
work would show that MOR-mediated signaling can not only protect against 
acute epithelial injury and acute, immune-mediated injury [70, 71], but also 
chronic immune-mediated injury.  This would establish pan-protective effects of 
MOR signaling in the intestine, and further build a case for the pursuit of clinical 
trials to study the use of opioids to treat gastrointestinal diseases such as IBD.   
Molecularly, the studies presented in this dissertation have demonstrated 
that MOR-mediated signaling can affect multiple pathways within enterocytes: 
UPR/autophagy, STAT3 and PI3K/AKT/GSK3β.  However, the exact 
mechanisms by which these pathways are activated and their specific molecular 
consequences have yet to be fully determined.  While the use of MORIEC-/- mice 
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in the I/R studies demonstrated that in this system MOR-mediated protection 
occurs through direct action on enterocytes, further studies need to be performed 
in the other models utilized in this dissertation to determine if MOR-mediated 
protection occurs via direct signaling on enterocyte-MOR or indirectly through 
other mediators such IL-22 (an inducer of STAT3) that then act upon the 
enterocytes.  Specifically, the DSS studies need to be repeated using the 
MORIEC-/- mice, including evaluation of enterocyte STAT3 activation upon DALDA 
administration in the face of DSS-injury.  In our zebrafish system, a tissue-
specific MORIEC-/- strain would need to be developed, to establish the cell 
compartment responsible for MOR-mediated protection from glafenine-induced 
injury.  However, the intestine-specific nature of glafenine-injury, as well as the 
rapid kinetics of injury in the system (within one hour of drug administration) 
suggests that DALDA acts on enterocytes directly.   
Assuming the effects we have observed in these studies are a result of 
direct action on enterocytes, more work still needs to be done to map out the 
pathways between MOR activation and end-result enhancement of proliferation, 
migration enhancement, autophagy and cell survival. Specifically, the importance 
of STAT3 activation in MOR-mediated protection needs to be further assessed.  
While our work with DSS suggested the involvement of enterocyte-STAT3 
activation in MOR-mediated protection, we did not see STAT3 enhancement in 
our I/R studies.  In the DSS system, STAT3IEC-/- knockout mice should be 
employed to determine the importance of STAT3 in MOR-mediated protection.  
However, this study will have its own limits as these mice exhibit exacerbated 
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DSS-damage due to their loss of enterocyte STAT3 [32], and consequently 
MOR-mediated protection may not be sufficient to overcome enterocyte-specific 
loss of STAT3 even if STAT3 is not central to MOR-mediated protection in this 
model.  Additionally, while STAT3 activation was not observed in the I/R studies, 
activation of STAT3 signaling has been linked to PI3K activation [287], which was 
observed in the I/R studies.  This suggests integration between STAT3 activation 
and the PI3K/Akt/GS3Kβ pathway in MOR-mediated signaling.  This is supported 
by both the literature (in particular the cardio-protective studies of opioids [89]), 
as well as our own studies in vitro, which showed that pharmacological inhibition 
of either JAK2 or PI3K resulted in loss of DALDA-induced STAT3 and GS3Kβ 
phosphorylation (Figure 34).   The fact that STAT3 activation was not observed in 
the I/R studies could also be a matter of kinetics and/or the fact that the ischemic 
tissues used in the Western blot analyses had high levels of innate proteolysis, 
which could have preferentially masked STAT3 activation; consequently, IHC 
studies should be undertaken.  Use of the STAT3IEC-/- mice in the I/R system 
could also beneficial in sorting out this unresolved issue.   
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Figure 34.  Phosphorylation of STAT3 and GSK3β by DALDA in CMT-93 
cells are both dependent on PI3K and JAK2 activity.  CMT-93 cells were 
stimulated with DALDA for 60 minutes, with 10 minutes of inhibitor pre-treatment 
where indicated.  Cells were directly lysed in 1X laemelli buffer and subjected to 
Western blot analysis.  AG490 is a JAK2 inhibitor.  Wortmannin (Wort) is a PI3K 
inhibitor.  Representative of 3 independent experiments.   
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A combined interpretation of the DSS and I/R studies alongside the in vitro 
work suggests that PI3K could serve as the central mechanism for the wide 
variety of intestinal protective effects induced by MOR signaling, including STAT3 
activation.  However, questions remain regarding the steps between MOR 
activation and STAT3 phosphorylation.  While MOR has been well-established to 
activate PI3K/Akt signaling [54, 89] and the cardio-protection literature suggests 
that MOR activates JAK2 (leading to STAT3 phosphorylation) [89], more work 
needs to be performed in the systems presented in this dissertation to link these 
two pathways.   
The zebrafish glafenine studies also present evidence that PI3K may be 
the mediator of MOR-induced enhancement of autophagy, the proposed 
mechanism of DALDA-mediated protection in this system.  Wortmannin 
administration blockaded DALDA-mediated protection from glafenine-injury in 
zebrafish, and PI3K signaling is known to induce autophagy [224].  Specifically, 
the PI3K regulatory subunit p85α has been shown in mouse embryonic 
fibroblasts to increase resolution of endoplasmic reticulum (ER) stress and 
prevent apoptosis via enhancement of s-XBP1 nuclear transport and activity 
[288], one of the UPR molecules modulated by DALDA in our zebrafish studies.  
However, further work needs to be performed to fully map out how MOR 
signaling up-regulates UPR and autophagy responses—including the 
involvement of PI3K activation, and the p85α subunit in particular, in these 
processes.  
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Despite the aforementioned remaining holes, this work paints a picture of 
MOR-mediated protection that involves a central role for PI3K signaling, which 
then induces numerous downstream protective signaling events, including Akt, 
GS3Kβ and STAT3 phosphorylation, and engagement of protective autophagy 
pathways.  An outline of the proposed mechanisms by which MOR signaling 
induces cyto-protection are presented in Figure 35.  
  
182 
 
 
Figure 35.  Proposed mechanisms by which MOR signaling engages cyto-
protection.   After activation of MOR by a ligand, we propose that the coupled 
Gβγ G-protein engages and activates PI3K.  This in turn engages three cyto-
protective cascades: 1) the PDK/Akt/GSK3β cascade, through the catalytic p110 
PI3K subunit, 2) enhancement of autophagy genes, through the PI3K p85α 
regulatory subunit, and 3) STAT3 phosphorylation through synergy between 
PI3K activation and JAK2 activation.    
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MOR therapy in humans: a case for the pursuit of clinical trials 
As discussed above, numerous GI pathologies including IBD [1, 11], I/R 
injury [3, 8, 9] and radiation injury [2, 7] involve loss of the intestinal barrier as a 
principal component of their pathogenesis.  Existing treatments of these 
pathologies do not address the intestinal damage directly, but either try to stop 
the source of the damage (via immunosuppression in the case of IBD [13-16, 
289]), or are merely supportive [6, 8].  Consequently, the ability to activate 
epithelial restitution represents a completely unexplored but potentially vital 
treatment modality that directly targets intestinal injury.  Currently, there are 
significant limitations to targeting epithelial restitution, as most recombinant 
growth factors (such as EGF) are very expensive and can have significant off-
target side effects.  While opioids also have noteworthy side effects, including the 
risk of dependency [54], narcotic bowel syndrome [91], and toxic megacolon [91], 
the class of compounds are also clinically well-understood and highly used, 
mitigating much of their risk.  Opioids are additionally relatively cheap and widely 
available.  The presence of multiple mu-opioid agonists in the pharmacopeia is 
another benefit of pursuing opioid-mediated therapy, as clinical trials (Phase I 
and some Phase II) could largely be skipped, as the toxicity and side effects of 
these drugs are already known.  Even more importantly, there already exists a 
peripheral-only acting MOR agonist that is highly used to treat diarrhea and is 
available over-the-counter: loperamide (Imodium®).  Consequently, clinical trials 
studying peripheral-MOR therapy (just like what is accomplished with DALDA in 
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our systems) could be easily undertaken, and a relatively low cost since drug 
develop is not a concern.   
Specifically, it would be ideal to pursue the use of loperamide (1-2 2 mg 
doses/day) to treat ulcerative colitis in patients that still have rectal/sigmoidal 
ulceration resulting in bleeding, despite 5-ASA and/or immunosuppressive 
therapy.  Since diarrhea is treated by loperamide therapy, this could not be an 
outcome of this study.  Rather, epithelial healing would be the primary outcome, 
as measured by colonoscopy imaging (with pathology samples) performed both 
before therapy was initiated and 4 weeks into therapy.  A secondary, clinical 
outcome would be the presence of visible blood in the stool. The cost of 
performing a randomized, double-blind trial on 30 patients has already been 
estimated, and is approximately $50,000.  If this trial were successful, it would be 
provide sufficient evidence to pursue a full-fledged Phase III trial, and also 
provide evidence to support the pursuit of loperamide for the study of intestinal 
I/R injury and radiation injury.   
The strong protection we observed with DALDA administration during 
ischemia-reperfusion injury is of great clinical interest as well.  I/R injury is a 
serious complication of surgeries and in pre-mature infants in the form of 
necrotizing enterocolitis, potentially leading to sepsis and multi-organ dysfunction 
syndrome [6, 8, 9, 21].  New therapies are desperately needed for the treatment 
of intestinal I/R injury, as current approaches are only supportive [6, 8].  Opiates 
have already been demonstrated to confer significant cardio-protection during 
ischemia/reperfusion injury in studies in both rodents and humans [86-89, 290], 
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including in randomized, double-blind clinical trials [265].  This work extends the 
protective observations to the intestinal system, and suggests that clinical trials to 
study the use of opioids to treat intestinal I/R injury would be viable.   
Summary 
This works establishes that MOR signaling is protective against multiple 
models of acute intestinal injury.  Engaging MOR signaling, likely in the 
enterocytes directly, results in the activation of multiple cell programs to enhance 
epithelial restitution and stave off IEC apoptosis.  This work provides sufficient 
evidence to warrant extending these observations into the clinic, with the 
initiation of clinical trials.  Numerous opioids are already commercially available 
and pharmacologically well understood, making the pursuit of clinical trials 
relatively inexpensive and easy to undertaken.  Such work could have profound 
benefits for patients suffering from a variety of intestinal diseases.    
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APPENDIX 1  
OTHER DATA 
Other data were produced during this dissertation, which either did not make into 
a manuscript, or still needs further work before being published.  These are 
presented below.  Each figure includes in its legend the relevant methods, and 
are cited elsewhere in the manuscript as appropriate.   
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Figure 36:  DALDA administration reduces bacterial dissemination to the 
liver and spleen.  Mice were subjected to ileal ischemia for 1 hour, followed by 
reperfusion for 4 hours before sacrifice.  Control samples are from mice 
sacrificed without ischemia being performed.  Healthy tissues were taken from 
ileum adjacent to the ischemic area.  A&B)  Tissue homogenates were plated on 
sheep BHI plates overnight in aerobic (A) or anaerobic (B) conditions and CFUs 
were counted and normalized to the grams of tissue in each homogenate.  
Representative of 3 or 4 mice per group.   
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Figure 37:  Tg(MPO:EGFP) zebrafish demonstrate increased neutrophil 
signal overlaying the intestine.  Zebrafish were administered glafenine using 
the same protocol as described elsewhere in this work.  Bars are 1 mm in length.  
Relative fluorescence intensity was analyzed over segment 2.  Representative of 
3 independent experiments, N as portrayed.  Wide-field fluorescence images 
were captured and analyzed using the same methodology as described in the 
text.   
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Figure 38:  Neutrophils are near, but not in the gut compartment.  Zebrafish 
larvae were administered 25 μM glafenine for 12 hours as described elsewhere.  
A) Correlation between formation of apoptotic tubes and tg(MPO:EGFP) signal 
increase.  N based on height of bars, pooled from 3 independent experiments.  
B) 3D confocal reconstructions of tg(MPO:EGFP) zebrafish with and without 
glafenine treatment.  Images are representative of 2 different fish per condition; 
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bars equal 50 μm.  Confocal images were captured with 1% agar embedded, 
anesthetized (alive) fish, using the same imaging setup as used for the confocal 
imaging of murine intestines described in the text.  C) EGFP positive cells from 
gut micro-dissections of tg(MPO:EGFP) zebrafish.  No significant difference 
between groups was found.  N≥6, pooled from 2 replicate groups.  Gut micro-
dissections were performed as described in the text and analyzed by eye with 
wide-field fluorescence microscopy.   
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APPENDIX 2 
HUMAN STUDIES IN IBS PATIENTS 
Manuscript to be written (data collection completed)—clinical data not presented 
here. 
Introduction and overview 
Probiotics have been shown to be beneficial in alleviating various 
functional GI symptoms, however, the mechanisms of these effects are unknown. 
The probiotic bacterium L-NCFM has been shown to increase expression of 
MOR in the intestinal mucosa and decrease intestinal pain sensation in animal 
studies [143], and recent clinical studies of IBS patients with diarrhea (IBS-D) 
demonstrated decreased levels of lactobacillus strains in patients suffering from 
IBS-D compared to healthy controls [291].  Other studies have demonstrated an 
important role for commensal bacteria in the protection from inflammatory pain 
[144]. 
Materials and methods 
Caucasian women (N=17) 18-70 years with mild to moderate abdominal 
pain were investigated. Colonic biopsies were collected during un-sedated, un-
prepped flexible sigmoidoscopy pre- and post- 21 days consumption of the 
probiotics at a total dose of 1.0 x 1010 CFU bid. Cellular RNA was extracted from 
the mucosal biopsies and reverse transcribed to cDNA. mRNA expression of 
mucosal MOR receptors was determined by RT-PCR on an ABI Prism HT7700 
Thermocycler (Applied Biosystems) via SybrGreen. Relative fold-changes were 
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determined using the ΔΔCT calculation method. Immunohistochemistry (IHC) for 
pSTAT3 was performed on paraffin-embedded sections of mucosal biopsies with 
monocloncal antibodies for pSTAT3(Y705) (Cell Signaling Technology Inc) were 
used at a 1:50 dilution. Slides were developed using horseradish peroxidase-
conjugated secondary antibody and a VectaStain Elite ABC Kit (Vector 
Laboratories Inc). 
Results 
Preliminary analysis of patients treated with the L-NCFM bacterium 
demonstrated a statistically significant decrease in bloating symptoms (data 
unavailable, in final processing).  Pre- to post-intervention with L-NCFM and B-
LBi07 or L-NCFM alone was associated with a 5.5-fold increase in MOR 
expression (8.2E-6 vs 1.5E-6 fold-over-β-actin, P=0.014; n=13). The increase in 
MOR expression was significantly (~10-fold) greater with L-NCFM alone 
compared to the combination of B-LBi07 and L-NCFM (1.1E-5 vs1.8E-6 fold-
over-β-actin post-treatment increase, P=0.022). Analysis of MOR expression on 
a per-patient-basis showed that patients treated with L-NCFM alone had a 39.9-
fold pre- to post-intervention increase in the levels of the receptor (P =0.0313). 
IHC for pStat3 showed increase in mucosal biopsies only in the L-NCFM group. 
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Figure 39:  Administration of L-NCFM results in increased MOR expression 
and downstream signaling in humans.  A&B) Real-time PCR for MOR 
expression relative to β-actin expression in colonic mucosa biopsies from human 
patients.  Analyzed using the ΔΔCt method.  A)  Pre verses post-treatment 
analysis demonstrates an induction of MOR expression with probiotic 
administration.  N = 13 per group  B) Analysis of NCFM + Bli07 vs NCFM alone 
demonstrates that NCFM alone is responsible for MOR induction, and that Bli07 
serves as a competitive agent for NCFM colonization. N = 7 per group C) IHC 
analysis of mucosal biopsies demonstrates downstream activation of MOR 
signaling with NCFM treatment, as measured by increased levels of STAT3 
phosphorylation.  Representative image from 3 separate samples per group.  
Scale bars are 100 μm.      
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Conclusions 
These results replicate in humans an observation seen in mice, with 
promising initial clinical findings.  It demonstrates the modulation of MOR 
signaling by pro-biotics, in addition to direct receptor activation, could be a viable 
avenue for MOR-mediated therapy in patients.  A pro-biotic approach has several 
advantages over pharmacological interventions, including less systemic side 
effects.   
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